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PREAMBLE 
In 1982 the structure of growth hormone releasing hormone (GHRH) was un­
raveled (1,2). Subseguently it was tested in healthy normal volunteers, 
predominantly males (3). We wondered whether there would exist a differ­
ence in GH responsiveness to GHRH between men and women. Later we extended 
this study to (tall) pubertal boys and girls. 
The well-known stunting of growth in children with hypercortisolism 
prompted us to investigate the GH response to GHRH in patients with 
Cushing's disease and Cushinq's syndrome due to an adrenocortical adenoma. 
To extend earlier studies which dealt with paradoxical reactions of GH 
in response to thyrotropin releasing hormone (TRH) and luteinizing hormone 
releasing hormone (LHRH) (4) in patients with acromegaly we performed GHRH 
tests in these patients, and compared the GH responses with those obtained 
after TRH, LHRH, somatostatin and bromocriptine. 
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Chapter 1 
REVIEW OF ANIMAL AND HUMAN STUDIES WITH GHRH 
1.1 ISOLATION AND CHARACTERIZATION OF GHRH 
As early as 1949 Harris (1) proposed that hypothalamic factors are secre-
ted into the hypothal amo-hypophyseal portal circulation and requlate ante-
rior pituitary function. In 1960 Reichlin (2) demonstrated, that lesions 
of the ventromedial nucleus of the rat hypothalamus resulted in impaired 
qrowth. Few years later Deuben showed that an extract of rat hypothalamus 
could stimulate GH release from rat pituitaries in vitro (3). In 1968 
Frohman (4) reported that electrolytic lesions of the ventromedial hypo-
thalamus in the rat decreased pituitary and plasma GH levels. In turn 
electrical stimulation of hypothalamic ventromedial and arcuate nuclei re-
sulted in increased GH levels (5). In 1971 the same authors (6) demonstra-
ted that intrapituitary administration of a partially purified extract of 
ovine hypothalamus in the rat led to an acute rise of GH levels. All these 
data pointed to the existence of a qrowth hormone releasinq factor 
produced by the hypothalamus. Durinq the next years several attempts were 
made to isolate and characterize this factor, none of which were, however, 
successful (7,8). The isolation of the qrowth hormone releasinq hormone 
(GHRH) was hampered because of the minute amounts present in the hypothal-
amus (10-50 fmol) and the existence of rather hiqh concentrations of a 
qrowth hormone release inhibitinq factor (SRIF) in the hypothalamus. The 
existence of the latter factor was proposed by Kruhlich et al.(9) and 
later Brazeau et al.(10) isolated the hormone from ovine hypothalami while 
on the search for the putative GHRH and characterized somatostatin. The 
final solution of the problem was postponed until a rich source of a GH-
releasinq factor, devoid of somatostatin became available. In this respect 
a number of clinical observations was useful. In the sixties and seventies 
few authors reported ca^es of acromeqaly caused by ectopicallv produced 
GHRH (11-15). Sönksen et al.(14) noted cure of acromeqaly after removal of 
a bronchial carcinoid tumor. In 1980 Frohman et al.(16) partially purified 
and characterized a peptide with qrowth hormone releasinq activity from 
extrapituitary tumors in patients with acromegaly. The limited quantity of 
available tissue, however, precluded further characterization. In 1982, 
Thorner et al.(17) from Charlottesville, Virqinia, described a patient 
with acromeqaly and Turner's syndrome, who after suraery proved to have 
somatotroph hyperplasia of the pituitary instead of the expected pituitary 
adenoma. After surqery the acromegaly remained active. An ectopic GHRF 
producinq tumor was suspected and an islet cell tumor was found in the 
tail of the pancreas. After successful resection of this tumor GH levels 
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fell within 2 hours and subsequently the patient was cured of her acro­
megaly. The group of Vale (18) isolated from this so-called Charlottes­
ville tumor a peptide with 40 aminoacids with a carboxyl terminal 
(GHRHi.4o). Within a few weeks Guillemin (at the same institute in La 
Jolla) reported the isolation of 3 peptides with growth hormone releasing 
orooerties (19,20) from a pancreatic tumor with multiple metastases 
obtained from a patient with acromegaly of Dr.Sassolas of Lyon (21). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
A Tyr Ala Asp Ala He Phe Thr Asn Ser Туг Arq Lys Val Leu Gl ν 
В 
С 
D I l e 
E 
F His Arq I l e 
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
A Gin Leu Ser Ala Arg Lys Leu Leu Gin Asp Ile Met Ser Arg Gin 
В 
С Asn 
D Asn 
E Asn 
F Tyr His Glu Asn 
31 32 33 34 35 36 37 38 39 40 41 42 43 44 
A Gin Gly Glu Ser Asn Gin Glu Arg Gly Ala Arq Ala Arg Leu 1 % 
В Arg 
С Arg 
D Arg 
E Arg 
F Arg 
FIG. 1. Amino acid sequence of A, hpGRF(l-44)NH2; B, porcine GRF; C, 
bovine GRF; D, ovine GRF; E, caprine GRF; F, rat GRF 
Gin 
Gin 
Gin 
Gin 
Gin Arg Ser 
Val 
Val 
Val 
Val 
Phe Asn OH 
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The longest peptide possessed 44 amino-acids with an amidated carboxyl-
terminal. The other 2 peptides were similar in structure except for a 
shorter length, GHRH^mjOH and GHRH^ayOH. The quantitatively major 
peptide was GHRHi_i,oOH. Subsequently it was shown by Bohlen et al. (22) and 
Ling et al. (23) that in human hypothalami 2 forms of GHRH are present 
namely бНРНі.ццМНг and GHRH^mjOH. The earlier designation human pancrea­
tic (tumor) GHRH could now safely be changed to GHRH. Shortly after the 
isolation of human GHRH, hypothalamic GHRH's from other species also were 
identified: rat GHRH (24) which is a 43 amino acid peptide with a free 
carboxyl terminus and 67% homology with human GHRHi-цц, porcine GHRH (25), 
bovine GHRH (26), ovine GHRH (27) and caprine GHRH (27) (Fig.l). All these 
other peptides are composed of 44 amino acids. By molecular cloning it was 
demonstrated that human GHRH is processed from two precursors namely pre-
pro-GHRH10/ and pre-pro-GHRH108 (28). A putative hydrofobic signal peptide 
of possibly 20 amino acids is joined to a pro-GHRH, 87 or 88 aminoacids 
long (28). The qene encoding human GHRH is located on chromosome 20 (29). 
1.2 DISTRIBUTION OF GHRH 
1.2.1 GHRH in normal tissues 
Neuronal cell bodies producing GHRH have been characterized by immunohis-
tochemistry, using antibodies against GHRH^no and СНРЩ.цц in the arcuate 
and the ventromedial nuclei (30-32) of human hypothalami. GHRH staining 
cell fibers are mainly found in the external layer of the median emi­
nence. These fibers are in close contact to the capillary loops that coa­
lescence to form the portal vessels. In human hypothalami highest concen­
trations of immunoreactive (IR) GHRH were found in the arcuate nucleus (83 
± 4 ng/ml protein). Lower quantities were present in other hypothalamic 
regions. In the upper portion of the pituitary stalk the highest concen­
trations of IR GHRH were found (1454 ± 48 ng/mg protein), whereas rather 
low levels were found at the distal end (121 ± 3 ng/mg). This concentra­
tion gradient suggests, that the peptide reaches the anterior pituitary 
mainly via the long portal vessels. Somatostatin has a pattern of distri­
bution along the pituitary stalk very similar to GHRH (33). Also in other 
species the presence of GHRH is restricted to only few areas in the brain, 
i.e. in rats in the arcuate, paraventricular and dorsomedial nuclei and 
around the ventromedial nucleus (34-39), in the monkey in the arcuate and 
ventromedial nucleus (40-43) and in the cat in the mediobasal hypothalamus 
(44). Phylogenetical ly of interest was the demonstration by immunohisto-
chemistry of GHRH in the nervous system of Aeshua Cyanea, an insect (45). 
Bosman et al.(46) found GHRH-like immunoreactivity (measured by a specific 
RIA for GHRHi.i^) in appreciable amounts in extracts of the normal human 
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pancreas. Lower concentrations were found in extracts of the thyroid, 
lung, stomach, duodenum, ileum, colon, adrenal, kidney and the placenta 
(47-49). It has to be added, however, that definite characterization of 
this GHRH awaits further evidence. In this context it is of interest to 
note that as far as pancreatic secretion of GHRH is concerned Kashio et 
al.(50) reported IR-GHRH in blood shortly after qlucose loading in healthy 
volunteers. 
1.2.2 GHRH in tumorous tissues 
Ectopic production of GHRH causinq acromegaly has been described above. 
Resides the earlier mentioned pancreatic tumors that produce GHRH, Roth et 
al.(51) very recently reported a patient with coexistinq acromegaly and 
pheochromocytoma, which produced GHRHi.^. GHRH-like immunoreactivity was 
also demonstrated in some small cell carcinomas of the lunq, medullary 
carcinomas of the thyroid, aastrinomas, qlucaqonomas, insulinomas and 
thymic and bronchial carcinoid tumors (47,52,53). Excessive production of 
GHRH with clinical acromegaly has been occasionally described in hypothal-
amic qanqliocytomas or hamartomas (54). 
1.2.3 GHRH and colocalization with other neuroactive substances 
Colocalization of GHRH and dopamine (55) and of GHRH with tyrosine hydrox-
ylase-! ike immunoreactivity (56,57) has been demonstrated in rat arcuate 
nucleus. These data point to a possible interaction between GHRH and dopa-
mine in the hypothalamus. Coexoression of GHRH-like immunoreactivitv and 
a-melanotropin-1ike immunoreactivity is present in some interneurones of 
rat lateral dorsal hypothalamus (58). Fuxe et al. (59) put forward the 
medianosome hypothesis-concept. The medianosome is defined as an inteqra-
tive unit, which consists of well-defined aqqreqates of transmitter iden-
tified nerve terminals, interactinq with one another in the external layer 
of the median eminence. These authors found the existence of putative 
medianosomes in rat hypothalami, consistinq predominantly of GHRH nerve 
terminals (costoring dopamine) as well as of SRIF and dopamine nerve ter-
minals. Other authors reported that GHRH-positive cell bodies in the arcu-
ate nucleus also contained neurotensin and/or qalanin-like immunoreactivi-
ties (38). 
1.3 IN VITRO STUDIES WITH GHRH 
1.3.1 In vitro studies with pituitary tissue 
Bindinq of GHRH to specific receptors has been reported for bovine anteri-
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or pituitary membranes (60), rat pituitary membranes (61) and intact rat 
pituitary cells in culture (62). Glucocorticoids enhanced GHRH receptor 
capacity (62). The number of GHRH binding sites was dramatically decreased 
after adrenalectomy and restored after chronic dexamethasone treatment 
(61). Recently Ceda et al.(63) reported that short term (< 4 h) incubation 
of cultured rat pituitary cells with dexamethasone inhibited GHRH-induced 
GH secretion, whereas longer incubations with the glucocorticoid enhanced 
both basal and GHRH-stimulated GH release. It is likely that thyroid-
hormones can modulate GHRH receptors on somatotrophs (64). To our 
knowledge, however, direct measurement of GHRH binding sites in hypothyro-
idism has not been reported. 
In primary cultures of dispersed rat anterior pituitary cells, GHRH spe-
cifically stimulated release of GH (18,19,65-72). No effect of physiologi-
cal doses of GHRH upon the secretion of ß-endorphin, follicle-stimulating 
hormone, luteinizing hormone, thyrotropin or prolactin has been reported. 
The dose of GHRH to elicit half maximal release of GH (ED50) ranges from 
0.5 to lx 10"1ІМ. This is a concentration comparable to the basal hypo­
physeal portal blood levels of other known hypothalamic hypophysiotropic 
hormones (73-75). At a concentration of Ю'^м GHRH, prolactin release in 
rat pituitary halves was slightly stimulated (76). In perifused rat pitui­
tary cells, however, GHRHi.^ stimulates release of stored prolactin 
without altering the release of newly synthesized prolactin (77). In peri­
fused rat anterior pituitary cells it has also been shown that the action 
of GHRH on (stored) GH release is very rapid i.e. within 1 minute (65,70, 
77-79). Stimulation of newly synthesized GH was rather shallow, requiring 
prolonged exposure to GHRH (77). The in vitro effects of GHRH on GH 
release by human pituitary tumor tissues have also been investigated (80-
83). In GH secreting adenomatous pituitary tissues, GHRH is capable of re­
leasing GH. No studies have been reported on the effect of GHRH on normal 
human somatotrophs. 
1.3.2 Mechanism of action of GHRH on somatotrophs 
Many hormones produce their biological effects by interfering with recep­
tors on the intramembranous adenylate cyclase system. A stimulatory effect 
of GHRH on adenylate cyclase has been reported (84-86). GHRH increases 
both extra- and intracellular cAMP accumulation (66,67,70,84-88). Extra­
cellular calcium is required for GHRH-stimulated GH release (66,68). Incu­
bation of normal rat pituitary cells with the calcium entry blocker vera­
pamil attenuates the GH response to GHRH (68). Cobalt (66,68) and inhibi­
tors of calcium-binding proteins (85) have a similar effect. Login et al. 
demonstrated rapid stimulation of calcium influx by GHRH, concomitantly 
with stimulation of GH release in rat anterior pituitary cells (89). There 
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is also a role for calmodulin, the Ca-receptor binding protein, in the 
GHRH-induced activation of adenylate cyclase. It has been demonstrated 
that a calmodulin antagonist abolishes GHRH-induced GH secretion and cAMP 
accumulation (85,90). In contrast, other authors found that a calmodulin 
antagonist increased the GHRH induced GH and cAMP levels (91) 
A role of prostaglandins in GH secretion has been indicated by demon­
strating that GHRH-induced GH release in vitro can be inhibited by the cy-
clooxygenase inhibitors aspirin and indomethacin (92). Other authors found 
no suchlike inhibition with indomethacin (93). GHRH stimulates GH and 
arachidomc acid release from rat anterior pituitary cells (94). Thus, 
while an interaction exists between Prostaglandines, GHRH and GH, the 
precise relationships remain to be classified. 
The relative contributions of the calcium-calmodulin system, the eico-
sanoid cascade and the phosphatidyl inositol-protein kmase-C pathway (69, 
95-97) in the regulation of GH secretion by GHRH remains to be determined. 
Prolonged penfusion of somatotrophs with GHRH not only results in imme­
diate release of stored GH but also in synthesis of new GH (77). GHRH 
stimulates transcription of the GH gene and increases GH messenger RNA in 
rat pituitary cells (98). 
1.3 3 Interactions of GHRH in vitro with other substances 
GH secretion is regulated principally by two factors, GHRH stimulates and 
somatostatin (SRIF) inhibits the release and/or synthesis of GH by the so­
matotroph. Unlike the other trophic hormones GH has no endocrine target 
organ. The peripheral effects of GH are mediated by somatomedins or also 
called insulin-like growth factors (99-101). In man at least 2 ma]or forms 
of somatomedins occur· insulin-like growth factor I or somatomedin-C 
(Sm-C) and insulin-like growth factor II or somatomedin A (Sm-A). Highly 
purified Sm-C can inhibit GHRH-stimulated GH release of rat pituitary 
cells in vitro (102). Recently it was demonstrated that Sm-A is a less 
potent inhibitor of GHRH-induced GH release than Sm-C (103). In rat ante­
rior pituitary cells in vitro, SRIF (SRIF 14 and SRIF 28) inhibits the GH 
response to GHRH in a non-competitive way (65,68,72,104,105). Thus GHRH 
and SRIF act via different receptors on the somatotrophs. GHRH has been 
shown to stimulate SRIF release from median eminence fragments in vitro 
(106). Subseguently it was shown that GHRH does so via ß-endorphin (107). 
Kraicer et al.(108) demonstrated that the timing of the episodic bursts of 
GH secretion is set by SRIF withdrawal, whereas the magnitude of the 
bursts is determined by the amount of GHRH impinging on the somatotrophs 
before and during SRIF withdrawal in penfused rat pituitary cells. There 
is also evidence that GH and Sm-C stimulate SRIF release from rat 
hypothalamus in vitro (109,110). The possibility remains that somatomedins 
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directly inhibit hypothalamic GHRH release. As far as we know no studies 
addressing this question have been reported in literature. It is well-
known that chronic GH excess bv implantation of a GH-producinq tumor in 
rats reduces hypothalamic GHRH content (111). This effect miqht be media-
ted by GH itself or by increased somatomedin production induced by GH. All 
these data point to very complex feedback mechanisms between GHRH, SRIF, 
GH and the somatomedins. This is also illustrated by data of Andhya et 
al. (112) and Katakami et al.(113). 
Thyroid hormones play an important role in the regulation of GH secre-
tion. Recently it has been reported that cultured anterior pituitary cells 
from hypothyroid rats have a reduced maximal GH response to GHRH (64). 
Triiodothyronine pretreatment enhances the response to GHRH of euthyroid 
rat pituitary cells in vitro (72). Dexamethasone pretreatment in the same 
way augments the GH response to GHRH at least in vitro (63,7?, 114,115). 
Borqes et al.(78) observed that prior exposure of rat pituitary cells to 
GHRH at maximal concentrations enabled TRH to become a secretaqogue of GH 
at the pituitary level, whereas TRH did not release GH by itself. The 
authors suggest that this might be the mechanism underlying the paradoxi-
cal GH response to TRH observed in some acromegalics. To our knowledge 
this study has not been performed with GH-secretmg adenomatous pituitary 
tissue from patients with acromegaly. 
1.3.4 Extrapituitary effects of GHRH 
A preliminary report showed that GHRH stimulates release of neurotensin 
and cAMP from a line of rat C-cells (116). In a detailed study it was de-
monstrated that GHRH also stimulated calcitonin release from the same cell 
line (117). 
Laburthe et al. reported that GHRH acts like vasoactive intestinal 
peptide (VIP) on human intestinal epithelial membranes (118). However, the 
very high concentrations of GHRH necessary to produce such effect make a 
physiological role of GHRH on intestinal membranes less likely. Recently 
rat GHRH has been shown to stimulate amylase release in a preparation of 
dispersed acini of a guinea-pig pancreas (119), probably by interacting 
with VIP receptors. In the dog, extrapituitary effects of GHRH on the en-
docrine pancreas have been demonstrated (120,121). These authors demon-
strated that GHRH produces a dose-dependent increase in insulin, glucagon 
and somatostatin from the isolated doq pancreas. In the human extrapitui-
tary effects of GHRH so far have not been reported. 
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1.4 EFFECTS OF GHRH IN VIVO IN ANIMALS 
1 4.1 Effect of iv GHRH on GH secretion in rats 
The first studies of GHRH in vivo were done in rats anaesthetized with so­
dium pentobarbital, which is known to inhibit the release of endoaenous 
GHRH and SRIF (122). Human GHRH 4 4, 4o and _Ъ1 proved to be eaually effec­
tive in releasing GH (123) The GH secretion induced by GHRH1.4i4 was dose-
dependent in the range from 50 nq to 1 μς. Maximum GH concentrations were 
achieved within 3 to 5 minutes following iv administration of GHRH. 
Baseline levels were reached 30 minutes following treatment. Later the 
same authors reported that maximum release of GH in the pentobarbital-an-
aesthetized rats was obtained with 4 μς/Ι^ GHRH (124,125). In the same 
study no change in the pituitary GH resoonse to GHRH was found with in­
creasing age of the rats (124) which is in contrast to data of Ceda et 
al.(126), showing a diminished pituitary responsiveness to GHRH in aaing 
male rats in vivo as well as in vitro. Sonntag et al.(127), however, re­
ported an age related impairment of the GH response to GHRH occurring in 
vivo, but not in vitro. There is no explanation for these discreoant 
results. 
When GHRH was given to conscious, freely moving rats, GH answers were 
highly variable, increases of GH only being observed in 30% of animals 
tested (128). When the animals, however, were pretreated with antibodies 
raised against somatostatin, the heterogeneity in GH responses could be 
completely eliminated (128). In the same study the animals were subjected 
to a 72-hour fast, a situation characterized by increased SRIF production 
(129). Administration of GHRH to these animals did not result in increased 
GH levels. Responsiveness could be restored by pretreating the animals 
with anti-SRIF (128). The same authors (128) also demonstrated that in 
freely moving rats the well-known pulsatile secretion of GH (130) could be 
completely deleted by treating the animals with antibodies raised aqainst 
GHRH. When the endogenous rat GHRH and SRIF were eliminated by appropriate 
antibodies, human GHRH iniected iv every hour was able to produce virtual­
ly reproducible GH resoonses (131,132). The dose-response curve of GHR4 
proved to be the same as previously reported in anaesthetized rats. 
All these data point to reciprocal effects of GHRH and SRIF in the regu­
lation of GH secretion. The interaction between GHRH and SRIF in vivo was 
nicely demonstrated by Plotski and Vale (133) measuring immunoreactive 
GHRH and SRIF levels in the hypophyseal portal blood of rats. They found 
that each GH secretory episode is initiated by pulsatile secretion of GHRH 
into the portal circulation which is preceded by or concurs with a moder­
ate reduction of inhibitory tone provided by portal SRIF. This study de­
monstrates that SRIF and GHRH are secreted in an oscillatory fashion and 
that both are 180 degrees out of phase with respect to each other. 
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The interaction between GHRH and SRIF is further delineated by the 
fact that intracerebroventricular (icv) iniection of a small dose of GHRH 
in conscious male rats causes a paradoxical decrease in GH secretion as 
seen by a suppression of the subsequent GH pulse (134). Prior iv iniection 
of anti-SRIF completely blocked the GH-suppressive effects of lev GHRH in-
dicating that icv GHRH probably acts by increasing SRIF secretion. In an 
elegant study Miki and Ono (135) very recently showed that the decline in 
hypothalarmc SRIF content, induced by treating rats with cysteamine, a 
potent depletor of SRIF, was accompanied with increased GHRH release. The 
authors speculated that SRIF withdrawal may be involved in triggering the 
episodic GHRH release in normal physiology. 
1.4.2 Sex difference in GH responsiveness to GHRH in rats 
There is a striking difference in GH secretion between male and female 
rats (130). Male rats have GH pulses occurring every 3 to 3.5 hour with 
peak GH levels of several hundred nanograms per ml. Between the pulses GH 
levels are low or undetectable. Female rats, however, exhibit a more 
stable GH secretion pattern with lower GH peak values and higher GH values 
between the peaks. The GH response to GHRH in vivo is reported to be sig-
nificantly higher in adult male rats than in adult female rats (125). This 
difference became clear after puberty (125). Gonadectomized male rats had 
a similar GH response to GHRH as adult female rats. When the intact and 
gonadectomized rats were pretreated with testosterone a significant en-
hancement of GH responsiveness to GHRH was seen. However, treating gonad-
ectomized female rats with 17-ß-estradiol did not change the GH response 
to GHRH (136). In vitro, no modulating effects of androgens or estrogens 
on GH response to GHRH was observed (136). This is in contrast to data of 
Evans et al. (137) who showed that exposure of rat anterior pituitary cells 
to testosterone or estrogen enhances respectively diminishes the GH 
response to GHRH. In in vitro penfusion studies of anterior pituitaries 
from gonadectomized male rats treated with testosterone Ohlsson et al. 
(138) showed the same enhancing effect of androgens on GHRH-induced GH 
release. 
Part of the sex difference in GH secretion can be explained by the 
greater number of somatotrophs in the male rat as compared to female rats 
(139) and the greater GH secretory capacity and sensitivity to GHRH in the 
former (139-141). Furthermore the sexual dimorphism in GH secretion is de-
termined by the complex interactions between GHRH and SRIF. The data could 
be put together by hypothesizing that in male rats, GHRH and SRIF are epi-
sodically released at 3 to 3.5 h intervals, with maximal GHRH secretion 
during GH peaks, while SRIF release is highest during GH troughs. In 
female rats. GHRH and SRIF secretion are more constant (97,142). Shulman 
et al.(143) reported that high doses of estrogens (5 and 50 nq) inhibited 
the GH secretory response to GHRH in castrated adult female rats in vivo 
and decreased Sm-C levels, whereas low doses (0.05 and 0.5 ug) increased 
Sm-C concentrations without altering GH responsiveness to GHRH. In vitro, 
Fukata and Martin (144) could not demonstrate an influence of testoster-
one, dihydrotestosterone and 17p-estradiol on GHRH-induced GH release in 
rat anterior pituitary cells. 
1.4.3 Continuous versus intermittent exposure to GHRH 
Wehrenberg et al.(145) demonstrated that continuous infusion of a large 
dose of GHRH to unanaesthetized rats increased plasma GH levels for sever-
al hours. This increase was followed by a progressive decline in GH 
despite continuation of the infusion. The counterregulatory effects of 
SRIF were eliminated bv pretreating the rats with an antiserum raised 
against SRIF. After 24 hours of GHRH infusion the rats received a bolus 
injection of GHRH. At this time, when 80% of the pituitary GH stores were 
depleted, the acute bolus injection of GHRH proved to be less effective in 
releasing GH than in control rats. In another study male rats, not pre-
treated with anti-SRIF, were exposed to a continuous infusion of a high 
dose GHRH for 8 or 31 hour (146). It appeared that the pulsatile secretion 
of GH in these animals was preserved. With this treatment the frequency of 
GH pulses was not altered, peak GH levels, however, were increased. The 
author explained the seemingly conflicting data by claiming that hypothal-
amic SRIF must be responsible for the intermittent secretion of GH during 
a continuous infusion of GHRH. Furthermore this author suggests that some 
desensitization or down-regulation of GHRH receptors or depletion of a 
readily releasable GH pool must have occurred, as the mean GH levels 
during the 8-hour infusion were higher than during the 31-hour infusion of 
GHRH. The same explanation - desensitization and/or depletion of readily 
releasable GH pools - can be given for the observed decrease in GH re-
sponsiveness to a bolus injection of GHRH after continuous infusion of 
GHRH (145). 
Intermittent administration of GHRH to rats enhances the GH response to 
GHRH (147). It has also been reported that pulsatile but not continuous 
infusion of GHRH enhances the pituitary GH content and growth in male rats 
with induced GHRH deficiency and in normal female rats (148). There is no 
ready explanation for the observed differences in GH secretion between in-
termittent and continuous administration of GHRH. It could be attributed 
to differences in the GH synthesis/release ratio or to different levels of 
GHRH-receptor down-requlation by the respective modes of administration of 
GHRH. Thus, in vivo, no final proof for the occurrence of GHRH desensi-
tization has been given. 
In this context it seems appropriate to discuss also the in vitro data 
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of the surmised GHRH down-requlation. Chronic exposure of cultured rat an­
terior pituitary cells to GHRH causes partial loss of GH responsiveness to 
GHRH (149). Seiffert et al.(150) demonstrated that pretreatment of rat an­
terior pituitary cells with GHRH leads to a down-requlation of the GHRH 
receptor, as the binding capacity of the GHRH receptor for GHRH was 
reduced with 40 to 70% without affecting the affinity for GHRH. Other 
authors, however, found no evidence of desensitization (151). Evidence in 
favour of down-regulation of GHRH in vitro was given by Simard and Labrie 
(152) and by Ceda and Hoffman (153). The precise mechanisms underlying the 
in vivo and in vitro observed desensitization, however, need to be clari­
fied. Very recently it was shown that SRIF co-incubation partially preven­
ted the down-regulation of GHRH receptors of rat anterior pituitary cells 
in culture pretreated with GHRH (154). 
1.4.4 Interaction of GHRH with biological substances and pharmacological 
agents 
Before the structure of GHRH was unraveled. Eden et al.(155) reported that 
Clonidine, an α-agonist, stimulates GH release in adult male rats probably 
by enhancing the GHRH secretion, not by inhibition of the somatostatin 
release, as Clonidine was still able to release GH when the animals were 
pretreated with anti-SRIF. These results were later confirmed by other 
authors (156-158). 
In adult male rats pretreatment with the cholinergic antagonist piren-
zepine and atropine significantly reduced the rise in GH induced by GHRH 
whereas pretreatment with the cholinergic agonist pilocarpine potentiated 
it (159). In vitro no effect of atropine or pilocarpine on GHRH-induced GH 
secretion was observed (159). Kakucska and Makara (160) found indirect 
evidence for a stimulatory role of acetylcholine on GHRH release by infu­
sion of acetylcholine into the third ventricle of rats, in which somato-
statinergic innervation of the median eminence was surgically cut off. In 
control rats, however, acetylcholine had no such an effect. 
There is also evidence that γ-aminobutyric acid (GABA) has a role in se­
cretion of GH, as icv injection of GABA increases plasma GH in conscious 
freely moving rats (161). Pretreatment of the rats with an antiserum 
raised against GHRH abolished GH release by GABA, indicating that GABA 
acts via GHRH. Fiók et al.(162), however, adduced evidence for an inhibi-
tory influence of GABA activity on the secretion of GHRH. 
Opioid peptides induce GH secretion by stimulating GHRH release (163). 
A similar conclusion was reached by Wehrenberg et al.(164). 
Also the GH secretion induced by serotoninergic mechanisms in the rat 
is - at least in part - mediated by GHRH (165). 
Hyperglycemia has been reported not to influence the GH release induced 
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by GHRH in anaesthetized rats (166). Locateli! et al.(167) described the 
effect of GHRH on GH secretion in male rats with diabetes induced by 
streptozotocin. They found increased pituitary GH responsiveness to GHRH 
in this model of diabetes. No ready explanation was given by the authors 
for this remarkable findinq (cf. paragraph 1.6.4.). Infusion of free fatty 
acids significantly blunted the GH release after GHRH, probably by in­
creasing SRIF secretion (166). 
The influence of thyroid hormones on GH secretion has been studied in 
thyroidectomized rats. GH secretion, pituitary content of GH and GH re­
sponsiveness to GHRH are significantly diminished in thyroidectomized rats 
(168). Hypothalamic GHRH content was also reduced. Cultured pituitary 
cells of thyroidectomized rats exhibited reduced GHRH sensitivity while 
the suopressive effects of SRIF on GH secretion were increased (168). Thy­
roxine replacement completely restored hypothalamic GHRH content and spon­
taneous GH secretion, whereas pituitary GH content and sensitivity to 
GHRH and SRIF in vitro were only partially restored. A similar conclusion 
was reached by Root et al.(169). These authors also studied the effect of 
short term administration of large amounts of thyroxine to rats on GH re­
sponsiveness to GHRH in vivo. They found no difference in GH response as 
compared to controls (169). 
Very recently Tannenbaum (170) reported that glucocorticoids ootentiate 
GH responsiveness to GHRH in vivo in rats during peak but not during 
trough periods of the GH rhythm. This contrasts with studies in patients 
with Cushing's disease, in whom the GH response to GHRH is blunted or even 
deleted (Chapter 3). 
From data mentioned above it ensues that GHRH secretion is influenced 
by α-adrenergic, cholinergic, serotomnergic, GABA-ergic and opioid 
factors and by glucocorticoids. Furthermore thyroid hormones are necessary 
for full activity of GHRH. Recently it was also demonstrated that GHRH 
produced a significant decrease in melatonin levels in pentobarbital an­
aesthetized adult male rats (171). On the other hand melatonin pretreat­
ment blunted the GH response to GHRH. Thus an inverse relationship exists 
between GH and melatonin. A similar reciprocal relation has been reported 
for GH and calcitonin (CT) (172). These authors demonstrated that the sup­
pression of GH levels found after icv injection of CT in rats could not be 
restored by pretreating the animals with anti-SRIF. GHRH imection one 
hour after icv CT failed to stimulate GH levels. 
1.4.5 Other biological effects of GHRH 
Vaccarino et al.(173) icv administered rat GHRH or human GHRH to fasted 
c.q. hungry rats and observed an increase in food intake as compared to 
vehicle injection. Peripheral injection of GHRH had no effect on food 
25 
intake, suggesting a centrally mediated effect of GHRH on eating behav­
iour. Imaki et al.(174), however, reported the opposite after icv iniec-
tion of GHRH to rats, i.e. a suppression of starvation induced feeding. 
Ehlers et al. (175) studied the effects of icv GHRH on electroencephalo-
graphic (EEG) and behavioral signs of sleep and wakefulness in adult male 
rats. An increase in slow wave sleep and corresponding EEG changes was re­
ported after icv GHRH. 
Clark and Robinson (148) demonstrated increased pituitary GH content and 
corresponding accelerated growth in female rats by long-term pulsatile in­
fusions of the active core of human GHRH (GHRH(i_29)NH2). Continuous 
infusion of GHRH, however, had no effect on growth and pituitary GH 
content. An indirect way of assessing the role of GHRH in the regulation 
of growth was reported by Hammer et al.(176). These authors could produce 
a strain of mice, containing in their genome the coding region of the 
human GHRH gene. Expression of this gene in the animals resulted in meas­
urable levels of GHRH and increased the concentrations of mouse growth 
hormone, which in turn accelerated growth rates relative to those in 
control mice. 
Accary et al.(177) described an extrapituitary effect of GHRH by demon­
strating an increased gastrin secretion after subcutaneous administration 
of the peptide. Hermansen et al.(120,121) reported dose dependent GHRH-me-
diated increases of insulin, glucagon and somatostatin from the isolated 
dog pancreas. A large dose of GHRH was able to stimulate exocrine pancrea­
tic secretion of the rat in vivo (178). Twice daily subcutaneous injec­
tions of rat GHRH to 24-day-old rats for 14 days increased gastric fundus 
weight concomitantly with DNA, RNA and protein contents, producing hyper­
plasia and hypertrophy within this gland (179). 
1.5 STUDIES WITH GHRH IN HEALTHY SUBJECTS 
1.5.1 Studies in normal men and women 
The first clinical study with GHRH in healthy volunteers was reported by 
Thorner et al.(180). Six normal young men received an iv bolus injection 
of GHRHi.iio (1 μοΑς) or placebo. All subjects had an increase in serum GH 
levels, whereas the concentrations of the other anterior pituitary 
hormones and the gastro-intestinal hormones did not change. There was a 
great variability in the GH responses. Dose-response relationships of GHRH 
were studied by Vance et al.(181). GHRH doses of 0.1, 0.33, 1.0, 3.3 and 
10 цд/кд body weight were given to 12 normal men. No relationship was 
found between the dose and the maximal GH answer. The two higher doses of 
GHRH, however, resulted in a more prolonged and in a biphasic pattern of 
GH release. Peak GH levels were reached within 30-60 minutes after GHRH. 
Again there was a great inter-subject variability. The only side effect 
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was a transient facial flushing. A dose of 1 μρ/Ι·^ GHRHi.^i» was reported 
by Gelato et al. to be maximally effective in releasing GH in normal young 
adult men and women (182). A similar conclusion was reached by Losa et 
al. reporting 50 μη GHRHi.m, or 1 цд/кд to be most effective (183). 
Sassolas et al.(184) concluded that 80 μg GHRHi.iti, is the optimal dose for 
GH release. In contrast to the data in rats, Gelato et al. (182) did not 
find a statistically significant difference in GH responsiveness to GHRH 
between men and women. We, however, found significantly higher GH respon­
ses to GHRH in young adult men than in young adult women (Chapter 2). In 
Chapters 2.1 and 2.2 and in the final section of this thesis we further 
comment these findings. Two studies have been performed addressing the 
guestion whether GH responsiveness to GHRH changes during the menstrual 
cycle Evans et al.(185) denied such influence, Egli et al.(186), however, 
reported that the GH response to GHRH was the lowest during the luteal 
phase of the menstrual cycle. 
1.5.2 Kinetic aspects of GHRH in normal subjects 
Frohman et al. calculated the metabolic clearance rate (MCR) and the 
plasma disappearance rate (tj) of GHRH^^g after a bolus iniection and 
continuous infusion with different doses of the peptide (187) GHRH levels 
were measured by radio-immunoassay. The MCR was 194 ± 17.5 liter/m? per 
day. The disappearance rate after the bolus injection could be divided in 
two linear phases- an eguil ibration phase (7.6 ± 1.2 m m ) and a subse-
guent elimination phase (51.8 + 5.4 m m ) . The latter value was not differ­
ent from that obtained after terminating the continuous infusion. A simi­
lar conclusion was reached by Sassolas et al. for GHRHj.t^, reporting a 
11 of the distribution phase of 6.8 ± 0.4 m m and of the elimination phase 
of 93 ± 2.98 m m (184). The reported tj of GHRH is much longer than for 
other hypothalamic hormones (TRH, LHRH, SRIF) which have tí values ranging 
from 1 to 10 m m (188-190). Very recently Frohman et al.(191) by means of 
high performance liquid chromatography (HPLC) demonstrated that GHRHi_i»i» 
is very rapidly enzymatically degradated to a biologically inactive 
cleaving product (GHRH^.i^)NH2), which still is measured in the radio-im-
munoassay and could account for the spuriously long tj of the elimination 
phase earlier mentioned. This author concluded that the real t \ of 
GHRHj.i,,, is 6.8 m m , well in line with the t 1 of other hypothalamic 
hormones. Until now, no such study has been published for GHRHJ^.^Q. 
1.5.3 Influence of age on GH responsiveness to GHRH 
There is controversy in literature regarding the influence of age on the 
GH response to GHRH in men. Shibasaki et al.(192) reported a lower or even 
27 
complete absence of the GH response after GHRHi.^ in males over forty 
years old Pavlow et al.(193), however, did not find aqe-dependent altera­
tions in the maqmtude of GH responses to GHRH in healthy aqinq American 
men. It is not known whether dietary, cultural or other differences 
between American and Japanese men may account for the observed discrepan­
cies As far as the prepubertal and pubertal aqe is concerned Schnock et 
al (194) and van Vliet et al (195) found that GH responsiveness to GHRH 
did not differ from that in adults. The interpretation of the preliminary 
results at younq aqe is seriously hampered by the low numbers of 
younqsters in the successive studies We further comment on this aspect of 
GH responsiveness to GHRH in Chapter 2.2 and in the final comments 
1.5 4 Hypothalamic hormones, neurotransmitters, druqs and other agents 
which interact with GH responsiveness to GHRH 
Under conditions of hyperglycemia GH responsiveness to GHRH in normal 
subjects is significantly diminished in comparison with the euqlycemic 
state (203-205). Raised levels of free fatty acids (FFA) have a similar 
inhibitory effect on GH responsiveness to GHRH (206). These effects of FFA 
and qlucose are probably mediated by SRIF. Therefore, it has to be empha­
sized that studies on interaction of GH responsiveness to GHRH by other 
agents, neurotransmitters, other releasing hormones, drugs, etc. have to 
be performed in the fastinq state. 
Sartorio et al.(207) administered to 10 normal men placebo, TRH, GHRH 
and simultaneously GHRH plus TRH on four separate occasions. TRH did 
neither stimulate GH release nor did it augment the GH response to the 
combined test. When, however, GHRH was given as 3 consecutive boli at 2-
hour intervals (at a dose of 25 μq) followed by a fourth iniection of 
either GHRH (25 μς), TRH (200 μς) or placebo it appeared that TRH caused a 
small but s^mficant increase of the GH response as compared to the pla­
cebo. The authors suçgest that GHRH exposure might contribute to the GH-
releasing activity of TRH in some pathological conditions, showing a para-
doxical GH response to TRH. 
In a number of studies combinations of hypothalamic releasing hormones 
(TRH, CRF, LHRH and GHRH) have been administered as bolus iniections. 
Sheldon et al.(208) found no apparent inhibition or synergism of the re-
leasing hormones when they were given as a bolus compared to the responses 
after testing each releasing hormone separately. In contrast Looy et al 
(209), with a similar study protocol found potentiation of the TSH 
response. These latter results were confirmed by Cohen et al.(210). 
Combined administration of GHRH and insulin elicited a significantly 
higher GH response than either agent alone, supporting the hypothesis that 
GHRH and insul in-induced hypoglycemia release GH via different pathways 
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which are at least in part additive. 
There is ample evidence that the cholinergic system is involved in GH 
secretion as blockade of GHRH-induced GH release is seen after pretreat-
ment of normal men with cholinerqic antagonists such as atropine or piren-
zipine (211-214). 
Dopaminergic and a-adrenergic blockade had no influence on the GH 
response to GHRH (213). Chibara et al.(200), however, found that L-Dopa 
stimulates GHRH release in humans. These data were confirmed and extended 
by Vance et al.(215) suggesting that dopamine infusion inhibits SRIF se-
cretion, which allows GHRH to have a greater stimulatory effect on GH se-
cretion. In contrast, Giusti et al.(216) reported that the simultaneous 
administration of GHRH and domperidone, an anti-dopaminergic drug, resul-
ted in a more marked GH increase than GHRH alone, suggesting that the do-
paminergic tone may play an inhibitory role on GH secretion in man. The 
8-adrenergic blocker propranolol enhances GH-secretion in response to GHRH 
in prepubertal children (217). Probably this effect is mediated by inhibi-
tion of SRIF-release. 
In addition to the complex network of neurotransmitters and neuropep-
tides involved in the control of GH secretion, the pineal gland plays a 
major role in the regulation of GH in rodents (218). In humans oral mela-
tonin administration has been demonstrated to enhance the GH response to 
GHRH probably at the hypothalamic level by modulating GHRH or SRIF (218). 
1.5.5 Feedback mechanisms 
Rosenthal et al.(219) studied the effect of pretreatinq six normal men 
with twice daily GH injections for five days on GH secretion induced by 
GHRH. After such treatment, a blunted response to GHRH was seen. In theory 
the reason for this blunting might be i) increased somatomedin levels, 
ii) increased somatostatin secretion or ili) a direct effect of GH on the 
somatotrophs. Very recently Ross et al. (220) demonstrated that an iv in-
jection of GH 3 hours prior to the GHRH test completely abolished the GH 
response to GHRH. This effect could not be mediated by somatomedin-C, as 
this growth factor was still not raised by the prior GH administration. 
Ross et al.(220) could not precisely delineate whether increased SRIF se-
cretion or a direct effect of GH on the somatotrophs must be held respon-
sible for the attenuated GH response to GHRH. These authors adduced some 
evidence that increased SRIF secretion as a cause was less likely as they 
did not observe such attenuation in children with extensive hypothalamic 
lesions and panhypopituitarism in whom they considered such increased SRIF 
secretion unlikely. Thus GH may regulate its own secretion independent of 
changes in Sm-C and SRIF. Very recently Hanew et al.(221) reported similar 
blunting of the GH response to GHRH in GH-deficient children with presumed 
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hypothalamic GHRH-deficiency qiven biosynthetic GH for 2 days. The authors 
therefrom deduced that GH blunts the GH response to GHRH through a direct 
effect on the somatotroph. 
1.5.6 Continuous versus pulsatile administration of GHRH to normal 
subjects 
Gelato et al.(222) administered a continuous infusion of 6НРНі_цц (1 μς/ 
kq/hr for 4 hours) to 15 young adult men. Peak GH levels were reached 
within 60-90 min and then fell progressively, but did not return to 
baseline levels. A GHRH bolus injection at the end of the continuous in­
fusion showed a markedly attenuated GH response compared to the response 
after saline infusion. Like in rats this effect could be mediated by re­
ceptor desensitization or down-regulation, depletion of a readily releas­
abie GH pool, a combination of both or by the counter regulatory rise in 
SRIF secretion. Vance et al.(223) demonstrated that continuous GHRH infu­
sion during 6 and 24 hour resulted in augmentation of pulsatile GH secre­
tion. A supramaximal bolus injection of GHRH at the end of the infusion, 
however, resulted in an attenuated GH response as compared to placebo. The 
data were interpreted to mean that there is a limited readily releasabie 
GH pool and/or partial refractoriness of the somatotroph after prolonged 
exposure to GHRH. To further resolve this issue the same authors adminis­
tered to normal subjects GHRH in a continuous infusion during 6 hours, and 
5,5 hour after starting the infusion either a supramaximal GHRH bolus in­
jection or insulin was given (224). The greater GH secretion was seen with 
the combination GHRH infusion plus insulin-induced hypoglycemia. The GHRH 
bolus injection after continuous infusion of GHRH resulted in a diminished 
GH response. The data suggest that the somatotrophs become partially re­
fractory to GHRH after prolonged exposure to GHRH, probably by partial de­
sensitization or down-regulation. Evidently, pituitary GH stores are not 
depleted as the somatotrophs are still resoonsive to insulin-induced hyoo-
qlycemia. A similar conclusion was reached by other authors (225). 
Decreased GH responsiveness to GHRH also has been reported to occur in 
normal subjects after repetitive or pulsatile administration of the re­
leasing hormone (226,227). Restoration of the GH response could be accom­
plished by pretreating the subjects with pyridostigmine an inhibitor of 
Cholinesterase and thus a cholinergic agonist (227). Therefrom the authors 
deduced that the decrease in GH responsiveness after pulsatile injection 
of GHRH may be due to inhibition of the SRIF release induced by the first 
GHRH pulse. 
So far, the limited experience with continuous and pulsatile adminis­
tration of GHRH in healthy subjects does not allow to draw firm conclu­
sions on the mechanism of decreased GH responsiveness to GHRH. Each of the 
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three mechanisms delineated in paragraph 1 5.5. must be kept in mind when 
interpreting GHRH studies either of the continuous or intermittent type. 
It does seem highly improbable that depletion of pituitary GH stores might 
be held responsible for the described phenomena. 
1.5.7 Plasma GHRH levels in normal subjects 
Penny et al.(196) developed an assay for measurement of GHRH-immunoreac-
tivity in peripheral plasma. The antiserum used equally binds СНРН^цц, 
GHRHi_m), and GHRH1.37. Normal levels were reported to vary from < 10 to 
60 ng/1. These authors subsequently reported that immunoreactive GHRH 
levels in normal subiects increased after ingestion of a mixed breakfast, 
suggesting a peripheral source of GHRH (50,197). Very recently they demon­
strated an increase in circulating GHRH levels after oral fat or protein, 
but not after oral carbohydrate, insulin-induced hypoglycemia or iv argi­
nine (198). No correlation was found between spontaneous pulses of GH se­
cretion and plasma GHRH levels, further suggesting the release of GHRH 
from a source outside the hypothalamus Knip et al.(199), however, demon­
strated that in normal children GHRH peaks preceded or coincided with the 
increase in GH secretion in 65% of the sleep related GH increments. 
Chihara et al.(200) measured immunoreactive GHRH levels using an anti­
serum specifically directed against GHRHj.^. Plasma GHRH levels ranged 
from 2.8 - 18 1 ng/1 and increased after administration of oral L-Dooa. In 
patients with hypothalamic lesions circulating GHRH levels were similar to 
those of normal subjects, indicating that the source of plasma GHRH is not 
solely the hypothalamus (50,201). Andhya et al. (112) reported plasma 
GHRH,^ levels in normal males, 21 - 39 yrs, ranging from 6.3 to 14 ng/1. 
Penny et al.(202) studied the distribution of the different molecular 
forms of GHRH in plasma by using HPLC. GHRH1.i4o was shown to be the pre­
dominant circulating molecular form, while GHRH^m, showed the greatest 
increase after a mixed meal. Furthermore, GHRH^ay and a yet unidentified 
factor, probably GHRHi.i^ were found. 
1.6 CLINICAL STUDIES WITH GHRH IN PATHOLOGICAL CONDITIONS EXCEPT ACRO­
MEGALY 
1.6.1 GHRH testing in patients with GH-deficiency 
Borges et al.(228) administered 10 μq/kq GHRH1.4i1 to 12 adult patients who 
presented in childhood with GH-deficiency. Eiqht of the 12 GH-deficient 
patients showed no significant response, while in the remaimnq 4 patients 
the mean peak GH level after GHRH was 3.9 ± 1.2 (S.D.) nq/ml. Sm-C levels 
increased in 8 of 10 patients with GH-def iciency 24 hour after GHRH іщес-
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tion. The authors concluded that at least some patients with GH-deficiency 
may have hypothalamic GHRH-deficiency. Schriock et al.(194) reported a 
negative correlation between chronological aqe and peak GH responses to 
GHRH in children and adolescents with severe GH deficiency Furthermore 
peak GH levels after GHRH were reached earlier in GH-deficient children 
and adolescents than in GH-deficient adults. Pintor et al.(229) observed a 
definite increase (> 5 ng/ml) in plasma GH levels in 11 out of 14 children 
with isolated GH-def iciency in response to GHRHi_4o (1 μς/Ι<ς). Gelato et 
al (230) reached a similar result, demonstrating a GH response to GHRHi_i»4 
in 17 out of 32 children with GH-deficiency (22 patients with idiopathic 
and 10 patients with organic GH-deficiency), which overlapped the response 
in age-matched normal children. Takano et al.(231,232) reported that 40% 
of patients with isolated GH-deficiency showed a GH response to GHRH^^i, 
(1 or 2 цд/кд) greater than 5 nq/ml Pertzelan et al.(233) studied 52 
patients with different forms of GH-deficiency (isolated, idiopathic mul­
tiple pituitary hormone deficiencies and organic multiple hormone defi­
ciencies). In the group with idiopathic GH-deficiency 50% had a GH 
response to GHRHi _i»u (> 3 ng/ml). In the group with organic GH-def iciency 
only 4 out of 14 patients showed a GH response. Sixty percent of the 
children with isolated GH-deficiency responded to GHRH. Pintor et al.(234) 
observed peak GH levels ranging from 6 to 43 ng/ml in 7 subiects with idi­
opathic GH-deficiency. Thus, the percentage of patients with GH responses 
to GHRH exceeding 5 ng/ml varies in literature from 20 to 100% with an 
overall mean value of 50% (97). In the majority of patients a subnormal GH 
response is present. All these data point to a defect in GHRH secretion 
in most patients with GH-deficiency. It has been suggested that the longer 
the duration of endogenous GHRH deficiency, the less the GH response to 
exogenous GHRH (194). One can speculate that a somatotroph, which is unre­
sponsive to an acute challenge of GHRH, could be stimulated by repetitive 
administration of GHRH in analogy to LHRH priming in hypothalamic hypogo­
nadism. GHRH priming by 1 μg/kq given once daily subcutaneousl ν for 5 days 
improved pituitary GH responsiveness in 11 out of 19 patients with GH-de-
ficiency (235). Before priming only 7 out of 38 patients showed a GH 
response (> 8 ng/ml) after the first GHRH challenge. Other authors, 
however, reported a restoration of GH responsiveness after repetitive ad­
ministration of GHRH in only 2 out of 8 children with idiopathic GH-defi-
ciency, who did not react to the first GHRH bolus injection (236). Borges 
et al.(237) administered GHRH every 3 hours for 5 days at a dose of 0.33 
цд/кд to six adult patients who presented in childhood with idiopathic GH-
deficiency. Before priming GH levels rose after first GHRH challenge in 
only 2 patients, whereas after GHRH priming GH responsiveness was restored 
in 3 patients. It has to be noted that in this study an increase of more 
than 1 ng/ml was already defined as a "response". All these results in-
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dicate that the somatotroph can be primed with repetitive administration 
of GHRH at least in some patients with GH deficiency. 
1.6.2 Therapeutic use of GHRH in children with GH-deficiency 
Thorner et al.(238) were the first to report acceleration of linear qrowth 
in 2 children with GH-deficiency by usinq GHRHj.^o qiven subcutaneoulsy 
every 3 hours for 28 weeks in a dose of 1 or 3 μαΑα. Short term (9-12 
days) iv infusion of GHRHi^ (1 μq/kq every 3 hour) resulted in an increase 
in lower leq qrowth velocity as measured by Valk's device (239) in 4 out 
of 7 children with GH-deficiency as compared to saline infusion (240). Si­
milar results were reached by Smith et al.(241) administering GHRHJ.^Q 
subcutaneously at mqht for four pulses at a dose of 1 μq/kq or ? μq/kq 
over 9 months to 5 GH-deficient children. Three patients responded to the 
treatment with an increase of growth velocity. One patient showed a modest 
increase in qrowth velocity with the higher dose. One subject did not 
react to the treatment. The qroup of Besser treated 18 prepubertal GH-de-
ficient children with twice daily subcutaneous injections of GHRH1.29 
(242). Twelve of the children showed a good response to GHRH. The re-
maininq 6 had a modest increase in heiqht velocity. Further studies are 
needed to establish the optimum dose and mode of administration of GHRH in 
GH deficient children. The results of the "GRF European Multicenter Study" 
have to be awaited. 
1.6.3 GHRH testing in short children 
Takano et al.(231,232) administered an acute bolus injection (iv) of 1 and 
2 μ ς / ^ body weight to 139 normal children with short stature (height 
below 2 S.D. of the mean height of Japanese boys and girls). Peak GH 
levels after 1 and 2 μg/kg GHRH were reached at 15 and 30 minutes respec­
tively (32 ± 4 and 32 + 2 ng/ml). Peak GH levels were greater after GHRH 
than after insulin-induced hypoqlycemia. Similar results were reported by 
other authors (195,233). Peak GH levels achieved after GHRH were not dif­
ferent from those in normal adults. However, acute GHRH testing cannot 
exclude disturbances in GH secretion in short children, as peak GH levels 
after GHRH testing poorly correlated with integrated 24 h mean GH levels 
in GH-deficient and short normal children and in children with growth 
hormone neurosecretory dysfunction (243). The latter group was defined by 
a mean serum 24 h GH concentration below 3 nq/ml and a normal response (> 
10 ng/ml) to classical GH provocative tests (243,244). Therefore the GHRH 
test cannot replace the classical GH provocative tests in the diagnostic 
work-up of children with short stature or delay in qrowth. 
Pretreatment of normal and short normal children with propranolol aug-
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mented the GHRH-induced GH release in all subjects (217). As mentioned 
earlier (par. 1.5.4.) this effect miqht be mediated by inhibition of SRIF 
secretion. In children with constitutional qrowth delay oxandrolone, an 
anabolic steroid, enhanced the GH secretion in response to GHRH (245). 
1.6.4 Use of GHRH in patients with diabetes mellitus 
Press et al.(246) administered 0.3 μq/kq GHRHi.i»o t o 12 poorly controlled 
type 1 diabetics and healthy control subjects. Although basal GH levels 
were elevated in the diabetics (7.1 ± 1.8 nq/ml), peak GH responses after 
GHRH were similar in diabetics and normal subiects (30 + 5 nq/ml). A group 
of well controlled type 1 diabetics (with insulin pump) showed normal 
basal GH levels and peak GH responses not different from the other 2 
grouos. The normal subjects had a marked suppression of the response to 
GHRH after glucose-loading. Thus, insufficient GH suppression of the pitu­
itary in response to hyperqlycemia exists in poorly controlled type 1 dia­
betes, thereby probably contributinq to this poor metabolic control. Simi­
lar results were reported by Sharp et al.(247). Kaneko et al.(248) demon­
strated that GH responses to GHRH were more pronounced in type 1 diabetics 
with retinopathy than in diabetics without this complication. The 2 aroups 
did not differ in biochemical characteristics. The authors have no expla­
nation for their findings. 
1.6.5 Studies with GHRH in morbid obesity 
Administration of GHRHi_iio (1 μςΑς) to 10 morbidly obese patients resul­
ted in markedly impaired GH responses as compared to normal weight 
controls (249). After achieving a normal weight, GH responsiveness to GHRH 
oartially restored. A negative correlation was found between the GH 
response to GHRH and the percentage of ideal body weight. The reversibili­
ty of the defect in GH secretion suggests that it is a consequence rather 
than a cause of obesity. Similar results were reported by other authors 
(250-253). 
1.6.6 Influence of thyroid status on GH responsiveness to GHRH 
In hypothyroidism a significant reduction in peak GH response and integra­
ted GH levels in response to GHRH is observed, compared to those in the 
euthyroid state (254). These results are in agreement with in vitro and in 
vivo observations in animals (see before) and were confirmed by other 
authors (255). However, in 3 out of 14 patients GH responsiveness to GHRH 
only partially restored after 6 weeks of thyroxine replacement, despite 
reduction of TSH levels. Further studies are needed to more precisely de-
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lineate when GH responsiveness to GHRH in hypothyroidism after starting 
th/roxine replacement is restored. 
1.7 CLINICAL STUDIES WITH GHRH IN PATIENTS WITH ACROMEGALY 
1 7 1 Pathophysiology of acromegaly 
l> first documented case of acromeqaly probably was the Egyptian pharao 
Akhn i'-on (256). The king had prognathism, enlargement of the nose and 
upper iaw and thickening of the face and lips, but normal sized hands and 
feet. Therefore the diagnosis of acromegaly is not entirely certain. 
Pierre Marie (257) was the first to describe the clinical features of 
acromegaly. Later it was found that the disease was associated with an en-
largement of the pituitary (258). Cushing (259) was one of the first to 
demonstrate that the features of acromegaly were reversible after pitui-
tary surgery (using the transsphenoidal approach). A role of a growth pro-
moting hormone produced by the pituitary was postulated since 1921 (260) 
as causative in the etiology of acromegaly. Confirmation of this hypothe-
sis was possible after assays of GH became available (261). Pituitary 
overproduction of GH could now be established as the cause of acromegaly. 
Pituitary adenomas are present in 15 to 25% of all subjects at autopsy 
(262), \t of which secreted GH (256). 
Very recently a new pathological classification of pituitary adenomas 
has been introduced by Melmed et al.(256,263). Tumors are classified ac-
cording to their GH content, their ultrastructural features and cytoqene-
sis. These authors classified the pituitary of patients with acromegaly in 
9 different categories. 
- The pure GH producing adenomas may either be densely granulated or 
sparsely granulated. The densely granulated adenomas contain large 
amounts of stored GH and grow slowly and have an insidious clinical 
course. They occur in 30% of acromegaly. 
- In contrast the sparsely granulated adenomas grow fast, locally invasive 
and often grow suprasellarly. Thirty procent of all GH producing adeno-
mas belong to this category. 
- Adenomas with a mixture of GH-producing and prolactin-producing cells 
compromise 25% of all adenomas. Usually they are associated with mild to 
severe acromegaly and elevated prolactin levels. 
- Acidophilic stem cell adenomas (10%) are composed of immature cells, 
which are believed to be the progenitor cells of both the GH and prolac-
tin producing cell. They grow rapidly and often locally invasive. Only 
one cell type is found which produces both GH and prolactin. 
- The mammasomatotroph adenomas (4%) are composed of one cell type, 
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supposed to be a more mature variant of the acidophil stem cell The 
same cell can simultaneously contain GH and prolactin The clinical 
course is usually mi Id. 
- The unclassified plunhormonal adenomas are also rare {6%) They are 
monomorph or plunmorph and can produce besides GH and prolactin other 
pituitary hormones predominantly TSH and ACTH. Accordingly the clinical 
spectrum of these adenomas is variable. 
- GH cell carcinomas are extremely rare They can give distant metasta-
ses. 
- GH cell hyperplasia is a morphological difficult diagnosis, which is 
often associated with ectopic or eutopic GHRH producing tumors The 
latter are hypothalamic tumors, such as hamartomas and qangl locytomas 
(54). By immunocytochemical staining GHRH has been localized in these 
tumors (54). The excessive GHRH production causes GH-cell hyperplasia. 
Fctopic, extrapituitary oroduction of GHRH by carcinoid tumors, lung 
adenocarcinomas and other tumors has been discussed in the first section 
of this introduction. 
- Rarely, no pituitary abnormality at all is found in patients with acro-
megaly. 
Until now the pathogenesis of acromegaly remains obscure Hypotheses have 
been put forward which state that the pituitary adenoma originates either 
from a primary pituitary defect of GH producing cells or from a hypothal-
amic dysregulation (256,264,265). According to the latter hyoothesis over-
production of GH can result from GHRH excess or defective secretion of 
SRIF. When endogenous SRIF deficiency is the cause of acromegaly one might 
expect that the GH overproduction can be corrected by exogenous SRIF infu-
sion. Endogenous GHRH excess, with normal or elevated endogenous SRIF se-
cretion should theoretically be less sensitive to exogenous SRIF infu-
sion. Hanew et al.(266) demonstrated that the higher SRIF responsiveness 
was found in those acromegalics whose GH levels anomalously rose after TRH 
or LHRH administration, not, however, in TRH or LHRH non-responders. Simi-
lar results were reported by Pieters et al.(265) showing that the subgroup 
of acromegalics, whose GH levels normalized after SRIF infusion, had a 
paradoxical GH increase after LHRH. These data and those of Hanew et al. 
(266) suggest that at least in some acromegalics endogenous SRIF deficien-
cy and/or SRIF resistance may contribute to the pathogenesis of the 
disease. We found a wide spectrum of sensitivity to the suppressive action 
of SRIF on basal and GHRH stimulated GH secretion in acromegalics. SRIF 
induced GH suppression was more pronounced in the patients with the lower 
basal GH levels, whereas inadequate suppression was observed in those with 
the highest levels (this thesis). Very recently Kelijman et al.(267) 
adduced similar evidence for this thesis, in studies both in vivo and in 
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vitro SRIF resistance thus may reflect an intrinsic abnormality of the 
neoplastic somatotroph 
Other factors which favour the hypothesis that acromeqaly is caused by 
a hypothalamic or central defect in GH modulation will be briefly 
discussed (256). The fact that sometimes a normal pituitary histoloqy is 
found in patients with acromeqaly (268,269) points to a hypothalamic or 
central oriqin After surqical removal of a GH secretinq adenoma, the GH 
responses to provocative stimuli often remain abnormal despite normali-
zation of basal GH levels (264). These data also suqqest that there is an 
abnormality in the control of GH requlation. As most acromeqalics respond 
to GHRH with a rise in GH secretion (81,82,270, this thesis. Chapter 4.4), 
the pituitary adenomas in these patients are not functiomnq completely 
autonomously. Older observations that the GH responses to GH-provocative 
stimuli, which act by central mechanisms (insulin, arqimne, exercise) are 
comparable in acromeqalics and normal subiects (271,272) also point to the 
persistence of hypothalamic control of GH secretion in acromeqalics. 
However, the fact that the suppression of GH secretion found in normal 
subjects after qlucose loadinq is usually absent in acromeqaly or that 
qlucose loadinq even qives rise to a paradoxical GH increase is also evi-
dence in favour of hypothalamic dysrequlation. The paradoxical decrease of 
GH secretion after dopaminerqic aqents (such as bromocriptine) in more 
than b0% of acromeqalics (273) in contrast to their GH-increasinq effect 
in normal subiects (215,274) also miqht reflect a disturbance in the in-
fluence of hypothalamic or higher structures on GH secretion in acromeqa-
ly. Another possibility, however, is a chanqe in the dopaminerqic recep-
tors on the adenomatous somatotrophs (264). Other authors suqqested a 
possible pathoqenetic role of an increased serotomnerqic tone in acro-
meqaly (275). The rare cases of GHRH secretinq hypothalamic hamartomas, as 
discussed previously, are a direct hypothalamic cause of acromeqaly. 
There is also, however, a lot of evidence suqqestinq that acromeqaly is a 
primarily pituitary disease. The findinq of normal pituitary tissue sur-
roundinq a GH-secretinq adenoma favours the concept that the adenoma is 
formed autonomously in the pituitary. The restoration of normal GH dynam-
ics followinq pituitary surqery for acromeqaly is said to be evidence in 
favour of a primary pituitary qenesis of acromeqaly (256). Persistence of 
abnormal GH responses to provocative stimuli (TRH or LHRH) after pituitary 
surqery can, however, also be interpreted as a permanent hypothalamic dys-
requlation in GH secretion (vide supra). Alternatively, residual adenoma-
tous tissues may be responsible for a persistent anomalous response. The 
fact that the abnormal and paradoxical GH responses to dopaminergic aqents 
and/or nonspecific releasing hormones are also found in cultured GH-secre-
tinq adenomas in vitro (276,277) lends support to the hypothesis of a pri-
37 
marily pituitary genesis of acromegaly. The abnormal GH responses to the 
fore-mentioned agents could be caused by the presence of receptors on the 
adenomatous tissues not expressed on normal somatotrophs. It is not clear 
whether these receptors are influenced or induced by hypothalamic factors, 
as might be the case in the paradoxical GH increments after TRH in various 
conditions as diabetes mellitus (278), anorexia nervosa (279), renal 
failure (280), chronic liver disease (281), primary hypothyroidism (282) 
and mental depression (283), clearly situations where no pituitary adenoma 
exists. 
Taken together there are arguments favouring a hypothalamic genesis of 
acromegaly, whereas other are more indicative of a pituitary origine of 
acromegaly. Combining the different hypotheses one could speculate that 
intrinsically abnormal somatotrophs in the pituitary could be transformed 
to autonomous adenomas under the influence of hypothalamic factors such as 
continuous stimulation by GHRH and/or diminished inhibition by SRIF (264). 
1.7.2 Studies with GHRH in acromegaly 
It was hoped that the availability of GHRH could afford new insights in 
the pathogenesis of acromegaly. Wood et al. (284) were among the first to 
administer a bolus injection of 100 μα G H R H ^ ^ to six acromegalics. The 
acromegalics could be divided in two groups, those with a GH response to 
GHRH not different from that in control subjects and whose GH levels sig­
nificantly suppressed after oral glucose, and those acromegalics with an 
exaggerated GH response to GHRH, whose GH levels did not suppress after 
oral glucose loading. Gelato et al. (285) reported a tendency for the GH 
response to GHRH to increase with increasing suppression to glucose, 
although the data lacked statistical significance. Losa et al.(286) did 
not find any correlation between the outcome of the GHRH test in acro­
megalics and other dynamic tests of GH secretion such as oral glucose 
loading. A number of authors (284-289) demonstrated a highly variable GH 
response to administration of an acute bolus iniection of GHRH to acro­
megalics, which partially overlapped the responses seen in normal 
subjects. In a study reported in this thesis Pieters et al. (Chapter 4.4) 
were the first to suggest that the large variability in the GH responses 
to GHRH was the consequence of the highly variable basal GH values, as 
they could calculate a highly significant close correlation between both. 
It has been suggested that GHRH does not stimulate GH release in acro­
megalics with the ectopic GHRH syndrome (53,287,290). However Barkan et 
al.(291) discussed an acromegalic patient with a GHRH producing carcinoid 
tumor who had a preserved acute GH response to exogenous GHRH. Therefore 
no pattern of GH secretion is diagnostic of acromegaly due to ectopic GHRH 
production (53). The only way to differentiate patients with acromegaly 
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due to ectopic GHRH production from acromegalics with a pituitary adenoma 
is by measuring plasma GHRH levels (196,292). Thorner et al.(292) measured 
plasma GHRH levels in 177 acromegalics. GHRH levels were maximally 62.5 
ng/1 in normal subjects and 82 nq/1 in the acromegalics. Thus there was a 
huge overlap in GHRH levels between normal subjects and patients with 
acromegaly. Three patients with known GHRH secreting tumors had GHRH 
levels, ranging from 2000 - 2440 nq/1. GHRH levels were measured using 
three different assays. Penny et al.(196) found immunoreactive GHRH levels 
in normal subjects ranging from < 10 to 60 ng/1, which completely 
overlapped the values found in 76 out of 80 acromeqalics. The remaining 4 
patients had values ranging from 92 to 25000 ng/1. The highest value was 
found in the only one patient with proven ectopic GHRH syndrome. 
Pieters et al. (Chapter 4.4) and Arosio et al.(293) investigated the 
effects of SRIF infusion on concomitant GHRH injection in patients with 
acromegaly. SRIF significantly suppressed GH levels in all patients and 
blunted the GH response to GHRH. The GH answer to GHRH was highly vari­
able. The authors suggested that the different GH responses to GHRH miqht 
reflect a different sensitivity of the adenomatous somatotrophs and a pos­
sible contribution of the normal somatotrophs to the GHRH-induced GH se­
cretion. No correlations were found between GH responsiveness to GHRH and 
the abnormal GH responses to TRH and dopamine infusion. 
Losa et al.(294) reported that GHRH induces prolactin secretion in acro­
megalics, but not in normal subjects. Most authors, however, do not give 
data on prolactin responsiveness to GHRH. 
Cozzi et al.(295) administered GHRH and TRH to 24 acromegalics before 
and during chronic bromocriptine (Br) treatment. Br did not alter GH re­
sponsiveness to GHRH, but reduced the GH response to TRH. It appeared that 
the initial GH response to GHRH was significantly lower in the Br nonre-
sponders (i.e. mean daily GH reduction during Br treatment less than 
50%). In contrast the GH response to TRH was most pronounced in the Br re-
sponders. From these data the authors suggested that in GH-secreting pitu­
itary adenomas, cells responsive to Br and TRH (lactotroph-like) and cells 
sensitive to GHRH (somatotroph-like) may coexist. Chiodini et al.(289) 
found an inverse correlation between the percentage of GH changes after 
GHRH and Br. No relationship was found between the GH responses to GHRH 
and to TRH. These data can be explained by a similar way of reasoning. 
Other authors, however, failed to find specific combinations of GH re­
sponses to GHRH, TRH, Br and LHRH (285,293,296,297). 
Losa et al.(298) administered a 50 μς bolus injection of GHRHi,,, to 9 
acromegalic patients, followed by a 2-hour infusion of GHRH (100 μ ς ^ ) , 
after which a second bolus injection of 50 μς GHRH was given and compared 
the results with those obtained in normal subjects. Normal subjects showed 
a steady decline of the initially increased GH levels, despite continua-
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tion of the GHRH infusion. In contrast, the GHRH-stimulated GH levels in 
the acromegalics did not decrease during the infusion. This difference 
could not be explained by differences in GHRH levels between the control 
subjects and the acromegalics. The authors hypothesized that the sustained 
elevation of GH levels in the acromegalics could be explained by a greater 
readily releasable GH pool and/or faster GH synthesis in the patients as 
compared to the controls. An alternative explanation might be that contin­
uous infusion of GHRH in normal subjects leads to desensitization (vide 
supra), which phenomenon is absent in acromegalics. The fact that in 
normal subjects GH responses to a GHRH bolus injection after continuous 
infusion of GHRH is inversely related to the amount of GH released during 
the infusion of GHRH (299) points to a limited pool of readily releasablp 
GH. A larger releasable GH pool in acromegalics is also compatible with 
the observation that GH responsiveness to GHRH in acromegalics is posi­
tively correlated with the basal GH level (286, Chapter 4.4). Shibasaki et 
al.(297) infused acromegalics and control subjects with 1 mg GHRH during 
150 minutes. At the end of the infusion a bolus injection of GHRH was 
given. The infusion of GHRH caused a sustained increase in GH levels both 
in the normal subjects and acromegalics. The subseauent bolus injection of 
GHRH at the end of the infusion, however, did not further increase GH 
levels in both groups. This latter observation is in agreement with the 
data of Losa et al.(298). The authors exolained the data by suggestina 
that desensitization occurs in normal subjects as well as in acromegalics 
Repetitive administration of GHRH (50 μς every 2 hours three time«; 
caused a blunting of the GH response after the second and third GHRH 
bolus in control subjects, but not in acromegalic patients (300). The 
larger readily releasable GH pool and/or faster GH turnover in the adenom­
atous somatotrophs was held resoonsible for the observed difference. A si­
milar study design was used by Spada et al.(301) to investigate whether 
desensitization occurs in acromegaly after continuous or repetitive admin­
istration of GHRH, in vivo and in vitro. In normal subiects a marked ele­
vation of GH levels was only observed after the first bolus GHRH, not 
after the second and third injection. In the acromegalics, however, the 
second and third imection of GHRH resulted in GH responses quite similar 
to those after the first one. In vitro, GHRH pretreatment of GH secreting 
adenomas in monolayer culture did not lead to a diminished GH response 
after an acute GHRH challenge. From these data the authors concluded that 
in acromegaly GH responsiveness to GHRH persists, despite continuous 
presence of GHRH, in vivo as well as in vitro. This phenomenon can at 
least in part be explained by assuming a primary impairment of the desen­
sitization process in acromegalics. However, the finding of elevated GH 
levels in acromegalics with ectopic GHRH production does not favour this 
hypothesis. 
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Nakagawa et al (302) studied the effect of dexamethasone (9 mq/day for 
2 days) on the GH response to GHRH in acromegaly Dexamethasone decreased 
GH responsiveness to GHRH in vivo In vitro, however, dexamethasone pre-
treatment potentiated the GH response to GHRH on monolayer cultures of pi-
tuitary adenomas of three of these patients. These results indicate that 
the GH potentiating effects of dexamethasone in vitro may be overwhelmed 
by other influences possibly induced by dexamethasone in vivo. Ceda et 
al.(63), however, observed a suppression of GHRH mediated GH release after 
4 hr of dexamethasone incubation of human pituitary tumor cells from an 
acromegalic patient. 
Pietschmann et al.(303) studied the GH response to GHRH before and after 
treatment with the cholinergic muscarinic receptor blocker atropine in 
acromegalics, patients with type I diabetes mellitus and normal subjects 
Atropine pretreatment virtually completely blocked the GH response to GHRH 
in the diabetics and normal subjects, but did not suppress the GH answer 
to GHRH in the acromegalic patients From these data the authors concluded 
that acromegalics have a defect in the cholinergic control of GH secre-
tion. 
In an elegant study Hanew et al.(304) investigated the effects of dopa-
mine (DA) on GH secretion in patients with acromegaly. The authors 
compared the GH-lowering effect of DA, which does not cross the blood-
brain barrier, with that of Br and L-Dopa (a precursor of DA), which both 
pass the blood-brain barrier. Furthermore the effect of combined adminis-
tration of L-Dopa and domperidone (a peripheral dopamine-antagomst which 
does not cross the blood-brain barrier and blocks the DA receptors in the 
pituitary) on GH secretion in acromegaly was studied. DA, L-Dopa and Br 
lowered GH levels in all the patients with the greatest decrease occurring 
after DA. Domperidone alone had no effect on GH levels. The combination of 
domperidone and L-Dopa, however, significantly increased GH levels. These 
data suggest that in acromegaly DA not only directly inhibits GH secretion 
in the pituitary but also indirectly stimulates this secretion via the 
hypothalamus. Probably DA acts by a central stimulating effect on GHRH 
release, although an inhibiting effect on SRIF release could not totally 
be excluded. The authors further suggested that there might be a defect in 
the GH negative feedback between pituitary and hypothalamus because the 
dopaminergic hypothalamic GH-releasing mechanism expectedly would be 
suppressed by the excessive GH secretion, which is obviously not the case. 
Taken together availability of GHRH has elucidated important aspects 
in the pathogenesis of acromegaly, although as yet no universally accepta-
ble theory has emerged. 
The discovery of GHRH as another hypothalamic releasing hormone provided a 
new tool to unravel the complex regulation of growth hormone production 
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and secretion. Together with somatostatin GHRH enables fine tuning of 
these processes at the hypophyseal level. Moreover, immunohistochemical 
studies with the use of GHRH-antibodies enables to get some insight in the 
complex interaction of growth hormone, somatostatin and GHRH at the hypo­
thalamic level. In recent years there is growing consensus that besides 
short loop feedback between hypophysis and hypothalamus, intra-hypothal-
amic ultra-short feedback contributes to regulation of hypothalamic hypo­
physeal physiological functioning. 
In pathology, the availability of GHRH for testing hypophyseal function 
has opened new vistas on the causes of growth disorders. Besides finding 
defects of GH synthesis and/or release in the hypophysis one has realized 
that also hypothalamic damage with resulting GHRH deficiency and/or uncon­
trolled production of somatostatin may be a cause of growth hormone defi­
ciency. Treatment of some forms of these disorders with GHRH has become a 
new and intriguing possibility as has been shortly reviewed in paragraph 
1.6.2 of this chapter. The study of GHRH-growth hormone relations in acro­
megaly may lead to better understandinq of the role of hyoothalamic and 
hypophyseal pathology in the causation of this disorder. 
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Chapter 2.1 
SEX DIFFERENCE IN HUMAN GROWTH HORMONE (GH) RESPONSE TO INTRAVENOUS HUMAN 
PANCREATIC GH-RELEASING HORMONE ADMINISTRATION IN YOUNG ADULTS 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, Th.J. Benraad*, J.van 
Laarhoven* and P.W.C. Kloppenborg 
Division of Clinical Endocrinoloqy, Department of Medicine, Denartment of 
Experimental and Chemical Endocrinology*, University of Nijmegen, The 
Netherlands. 
ABSTRACT 
Intravenous administration of a 100 цд dose of human pancreatic 
growth hormone releasing hormone (hpGHRH1.lt4, indicated by GHRH) 
disclosed a sex difference in GH responsiveness. The maximum GH 
increments (41 + 11 (S.E.M.) vs 1 5 + 4 ng/ml, p* < 0.05) and the 
areas under the curves (419 + 105 vs 148 + 53 area units, p* < 
0.05) were significantly higher in 12 men than in 10 women. No 
significant correlation was found in either group between the 
basal plasma estradiol or testosterone levels and the maximum or 
integrated GH response to GHRH. 
Serum prolactin levels significantly increased in both groups 
within 5 minutes after GHRH injection (men: ρ < 0.001 vs t = 0 and 
women: ρ < 0.05 vs t = 0). The areas under the curves of the pro­
lactin responses (355 +_ 184 vs 189 +_ 73 area units) and the maxi­
mum prolactin increments (58 +_ 18 vs 36 + 6 mU/1, p* > 0.10) were 
similar. 
In conclusion, a sex difference in GH responsiveness to GHRH was 
found between young adult men and women. Recent in vivo and in 
vitro data reveal a similar sex difference in rodents and an en­
hancing effect of androgens, but not estrogens, on the growth 
hormone response to GHRH. These findings support the theory that 
in humans testosterone also plays a key role in the genesis of 
this sex difference. 
J Clin Endocr Metab 1986 (62): 336-341 
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INTRODUCTION 
Aqents known to cause increase in circulating growth hormone (GH) levels 
cause more consistent responses in cyclic adult women than in either post­
menopausal women (1,2) or men (1,3-5). Significantly higher GH responses 
to arginine or insulin induced hypoglycemia have been reported in mid- or 
postcyclic women than in men (4). Merimee et al.(4) demonstrated that ad­
ministration of estrogens, but not androgens, augmented the arginine 
induced GH response. Other authors, however, found an enhancing effect of 
androgens on GH secretion (6,7). In contrast to earlier studies with adult 
subjects, Pieters et al.(8) reported a two-fold increased GH response in 
boys as compared to girls after glucose loading. 
Thus far, firm evidence supporting a sex difference in GH responsive­
ness to growth hormone releasing hormone (GHRH) is lacking (9,10). This 
lack of data prompted us to compare the effect of intravenous GHRH admin­
istration on GH in young adult men and women. Furthermore, we assessed 
whether GHRH elicits a prolactin increase and, if so, whether there is a 
difference in prolactin responsiveness between sexes. 
MATERIALS AND METHODS 
Ten normal women (mean age 23.5 + 2.4 (S.D.) years, Rohrer index (weight 
(kg)/height3(cm) χ 10.000) 0.118 + 0.01 (normal value 0.113 - 0.130 for 
women 20-24 year old) and 12 normal men (mean age 23.3 + 3.2 years, Rohrer 
index 0.118 +0.01) (normal value 0.115 - 0.130) were studied. None of the 
subjects was taking any medication. Six women were studied during the 
luteal phase of the menstrual cycle, while the remaining four were in the 
follicular phase. Plasma levels of estradiol were measured to confirm the 
stage of the menstrual cycle. After an overnight fast, all subjects ran­
domly received 100 μq growth hormone releasing hormone (hpCHRHj^ .i,!,, 
Bachern, Torrance, CA, U.S.A.) or placebo (saline 0.951!) by i.v. bolus in­
jection at 9.30 a.m. Each subject served as his/her own control. 
Throughout the test, the subjects stayed fasted and remained in bed. Blood 
samples for hormone assay were taken via an indwelling venous cánula at 
-60, 45, 30, 15 and 0 minutes before and at +5, 10, 20, 30, 45, 60, 90 and 
120 minutes after the GHRH or saline injection. 
The GH concentration in plasma was measured by RIA using standards 
obtained from the Medical Research Council, London U.K. (66/217). The 
antibody used did not cross-react with thyroid stimulating hormone (TSH), 
luteinizing hormone (LH), follicle stimulating hormone (FSH), human chori-
onic gonadotrophin (hCG) or human placental lactogen (hPL). Mean inter-
assay coefficients of variation were 13.1%, 12.45! and 12.6?! at a mean GH 
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concentration of 7, 12 and 28 ng/ml, respectively. 
Prolactin concentrations in plasma were measured by RIA, using k i t - r ea -
gents (Immuno Nuclear Corporation; S t i l lwater , MN). The antiserum had v i r -
tua l l y no cross reac t i v i t y with GH (0.12X), TSH, hCG, and hPL. Standards 
were calibrated against MRC Standard 75/504 ( i . e . 1 ng/ml Immuno Nuclear 
Prolactin Standard was equivalent to 20 mIU/1 of MRC 75/504). The lower 
l im i t of assay detection was 70 mIU/1. The mean interassay coef f ic ient of 
variat ion was 6.9% and 7.3% at a mean prolact in concentration of 252 and 
1012 mIU/1, respectively. 
Testosterone (11) and estradiol (12) were measured by radio-immunoassay 
with prior chromatographic pur i f i ca t ion . Plasma Cortisol (13) was measured 
without pr ior pu r i f i ca t i on . The intra-assay coeff ic ients of var iat ion were 
4% (Cor t iso l ) , 4% (testosterone) and 3% (es t rad io l ) . 
To avoid interassay var iat ion al l samples from a sinqle subject were 
measured in the same assay. 
Areas above baseline of the GH and prolact in response curves were calcu-
lated by trapezoidal integrat ion. S ta t is t i ca l analysis was performed 
using Student's paired (p denoted by p) and unpaired (p*) t - t e s t s , 
Friedman's non parametric analysis of variance (p**) and Spearman's rank 
correlat ion test (p * * * ) . 
Unless stated otherwise the mean values + 1 S.E.M. are given. 
RESULTS 
SIDE EFFECTS 
Mild flushing of the face and chest or a sense of warmth occurred in ap-
proximately 50% of the subjects after GHRH injection. No side effects 
occurred after saline injection. 
EFFECT OF I.V. SALINE AND GHRH ON PLASMA GH LEVELS (Table 1, Fig.l and 2) 
The mean basal plasma GH level in men, though slightly higher than in 
women, did not differ significantly between the 2 groups, before the 
saline (3.1 + 1.1 vs 1.1 + 0.2 nq/ml) or GHRH injection (4.3 + 1.8 vs 2.2 
+ 0.6 ng/ml) (p* > 0.10). 
Saline injection did not alter serum GH levels in either groups 
(Fig.l). In contrast, within 5 minutes, GHRH significantly increased GH 
both in men and women (p < 0.01) with maximum levels reached within 45 
minutes in all but two subjects. Remarkably, the GH response to GHRH at 45 
minutes was significantly higher in men than in women (31 + 7 vs 10 + 4 
ng/ml, p* < 0.025), and there was a tendency to higher levels in men than 
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GH(ng/ml Fiq. 1. The m - ч um
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.M 
responses to . \ . bol ur> 
injection of GM'ii 100 μς 1 or 
saline in 10 healthv youiuj 
adult women (o o) and 12 
men (· «). The asterisk 
indicates the stat іч1" і^ ні 
significance of the di f fei no­
ces between men and wamon at 
the time of I he peak . ilue, 
*p<0.025. 
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Fig. 2. The mean maximal 
serum GH responses to i.v. 
bolus injection of GHRH (100 
μg) in 12 healthy adult young 
men and 10 women in relation 
to the baseline GH level. The 
asterisks indicate the sta­
tistical significance between 
the mean maximal GH responses 
in subjects with baseline 
serum GH < 1 ng/ml or > 1 
ng/ml (*p<0.025). 
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FIG. 3. The mean serum p r o l a c t i n responses t o i . v . bolus i n j e c t i o n of 
GHRH (100 μq) (o -o) or s a l i n e ( · 1) in 12 h e a l t h y youna a d u l t men 
(uDPer panel) and 10 women (lower p a n e l ) . The a s t e r i s k s i n d i c a t e the s t a ­
t i s t i c a l s i g n i f i c a n c e between the GHRH and s a l i n e curves at the t ime of 
the peak value (*p < 0 . 0 5 , **p < 0 . 0 0 5 ) . 
69 
in women at 30 and 60 minutes. The maximum GH increments (41 + 11 vs 15 + 
4 ng/ml, p* < 0.05) and the areas under the curves of GH chanqes (419 ^ 
105 vs 148 + 53 area units, p* < 0.05) were also significantly hiqher in 
men than in women. The maximum GH responses to GHRH were similar in the 
follicular and luteal phases of the menstrual cycle (16 + 6 vs 18 + 6 ng/ 
ml, P* > 0,10). Taking into account the baseline values and subsequent GH 
responses to GHRH, subjects with basal GH levels less than 1 nq/ml had 
lower responses than those with hiqher baseline GH levels (men 78 + 18 vs 
24 + 9 nq/ml, p* < 0.025, women 26 + 4 vs 7 + 3 nq/ml, p* < 0.025) 
(Fig.2). In both qroups, the number of subjects with basal GH levels ex­
ceeding 1 nq/ml did not differ significantly. The mean plasma testosterone 
levels before the saline and GHRH injections were similar in men (679 + 76 
vs 606 +_ 51 nq/100ml). The mean plasma testosterone levels before saline 
and GHRH in women were siqnificantly different (55 +_ 1.9 vs 71 +_ 6.8 nq/ 
100ml respectively, ρ < 0.05) before GHRH. The correspondinq plasma estra­
diol levels were 3.5 + 0.3 vs 3.8 + 0.2 in men (p > 0.10) and 8.6 + 2.4 vs 
10 + 1.9 ng/100ml in women (p > 0.10) (men vs women, p* < 0.001 for saline 
and GHRH). 
No correlation was found in either group between the basal plasma estra­
diol or testosterone levels and the maximum or integrated GH responses to 
GHRH (p*** > 0.10). 
EFFECT OF I.V. SALINE AND GHRH ON PLASMA PROLACTIN (Fiq.3) 
The mean basal plasma prolactin level in women was siqnificantly hiqher 
than in men before both the saline and GHRH iniection (237 +_ 33 vs 153 +_ 
15 mU/1, p* < 0.02 and 290 + 36 vs 145 + 13 mU/1, p* < 0.005 respective­
ly). After i.v. saline injection, plasma prolactin levels siqnificantly 
decreased (p** < 0.0005) in both groups. Within 5 minutes, GHRH iniection 
significantly increased plasma prolactin levels, both in men (p < 0.001 vs 
t = 0) and women (p < 0.05 vs t = 0). Thereafter, prolactin levels re­
mained elevated for 20 - 30 minutes after the injection and then decreased 
(Fig.3). A statistically significant correlation was not found between the 
maximum prolactin and GH increments for either group (women r = -0.20, men 
r = + 0.02, p*** > 0.10). The areas under the curves of prolactin changes 
(355 + 184 vs 189 +_ 73 area units) and the maximum prolactin increments 
(58 + 18 vs 36 + 6 mU/1, p* > 0.10) were similar in both groups. 
EFFECT OF I.V. SALINE AND GHRH ON PLASMA CORTISOL (Fig.4) 
Plasma Cortisol levels significantly decreased in both men and women after 
saline and GHRH injection (p** < 0.0005). No statistically significant 
difference was found between the basal plasma Cortisol levels (men 0.31 + 
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0.03 and 0.33 + 0.04, women 0.34 _+ 0.02 and 0.36 + 0.05 μΐηοΐ/ΐ, respec­
tively before i.v. saline and GHRH) of the decrements at any time interval 
throughout the test. Blood glucose levels did not change in both groups 
throughout both tests (p** > 0.10) (data not shown). 
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FIG. 4. The mean Cortisol responses to i.v. bolus injection of GHRH 
(o o) or saline (· ·) in 12 healthy young men (upper panel) and 10 
women (lower panel). 
DISCUSSION 
Administration of human pancreatic growth hormone releasing hormone evoked 
different responses in men and women. Young adult men had a maximum and 
integrated GH response almost two times that of young adult women. The 
higher GH response to GHRH in men disagrees with earlier studies which 
described a sex based difference in GH response to stimuli (such as argi-
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nine or insulin-induced hypoglycemia) in favour of women. Pretreatment of 
the men with estrogens, not androgens, abolished this sex difference 
(1,4,5). 
Increased GH responsiveness to GHRH in men as compared to women has 
not been reported previously. In a meticulous study. Gelato et al.(9) 
found no sex differences in GH responses to GHRH between 4 groups composed 
of 5 to 8 men or 5 to 8 women in the midfoll icular or midluteal phase, 
given an i.v. bolus injection of 0.01 to 10 μς/Ι<ς GHRH. Japanese investi­
gators reached a similar conclusion (14). Other authors simultaneously ad­
ministering 4 releasing hormones, including GHRH, found no difference 
between men and women (10) or a higher response in the women (15). It is 
difficult to explain why the GH response to GHRH in the present study was 
almost twice as high in men as in women, despite lower doses of GHRH on a 
body weight base (1.4 + 0.3 vs 1.7 + 0.1 μ ς Α ς , ρ* < 0.001) or per m 2 body 
surface (0.53 + 0.02 μα/πι2 vs 0.58 + 0.02 μg/m2, p* < 0.001) in the men. 
Since blood glucose levels were similar in both groups, before and during 
the test, differences in glycemia cannot account for the sex difference 
(16). In an earlier study (8), a similar sex difference in GH responsive­
ness to glucose loading was reported between boys and girls tested soon 
after onset of puberty. This difference could not be accounted for by 
stress factors, since the tendency for serum GH levels to rise after 
stress is more pronounced in women than in men (17). In the present study, 
a relationship was found between basal serum GH levels and the response to 
GHRH, i.e. higher basal values correlated with higher GH increases. Simi­
larly high basal GH levels were found in both groups. However, the basal 
GH levels in men were slightly, but not significantly, higher than in 
women. Moreover, the GH response to GHRH was similar in both the follicu­
lar and luteal phases of the menstrual cycle, confirming recent data of 
Gelato et al.(9) and Evans et al.(18). These authors concluded that the 
failure to find a phase related difference in GH responsiveness could be 
construed as evidence against any direct action of estrogens on somato-
tropes (17). The response difference between men and women, therefore, 
cannot be attributed to differences in circulating estradiol levels, which 
were lower in men than in women. Interestingly, a similar sex difference 
in GH responsiveness to GHRH recently was reported in rats (19,20). 
Wehrenberg et al. (19) demonstrated that intact 60 day old male rats had a 
significantly greater GH response to GHRH than female rats. Testosterone 
treatment greatly enhanced this GH increase both in intact and gonadecto-
mized male rats, whereas estradiol had no such effect in female rats. This 
sex difference in GH response to GHRH was absent in 30 day old rats. In a 
preliminary study on GH responsiveness to GHRH in early puberal girls and 
boys, we also failed to demonstrate a sex difference. Evans et al.(20) re­
cently presented in vitro evidence for a gender-dependent difference in 
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GHRH-stimulated GH release. They further demonstrated that testosterone, 
not estradiol, enhanced the GHRH-mediated GH release by perifused male rat 
pituitary cells. Together, the data suggest that androgens may play an im­
portant role in modulating the pituitary GH response to GHRH. 
In the present study in both men and women a slight, but statistically 
significant, rise in plasma prolactin was observed. This rise confirms 
data of Sassolas et al.(21), Borges et al.(22), Pieters et al.(23) and 
Goldman et al.(24) but contradicts data of most other authors (9,25-27), 
using doses of GHRH up to 1 μς/Ι^. No sex difference in prolactin respon­
ses could be demonstrated despite higher basal serum prolactin levels in 
women. The transient rise in these subjects was not an artifact since the 
prolactin peak occurred before the peak of GH and disappeared before GH 
reached its peak. Furthermore, cross reactivity of GH in the prolactin 
assay was minimal (0.12%). Stress factors can be excluded since no rise in 
prolactin occurred after saline injection. The rise in prolactin levels 
was slightly but not significantly greater in women than in men. Concomi­
tant secretion of GH and prolactin by GHRH recently was reported in 
cultured pituitary somatotroph adenoma cells from acromegalic patients 
(28). Furthermore, in rats the presence of cells secreting both GH and 
prolactin has been demonstrated in pituitary cultures (29). It is not 
known if these dually secreting cells are also present in humans or if the 
1actotrophs possess receptors for GHRH. 
The present study presents evidence for the presence of a sex differ­
ence in GH responsiveness to GHRH in young adults which cannot be accoun­
ted for by differences in circulating estradiol levels. Recent in vivo and 
in vitro data reveal a similar sex difference in rodents and an enhancing 
effect of gonadal androgens, not estrogens, on the GH response to its re­
leasing hormone in these animals. These findings support the theory that 
testosterone may also play a key role in the genesis of this sex differ­
ence in humans. 
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Chapter 2.2 
SEX DIFFERENCE IN GROWTH HORMONE RESPONSE TO GROWTH HORMONE RELEASING 
HORMONE BETWEEN PUBERTAL TALL GIRLS AND BOYS 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, Th.J. Benraad, P.W.C. 
Kloppenborg 
Division of Clinical Endocrinoioqy, Department of Medicine and Department 
of Experimental and Chemical Endocrinoioqy (ThJB), University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
In adult rats and also in younq adults a sex difference in GH re­
sponsiveness to qrowth hormone releasing hormone (GHRH1.44, in­
dicated by GHRH) has been reported in the literature with the 
hiqher responses in males. In younq rats, however, the reverse has 
been found i.e. a hiqher GH response in females than in males. 
This discrepancy prompted us to compare GH responsiveness to GHRH 
in midpubertal tall qirls (n=10) and boys (n=8). 
Intravenous bolus administration of 100 μς GHRH to these adoles­
cents disclosed a sex difference in GH responsiveness. At all time 
intervals up to 30 minutes after the bolus the GH responses to 
GHRH in the qirls were siqnificantly hiqher than in the boys (P < 
0.025 - Ρ < 0.05), whereas the peak GH increments (34 ± 4 vs 19 ± 
3 nq/ml, Ρ < 0.02) were about twice as high in the former as in 
the latter. 
The data suggest that like in rats, also in humans, sex related 
changes in pituitary GH sensitivity to GHRH may be an important 
factor in the pubertal qrowth and development at least in tall 
qirls and boys. 
Acta Endocrinol (Copenh) 1987 (116): 161-164 
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INTRODUCTION 
Recently we reported a difference in qrowth hormone (GH) responsiveness to 
growth hormone releasing hormone (GHRH) between young adult women and men 
with the higher response in the latter (Smais et al.1986). Earlier a sim-
ilar sex difference had been found in adult rats (90-150 days old) (Evans 
et al.1985; Wehrenberg et al.1985). In young rats (30 days old), however, 
the reverse was demonstrated i.e. a higher GH response to GHRH in females 
than in males (Heiman et al.1984; López et al.1986). These divergent data 
prompted us to investigate the GH response to a GHRH bolus injection in 
(tall) midpubertal adolescents. 
PATIENTS AND METHODS 
Eight pubertal boys and 10 pubertal girls attended our outpatient depart-
ment because of tall stature. In all of them height exceeded the 90th per-
centile (P90) of the height distribution in normal children. In 9 of the 
girls and 4 of the boys height exceeded the 97th percentile. 
The study protocol was approved by the hospital ethics committee and in-
formed consent was obtained from all subjects. After an overnight fast all 
patients received 100 μς GHRH (human pancreatic GHRH1.44, Bachern, 
Torrance, California) by i.v. bolus injection at 09.00 h. The tests were 
performed with the patients fasting and at bed rest. Blood samples for GH 
assay were taken via an indwelling intravenous cannula at -30 and 0 
minutes before and at 5,10,20,30,60 and 120 minutes after GHRH administra­
tion. 
The GH levels were determined by specific radio-immunoassay as des­
cribed earlier (Smais et al.1986) with a coefficient of variation of 
13.1*. Testosterone (Smais et al.1976) and oestradiol (Smals et al.1984) 
were measured by RIA with prior chromatographic purification. The intra-
assay coefficients of variation were 4% and 3% respectively. 
Statistical analysis was performed using Wilcoxon's two sample test (P 
denoted by P), Fisher's Chi-sauare test (P*), Wilcoxon's paired rank test 
(P**) and Spearman's rank correiationtest (P***). 
Unless stated otherwise the mean values ± S.E.M. are given. 
RESULTS 
CLINICAL CHARACTERISTICS (Table 1) 
The groups were comparable in clinical characteristics such as chronologi-
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TABLE 1. CHARACTERISTICS OF 8 BOYS AND 10 GIRLS WITH TALL STATURE. THE 
MEAN VALUES ± S.D. ARE GIVEN 
Chronoloqical age (years) 
Skeletal age (years) 
Pubertal stage according to 
Tanner = P4 
Height above 97th percentile 
Alkaline phosphatase (U/l) 
Menarche present 
Plasma testosterone (nmol/1) 
Plasma estradiol (nmol/1) 
TALL BOYS 
14.8 + 0.6 
14.6 ± 2.2 
7 / 8 
4 / 8 
271 t 87 
-
12 ± 5.5 
-
TALL 
14.6 
13.8 
10 
9 
166 
8 
0.2 
GIRLS 
t 1.8 
t 1.4 
/ 10 
/ 10 
± 82 
/ 10 
-
t 0.04 
Ρ VALUE 
Ρ = N.S. 
Ρ = N.S. 
P*= N.S. 
P*= N.S. 
Ρ < 0.02 
N.S. = not statistically significant 
40 
30. 
20 
10. 
0 
-10 
'GHRH 
ι 
-30 0 30 60 120 
time(min) 
FIG. 1. The mean GH increments to GHRH injection in 10 tall girls 
(· 1) and 8 tall boys (o -o). The asterisks indicate the statistical 
significance of the difference in GH levels at the respective time inter­
vals. (*P < 0.05, **P < 0.025). 
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cal aqe, skeletal aqe as determined by the method of Greulich and Pyle 
(1949) and stage of puberty. As was expected the alkaline phosphatase (AF) 
levels in the boys were significantly higher than those in the girls. 
8ASAL GH LEVEL AND GH INCREMENTS AFTER GHRH (Fiq.l) 
The mean basal GH level at t= 0 minutes did not differ between the boys 
and girls (6.5 ± 2.0 vs 10 + 2 μρ/1, Ρ > 0.10). Five of the 8 boys and 7 
out of 10 girls had basal GH levels exceeding 5 μς/1 (Ρ* > 0.10). It has 
to be noted, however, that in both groups the mean GH level at t= 0 min 
was significantly higher than at t= -30 min (Ρ** < 0.02, girls, Ρ = 0.05, 
boys). 
After administration of GHRH, GH levels increased in all subjects. At 
all time intervals up to 30 min after the bolus injection, the mean 
plasma GH increments (AGH) in the girls were significantly higher than in 
the boys (P < 0.025 - Ρ < 0.05). Peak GH levels were achieved at 20 min 
after GHRH administration in both girls (range 5 to 30 min) and boys 
(range 10 to 60 min) (Ρ > 0.10). The mean maximum GH increments were sig­
nificantly higher in the former than in the latter (34 ± 4 vs 19 ± 3 μρ/1, 
Ρ < 0.02). No correlation was found between the basal GH levels and the 
maximum GH increases after GHRH injection either in the boys (r= +0.29, 
P*** > 0.10), or in the qirls (r= +0.16, P*** > 0.10). 
It should be noted that the GH profiles after GHRH administration in 
girls differ from those in the bovs: a quicker and higher GH increment is 
followed by a steep decline, whereas in the boys the decline is more 
sluggish (mean slope from peak to 120 min 38 ± 4 deqrees for the girls vs 
2 3 + 5 degrees for the boys, Ρ < 0.05). 
RELATION BETWEEN GH RESPONSES TO GHRH AND BASAL ALKALINE PHOSPHATASE, TES­
TOSTERONE AND 0ESTRADI0L LEVELS 
Neither in the boys (r= -0.59, 0.05 < P*** < 0.10), nor in the qirls (r= 
+0.43, P*** > 0.10) was a statistically significant relation found between 
serum AF levels and the GH increments in response to GHRH. Furthermore, 
there was no significant relation between basal plasma testosterone levels 
in the boys (r= +0.25, P** > 0.10) or oestradiol levels in the qirls (r= 
+0.04, P*** > 0.10) and the respective GH increments after GHRH adminis­
tration. 
DISCUSSION 
Administration of GHRH disclosed a difference in GH responsiveness between 
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midpubertal tall boys and qirls, the mean GH responses in the latter being 
about twice as high as in the former. Moreover, in the girls the decline 
after achieving the maximum was faster. This sex difference was found in 
the absence of overt differences in clinical characteristics between the 
two groups, as the mean chronological age, bone age, and the stage of pu­
berty were similar. Only plasma AF levels were significantly higher in the 
boys than in the girls which is normal for this stage of puberty (Round et 
al.1973; Pieters et al.1980). No statistical significant correlation was 
found between AF levels, reflecting growth velocity, and the GH responses 
to GHRH. 
Our finding of a higher GH response to GHRH in midpubertal tall girls 
than in boys is reminiscent of earlier studies (Sperling et al.1970) re­
porting a sex difference in GH release after arginine stimulation and are 
in line with data read from the figures of Gelato et al.(1986), using GHRH 
testing in normal statured midpubertal adolescents. The finding of 
Argente et al.(1986) of significantly higher circulating GHRH levels in 
normal midpubertal girls than in boys may point to a more pronounced hyoo-
thalamic drive on GH secretion from the somatotropes in the former, which 
is also reflected by the reported slightly higher serum somatomedin levels 
in girls than in boys (Gourmelen et al.1984; Argente et al.1986). It 
cannot be excluded that stress evoked by testing per se plays a role in 
the different GH responsiveness to GHRH between girls and boys, as girls 
are reportedly to be more prone to stress induced GH increases than boys 
(Daughaday 1974). Indeed in both groups GH levels already increased 
before the bolus injection of GHRH, but these increments were similar in 
the girls and the boys. 
It should be noted that in the present study the sex difference in GH 
responsiveness to GHRH was only demonstrated for tall adolescents and 
therefore may not be pertinent to normally statured girls and boys. It is 
known that tall adolescents may differ in several aspects from their nor­
mally statured peers as they have higher basal 24 hour GH secretory 
patterns (Albertsson et al.1984; Hindmarsh et al.1986) and significantly 
higher somatomedin levels (Evain-Brion et al.1983; Gourmelen et al.1984). 
In the tall adolescents of the present study, the basal plasma GH levels, 
although rather high, were similar in both groups of girls and boys. 
Moreover, the latter evinced a similar peak GH response to a GHRH bolus 
injection as 6 boys with normal stature in the same stage of puberty (9 ± 
3 vs 9 ± 7 μς/1, respectively, Ρ > 0.10) (Smals et al., unpublished obser­
vations). Therefore in our opinion tall stature per se is not likely to be 
responsible for the sex difference in GH responsiveness between girls and 
boys. Unfortunately, data on GH responsiveness to GHRH in midpubertal 
normal girls are lacking. 
We have no explanation for the sex difference in GH responsiveness to 
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GHRH in favour of the (tall) girls, which is completely contrary to the 
response in young adults, where GH responsiveness is more pronounced in 
the men. In rats, a similar change in male and female GH responsiveness to 
GHRH has been reported during pubertal development: in 30 day old rats 
there is a sex difference in GH responsiveness to GHRH in favour of the 
females (Heiman et al.1984: Lopez et al.1986). In contrast in adult rats 
(90-150 days) the GH answer is more pronounced in males than in females 
owing to the greater proportion of somatotrophs in the pituitary (Leong et 
al.1985; Ho et al.1986) and their greater sensitivity to GHRH (Ho et al. 
1986), probably evoked by the stimulatory effect of testosterone (Evans et 
al.1985: Wehrenberq et al.1985; López et al.1986). 
The data in the present study suggest that like in rats, sex related 
changes in pituitary GH sensivitity to GHRH may be an important con-
stituent of Dubertal development also in humans. Our data urge to prudence 
in the interpretation of results of GHRH testing which obviously differ 
according to aqe, sex, stage of puberty and perhaps the state of mental 
arousal. 
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Chapter 3 
HUMAN PANCREATIC GROWTH HORMONE RELEASING HORMONE FAILS TO STIMULATE HUMAN 
GROWTH HORMONE BOTH IN GUSHING'S DISEASE AND IN GUSHING'S SYNDROME DUE TO 
ADRENOCORTICAL ADENOMA 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, Th.J. Benraad*, P.W.C. 
Kloppenborg 
Division of Clinical Endocrinology, Department of Medicine, Department of 
Experimental and Chemical Endocrinology*, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
An absent or severely blunted hGH response to an i.v. bolus iniec-
tion (100 μη) of human pancreatic growth hormone releasing hormone 
(hpGRF!-^) was found in 7 female Gushing patients (5 with pitui­
tary dependent Gushing's disease and 2 with Gushing's syndrome due 
to an adrenal adenoma) and 4 men with pituitary dependent 
Gushing's diseasp. Three of the female patients and three of the 
male patients had an adeguate hypoglycemia after insulin adminis­
tration. All these patients showed an absent or blunted hGH 
response after insulin-induced hypoglycemia. The GHRH data in 
these patients are in agreement with those in older literature on 
hGH responsiveness to stimuli like L-Dopa, arginine and insulin-
induced hypoglycemia. It is concluded that hypercortisolism in­
hibits hGH release to various stimuli at the pituitary level. 
Clin Endocrinol 1986 (24): 401-407 
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INTRODUCTION 
It has been known for many years that the increase in plasma growth 
hormone in response to stimuli such as insulin-induced hypoglycemia 
(Demura et al.1972, Krieger & Luria 1977), arginine (Demura et al.1972), 
lysine-8-vasopressin (Demura et al.1972) and L-Dopa (Krieger 1973) is 
impaired in patients with Cushinq's disease and Cushing's syndrome, and 
normalize after correction of the hypercortisolism (Demura et al.1972; 
Suda et al. 1980; Kuwayama et al. 1981). So far it is not known whether this 
defect in growth hormone secretion has its origin in the pituitary or in 
the hypothalamus. In contrast to the in-vivo defect of growth hormone se­
cretion in endogenous hypercortisolism, in-vitro studies indicate an 
enhanced growth hormone response to growth hormone releasing hormone 
(GHRH) after preincubation of cultured pituitary cells with dexamethasone 
(Vale et al.1983). Similarly, short term administration of dexamethasone 
to intact and adrenalectomized rats also increases the growth hormone 
response to GHRH (Wehrenberg et al.1983). 
These conflicting data prompted us to investigate the response of human 
growth hormone (hGH) to GHRH in patients with Cushing's disease (CD.) and 
with Cushing's syndrome due to an adrenocortical adenoma (CS.). 
MATERIAL AND METHODS 
Approval for the study was obtained from the hosoital ethical committee. 
Seven women (mean age 35 ± 11,7 S.D. year, range 20-51 year) with oroven 
hypercortisolism (5 with C D . and 2 with CS.) and 4 men (mean aqe 37,6 ± 
14,6 year, range 17-53 year) with C D . were studied (Table 1). Twenty-two 
healthy subjects (12 men, mean age ± S.D. 23,3 ± 3,2 year and 10 women, 
mean age 23,5 ± 2,4 year) served as controls. Due to the very recently 
demonstrated sex difference in hGH response to GHRH (Smais et al.1986), 
the hGH data in the male and female Cushing patients and controls were 
considered separately. Informed consent was obtained from all patients and 
control subjects. 
At 8.30 a.m. the patients and controls received 100 μq human pancreatic 
growth hormone releasing factory.44 (Bachern, Torrance, California 
U.S.A.) by bolus i.v. injection. Blood was collected from an indwelling 
intravenous heparin lock cannula. Blood samples for hormone assay were 
collected at -30, 0, 5, 10, 20, 30, 60 and 120 minutes after the injec­
tion. 
All but one patient also underwent an insulin tolerance test (0,1 - 0,2 
U/kg i.V., Actrapid Novo, Copenhagen, Denmark). The hypoglycemic response 
to the insulin injection was considered adequate when the glucose level 
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was equal to or less than 2,2 nrnol/l and siqns of neuroqlycopenia were 
present. Three women and three men had an adequate response accordino to 
th is protocol. 
Plasma hGH and Cortisol levels were measured by RIA as reported e a r l i e r 
(Smais et al.1985; Smals et al.1978). 
S t a t i s t i c a l analysis was performed using Wilcoxon's two sample t e s t . 
Unless stated otherwise the mean + 1 S.E.M. are qiven. 
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RESULTS 
SERUM hGH RESPONSE TO GHRH (Fiq.l and 2) 
The seven women with C D . or C S . showed either no rise or only a blunted 
response of hGH levels after GHRH as compared to the female controls (mean 
maximum hGH increment 1,7 +0,58 vs 1 5 + 4 nq/ml, Ρ < 0.001). None of the 
four men with Cushing's disease showed a hGH rise after GHRH, which is in 
contrast with the clear hGH rise seen in 12 healthy men (mean maximum hGH 
increment 0 vs 41 + 11 nq/ml, Ρ < 0.01). 
SERUM hGH RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA (Fiq.3) 
The mean restinq qlucose level in the 11 patients with C D . or C S . (4,5 + 
0,2 mmol/1) did not differ significantly from that in the 22 controls (4,3 
± 0,1 rrmol/l). 
After insulin administration one female patient with C D . (patient 1) 
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FIG. 1. Response of hGH to GHRH (100 μq i.v.) in 7 women with Cushinq's 
syndrome (patients 1 to 5 with pituitary dependent Cushinq's disease and 
patients 6 and 7 with Cushinq's syndrome due to an adrenal adenoma) (upper 
panel) compared to the response of hGH to GHRH in 10 normal controls 
(lower panel). The P0 to Pi00 values are depicted for the subjects. 
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FIG. 2. Response of hGH to GHRH (100 μς i.v.) in four men with pituitary 
dependent Cushing's disease (upper panel) compared to the response of hGH 
to GHRH in 12 normal controls (lower panel). The PQ to P 1 0o values are 
depicted for the control subjects. 
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FIG. 3. Response of hGH to i.v. insulin induced hypoglycemia (0,1 - 0,2 
U/kg bodyweight) in female Gushing patients (patient 1 with pituitary de­
pendent Cushing's disease and patients 6 and 7 with Cushing's syndrome due 
to an adrenal adenoma) (upper panel) and male patients with pituitary de­
pendent Cushing's disease (lower panel). 
and 2 female patients with C S . (patients 6 and 7) had an adequate hypo­
glycemia after insulin administration. Only one patient showed a hGH 
response that fell within the range found in control subjects (uhGH > 10 
nq/ml). In the remaining female Cushing's patients the hGH response after 
insulin induced hypoglycemia was blunted. The 3 men with Cushing's disease 
who all showed adequate hypoglycaemia did not show any rise of their hGH 
levels after insulin-induced hypoglycemia. 
89 
RESPONSE OF CORTISOL TO GHRH 
In contrast with the control subiects in whom plasma Cortisol levels 
significantly fell throughout the test (0,34 ± 0,03 μπιοΐ/ΐ at t=0 m m to 
0,22 ± 0,02 at t= 120 m m , Ρ < 0,001), in the Cushinq patients the levels 
virtually remained unchanged (0,55 ± 0,06 μτηοΐ/ΐ at t=0 m m and 0,57 + 
0,04 at t= 120 m m , Ρ > 0,10), due to the absence of the diurnal decrease 
in plasma Cortisol in these patients. 
During insulin hypoglycemia plasma Cortisol levels also did not change 
significantly in the patients (basal value 0,57 ± 0,06 μΐηοΐ/ΐ, oeak value 
0,55 ± 0,02 μΐηοΐ/ΐ) 
None of the patients with C D . showed a paradoxical increase of Cortisol 
after the GHRH bolus injection in contrast to the earlier reported para­
doxical ACTH and Cortisol response after TRH and LHRH (Krieger & Luna 
1977; Pieters et al.1982) 
No side effects other than a transient flushing in the face and/or upper 
trunk were noted either in the control subiects or in the patients given 
GHRH. 
DISCUSSION 
This study demonstrates for the first time that the response of hGH to 
GHRH is absent or at least blunted in both male and female patients with 
C D . or C S . 
Moreover, our data corroborate findings of Krieger К Luna (1977) and 
Demura et al.(1972) who reported absent or blunted hGH responses after in­
sulin-induced hypoglycemia in a similar group of patients. The findings of 
unresponsiveness of hGH to insulin-induced hypoglycemia as well as to GHRH 
in patients with C D . and C S . together strongly suggest that hyper-
cortisolism interferes with hGH release at the pituitary level. However, 
loss of pituitary responsiveness due to long term GHRH deprivation cannot 
be excluded as its cause. Recently (Chihara et al.1985) it has been demon­
strated that in some patients with idiopathic growth hormone deficiency or 
a hypothalamic germinoma the blunted (but never absent) hGH response 
pattern to GHRH could be restored by repetitive intravenous administration 
of GHRH, suggesting that prolonged deprivation of endogenous GHRH may be 
the cause of the growth hormone deficiency. We consider that a similar 
mechanism may be a possible explanation for the blunted hGH response to 
GHRH in both C D . and C S . but have not yet tested this hypothesis. 
Our in-vivo results are in sharp contrast to the in-vitro response of 
growth hormone to GHRH. Vale et al.(1983) demonstrated that pretreatment 
of cultured rat pituitary cells with dexamethasone enhanced the growth 
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hormone response to GHRH. In their experiments dexamethasone increased the 
sensitivity of cultured pituitary cells to GHRH and decreased the sen­
sitivity to somatostatin. In vivo, Wehrenberq et al.(1983) found an 
enhanced qrowth hormone response to GHRH in intact and adrenalectomized 
rats after the administration of dexamethasone durinq 7 days before the 
test. It seems possible that only short lastinq hypercortisolism enhances 
the qrowth hormone response to GHRH, whereas chronic hypercortisolism 
leads to a blunted response. The data in the present study obviously do 
not allow us to draw conclusions in this respect. Nakaqawa et al.(1985), 
however, very recently demonstrated that short-term dexamethasone adminis­
tration (9 mq daily for 2 days) significantly reduced the hGH response to 
GHRH in six patients with acromeqaly, whereas in vitro the monolayer 
cultured pituitary adenoma cells of three of these patients showed an 
enhanced hGH release after 2 days of dexamethasone pretreatment. These 
results were interpreted to mean that in vivo, factors which are so far 
unknown, override the potentiating effect of dexamethasone on the somato­
troph observed in-vitro. 
Finally it might be argued that increased blood qlucose levels in C D . 
and C S . inhibit the hGH response to GHRH as has been recently demonstra­
ted in control subjects (Sharp et al.1984; Masuda et al.1985) after 
qlucose loadinq. An argument against this hypothesis is that the basal 
glucose levels in our patients did not differ siqnificantly from those in 
controls. From our limited experience we conclude that hypercortisolism 
inhibits hGH release to various stimuli at the pituitary level. 
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Chapter 4 
STUDIES WITH GHRH IN ACROMEGALY 
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Chapter 4.1 
SEX DIFFERENCE IN THE RELATION BETWEEN SELLAR VOLUME AND BASAL AND 
GH-RELEASING HORMONE (GHRH) STIMULATED GH IN ACROMEGALY 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, P.W.C. Kloppenborg 
Division of Clinical Endocrinology, Department of Medicine, University of 
Nijmegen, Nijmegen, The Netherlands. 
ABSTRACT 
Sellar volume and both basal (r= +0.54, D < 0.02) and growth 
hormone releasing hormone (GHRH)-stimulated (r= +0.41, ρ < 0.05) 
growth hormone (GH) levels were d i r e c t l y correlated in a group of 
28 acromegalics as were the l a t t e r indices (r= +0.82, ρ < 0.001). 
Subdividing the patients according to sex, only in the men a close 
r e l a t i o n was found between sel lar size and both basal (r= +0.77, ρ 
< 0.02) and stimulated GH (r= +0.71, ρ < 0.02), not in the women 
(r= +0.12 and r= +0.02 respectively, ρ > 0.10). 
The presence of a t i g h t re lat ion between sel lar volume and basal 
and GHRH stimulated GH levels in male acromegalics and i t s 
complete absence in women are equally intr igu ing and await further 
e lucidat ion. A modulating role of gonadal steroids in the genesis 
of t h i s sex difference remains to be assessed. 
Submitted 
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INTRODUCTION 
Sellar enlargement occurs in the majority of patients with acromegaly 
(Pieters et al.1982; Hanew et al.1987). Jadresic et al.(1982) demonstrated 
that there is a sex difference in sellar volume between acromegalic women 
and men, with the greater volume in the latter. Furthermore, a direct re­
lation has been found between basal GH levels and the size of the pitui­
tary adenoma as reflected by the sellar content by most (Jadresic et al. 
1982; Wright et al.1969; Klijn et al.1980; De Pablo et al.1981; Hulting et 
al.1982), but not all authors (Quabbe 1982). No due attention, however, 
was paid to the sex of the patients. Recently a positive relation between 
basal GH levels and the GH response to GH-releasing hormone (GHRH) has 
been demonstrated in these patients (Pieters et al.1984; Losa et al.1985: 
Pietschmann et al.1986; Smais et al.1987). Such relation was, however, not 
found by others (Chiodini et al.1985; Gelato et al.1985; Giusti et al. 
1985). As the GH answer to GHRH may better reflect activity of the acro­
megaly (Wood et al.1983) than the basal GH level, we wondered whether 
there is a more close relation between sellar volume and the GH response 
to GHRH. In addition we investigated whether there is a sex difference in 
the relations between these parameters. 
MATERIALS AND METHODS 
Twenty-eight patients (12 men and 16 women) with active acromegaly (mean 
age ± (S.D.) 46 ± 13,1 year) participated in this study. Four patients un­
successfully underwent transsphenoidal surgery. Patient nr 1 in addition 
underwent irradiation on the pituitary without remission sofar. Informed 
consent was obtained from all patients after approval of the protocol by 
the hospital ethics committee. All tests were performed at 9.00 h with the 
patients fasting and at bed rest. Growth hormone releasing hormone 
(hpGHRHi_44 100 μς, Bachern Ltd, Torrance, California) was given as a 
bolus injection. Blood samples for GH assays were obtained via an intra­
venous cánula at -30, 0, 5, 10, 20, 30, 60 and 120 minutes after GHRH in-
jection. 
The GH levels were determined by specific radio-immunoassay as 
described earlier (Smais et al.1986) with an interassay coefficient of 
variation of 13%. Only the maximal absolute GH increments after GHRH ad-
ministration are given. Sellar volume was determined according to the 
method of Di Ghiro (1962) (normal values < ПООтліЗ). in 6 patients there 
was suprasellar extension of the adenoma. 
Statistical analysis was performed using Spearman's rank correlation 
test (P) and Wilcoxon's two sample test (P*). 
Unless stated otherwise the mean ± S.E.M. is given. 
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RESULTS (Table 1, Fiq.l) 
RELATION BETWEEN GH INCREMENTS AFTER GHRH ADMINISTRATION AND BASAL GH 
LEVELS 
The mean basal GH level increased from 47 ± 19 nq/1 to a peak level of 220 
± 57 ng/1 after the GHRH bolus injection. A striking correlation was found 
between basal GH levels and the absolute GH increments (r= +0.82, ρ < 
0.001). After exclusion of the data of the 6 patients with suprasellar ex­
tension of their adenoma, the correlation was still statistically signifi­
cant (r= +0.75, ρ < 0.001). In male acromegalics the correlation was r= 
+0.84, ρ < 0.01 (n=12) and in the female patients r= +0.76, ρ < 0.01 
(n=16). Similar correlations were found excluding the patients with supra­
sellar extension of the tumor 
RELATION BETWEEN BASAL GH LEVELS AND SELLAR VOLUME 
The mean sellar volume in the whole group of acromegalics was 2295 t 221 
mm^. In 3 patients a normal sellar volume was found. Sellar size was 
similar in the male and female acromegalics. Sellar volume was not related 
to age (r= +0.08, ρ > 0.10) or to the duration of the disease, neither in 
the men (r= +0.14, ρ > 0.10) nor in the women (r= +0.04, ρ > 0.10). A sta­
tistically significant correlation could be demonstrated between sellar 
volume and basal GH level for the whole arouo of patients (r= +0.54, ρ < 
0.02). Excluding the six patients with suprasellar extension, the cor­
relation coefficient was r= +0.53 (p < 0.02, n=22). Subdividing the 
patients according to sex, a close relation between sellar volume and 
basal GH was only found in the men, not in the women (Fiq.l). Exclusion of 
those patients who showed suprasellar extension virtually did not change 
these correlations. It has to be noted that the women were older (p* < 
0.02) than the men (Table 1). 
RELATION BETWEEN ABSOLUTE GH INCREMENTS IN RESPONSE TO GHRH AND SELLAR 
VOLUME 
A statistically significant correlation was found between sellar volume 
and the maximum GH increments after GHRH administration for the whole 
group as well as for the group of patients without suprasellar extension 
of their adenoma (r= +0.41, ρ < 0.05, n=28 and r= +0.44, ρ < 0.05, n=22, 
respectively). Again, subdividing the patients according to sex, only in 
men a tight relation was found between sellar volume and stimulated GH, 
not in the women (Fig.l). The data virtually did not change after ex­
cluding the patients with suprasellar extension. 
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TABLE 1. AGE, SEX, SELLAR VOLUME, BASAL GH AND MAXIMUM GH INCREMENTS 
AFTER GHRH ADMINISTRATION IN 28 PATIENTS WITH ACROMEGALY 
PATIENT 
NR 
* 1* 
+ 2 
•» 3 
->• 4 
5 
6 
7 
8 
->• 9* 
> 10 
11 
12 
13 
14 
15 
16 
17 
18* 
19 
20 
21 
22 
23 
24 
25* 
26 
27 
28 
AGE 
YRS 
28 
25 
61 
36 
57 
39 
41 
61 
21 
36 
38 
45 
62 
66 
65 
42 
36 
39 
50 
31 
34 
39 
41 
73 
52 
50 
47 
41 
SEX 
F 
M 
F 
F 
F 
M 
F 
F 
F 
M 
M 
F 
F 
F 
F 
F 
M 
M 
M 
M 
M 
M 
F 
F 
F 
M 
F 
M 
MEAN VALUES: 
MEN: 38±(SD)7 
WOMEN: 50± 19.7*** 
ALL: 46± 13.1 
DURATION 
DISEASE 
(yrs) 
5 
6 
9 
7 
> 1 
15 
9 
6 
6 
4 
3 
4 
7 
7 
8 
16 
2 
> 8 
10 
6 
7 
3 
2 
3 
> 8 
10 
5 
1 
6±(SD)4 
6± 3.5 
6± 3.7 
OF 
2233 
2341 
2295 
SELLAR** 
VOLUME 
(ггапЗ) 
1920 
6670 
4460 
2023 
3308 
3200 
1800 
1853 
2380 
1785 
2300 
2048 
2600 
2907 
2660 
1785 
1365 
1890 
1944 
599 
2707 
880 
2400 
1360 
2016 
855 
1944 
2600 
± 465 
± 186 
± 221 
BASAL 
(nq/ml) 
230 
142 
100 
75 
67 
65 
63 
54 
36 
34 
29 
28 
22 
22 
22 
20 
19 
14 
4 
9 
70 
10 
17 
6 
6 
10 
100 
37 
37 ± 
54 + 
47 ± 
GH 
11 
14 
19 
GH INCREMENTS 
AFTER GHRH 
(nq/ml) 
765 
142 
850 
165 
43 
172 
36 
292 
150 
211 
9 
117 
118 
31 
103 
142 
33 
14 
8 
2 
30 
5 
15 
5 
2 
1 
825 
44 
100 ± 69 
229 ± 75 
174 t 50 
Patients who underwent unsuccessful transsphenoidal surgery. 
nr.l in addition was radiated on the pituitary 
Normal < 1100 mm3 
Patients with suprasellar extension 
p* < 0.02 
Patient 
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ALL ACROMEGALICS 
(л = 28) 
SV SV 
GH + 0 . 8 4 ΔβΗ GH + 0 . 7 6 дбН 
p < 0 . 0 1 p < 0 . 0 1 
ACROMEGALICS 
WITHOUT SUPRASELLAR 
EXTENSION 
(η = 22) 
SV SV 
GH + 0 . 7 9 A G H GH + 0 . 6 4 A G H 
p < 0 . 0 2 p < 0 . 0 5 
F I ( J . 1. Spearman's rank c o r r e l a t i o n c o e f f i c i e n t s between s e l l a r volume 
(SV), basal GH and GHRH s t i m u l a t e d GH (дбН) in 28 acromeqalics (12 men and 
16 women) (upper p a n e l ) . The data f o r the 22 acromeqalics w i t h o u t supra­
s e l l a r extension of the tumor are qiven in the lower panel . 
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DISCUSSION 
This study is the first demonstrating a close relation between sellar 
volume and both basal and GHRH-stimulated GH in male, not however in 
female acromegalics. Scrutinizing the data of Hultinq et al.(1982) we 
could deduce a similar statistically significant relation between the size 
of the sella and basal GH levels in their male (r= +0.52, ρ < 0.05), but 
not in their female patients with acromegaly. Similarly analyzing the data 
of Klijn et al.(1980), again a tight correlation between both parameters 
was only found in the male acromegalics (r= +0.79, ρ < 0.001). A ready ex­
planation for this discrepancy between male and female patients with acro­
megaly cannot be given. The only difference between male and female acro­
megalics reported in a large group of patients (Jadresic et al.1982) was 
the presence of a smaller mean sellar volume in female patients than in 
men. In our patients no statistically significant differences were found 
between males and females in sellar volume, duration of the disease, basal 
GH levels and the presence of suprasellar extension. The mean age of the 
male acromegalics was, however, significantly lower than that of the 
female patients, which is in agreement with data of Lawrence et al.(1970) 
but contrasts with those of Jadresic et al.(1982) This difference in age 
cannot simply explain the divergent results obtained in male and female 
patients with acromegaly, unless one expects the well-known protective 
effects of estrogens (Clemmons et al.1980) to be responsible for a lesser 
GH effect on target tissues thereby probably delaying the expression of GH 
excess in women. In this context fits the finding of a tendency for a 
greater sellar volume in the postmenopausal than in the premenopausal 
women from this study (cf Table 1). A modulating effect of estrogens on 
sellar volume therefore remains more than an educated guess. By a similar 
way of reasoning an enhancing effect of circulating testosterone on tumor 
growth also cannot be excluded. 
Another possible explanation for the lack of a statistically signifi­
cant correlation between sellar size and both basal and GHRH-stimulated GH 
levels in women might be that pregnancy in some of them could have led to 
an increase in pituitary volume or tumor volume which regressed post 
partum. 
Wood et al.(1983) suggested that GH responsiveness to GHRH might be a 
better indicator of disease activity than GH which is known to be rather 
poorly correlated with the signs and symptoms of disease activity in acro­
megaly (Jadresic et al.1982; Quabbe 1980). Therefore an association 
between GH responsiveness to GHRH - which is determined by the basal GH 
level - and disease activity of acromegaly is not obvious. Indeed it 
appears from this study that basal and stimulated GH are equally effective 
in predicting sellar volume in patients with acromeqaly, at least in men. 
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In summary, our data show that there is a close linkage between sellar 
volume, basal GH level and GH responsiveness to GHRH, at least in male 
acromegalics. The presence of these tiqht relations in men and their 
absence in women with acromeqaly are equally intriguing and await further 
elucidation. A modulating role of gonadal steroids, if any, in the genesis 
of this sex difference remains to be assessed. 
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Chapter 4.2 
THE HIGHER THE GROWTH HORMONE (GH) RESPONSE TO GROWTH HORMONE RELEASING 
HORMONE (GHRH) IN ACROMEGALY, THE LOWER THE RESPONSE TO BROMOCRIPTINE (Br) 
AND THYROTROPIN RELEASING HORMONE (TRH) 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, Α.R.M.M. Hermus, Th.J. 
Benraad, P.W.C. Kloppenbrq 
Division of Clinical Endocrinology, Department of Medicine, and Department 
of Experimental and Chemical Endocrinology (ThJB), University of Nijmegen, 
Niimeqen, The Netherlands. 
ABSTRACT 
In acromegaly a direct relation has been demonstrated between growth 
hormone (GH) responsiveness to thyrotropin releasing hormone (TRH) and 
to the dopaminergic agent bromocriptine (Br). Recent data show an 
inverse relation between GH responsiveness to Br and to growth hormone 
releasing hormone (GHRH), but not between the GH responses to GHRH and 
TRH. 
Thirty-one acromegalic patients, 18 women and 13 men (age 46.2 ± 13 
years) were studied. Four patients had been treated, but all still had 
active disease. The GH responses to GHRH (hpGHRHj.i,!,, Bachern 100 μη 
i.v. bolus), TRH (Thyroliberin^ Hoechst 200 μη i.v. bolus) and Br 
(ParlodelR 5 mg orally) were assessed in most of the patients. The 
GH responses to GHRH showed a wide intermdividual variation (AGH 1-
995 ng/ml), which correlated significantly with the basal GH levels 
(r= +0.85, P<0.0001, n=31). GH increments in response to GHRH were in­
versely related to the responses to Br, i.e. the lower the GH increase 
after GHRH the greater the GH decrease after Br (r= -0.49, P<0.01, η = 
30). This decrease correlated with the basal prolactin level (r= 
+0.45, P<0.02, n=29) and also the GH response to TRH (r= +0.66, Ρ < 
0.0001, n=30). An inverse correlation was also found between the GH 
responses to TRH and to GHRH (r= -0.43, P<0.02, n=29). 
The data are consistent with the existence of GH secreting adenomas 
which are more sensitve to GHRH and less to Br and TRH (pure somato­
troph adenomas) and of mixed (lactotroph-like) adenomas responsive to 
TRH and Br but less responsive to GHRH. 
Clin Endocrinol 1987 (27): 43-47. 
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INTRODUCTION 
Growth hormone secretion in acromegalic patients with mixed GH and prolac­
tin containing tumours is more sensitive to dopaminergic drugs and TRH 
than in patients with pure GH-secreting adenomas (Liuzzi et al.1974; 
Ishibashi 8. Yamaji 1979,1985; Lamberts et al .1983,1985). Recently Chiodini 
et al.(1985) and Cozzi et al.(1986) reported that patients responsive to 
Bromocriptine (Br) have lower GH responses to GHRH than acromegalics which 
are non-responsive to the dopaminergic agent. This suggested the presence 
of GH secreting cells with membrane dopamine receptors similar to those on 
the lactotrophs which respond poorly to GHRH, in the tumours of the Rr re-
sponders. Such dedifferentiation of the somatotrophs to more primitive 
lactotrophs would not only make these cells more sensitive to Br but also 
to TRH. Therefore, if Chiodini's hypothesis were true, GH responsiveness 
to Br and TRH on the one hand and to GHRH on the other should be inversely 
related. Such a relationship has been established for GHRH and Br, but not 
for GHRH and TRH. This work now shows that the GH response to GHRH is in­
versely related to the GH responses to both Br and TRH, and provides 
evidence in favour of the hypothesis. 
MATERIALS AND METHODS 
Thirty-one patients (18 women and 13 men) with active acromeqaly (mean age 
46.2 ± 13, range 21-73 yr) were studied. Four had previously been treated 
without success by transsphenoidal pituitary surqery. One patient had had 
pituitary irradiation. Informed consent was obtained from all oatients 
after approval of the protocol by the hospital ethical committee. All 
tests were performed in the morning after an overnight fast. Growth 
hormone releasing hormone (hpGRFi.i^ 100 μq, Bachern Ltd, Torrance CA) and 
thyrotropin releasing hormone (Thyroliberin^ 200 μg, Roche Ltd, Basle, 
Switzerland), were administered in random order on separate days at 09.00 
h with the patients remaining in bed. Blood samples for GH and prolactin 
assays were obtained via an indwelling intravenous cánula at -30, 0, 10, 
20, 30, 60 and 120 minutes after the releasing hormone. On a separate oc-
casion in the study period a bromocriptine (Br) test was performed, the 
patients receiving 5 mg Br orally at 8 a.m. Blood for growth hormone assay 
was sampled immediately before and at 1, 2, 3, 4 and 5 hours after Br in-
gestion. In patients numbered 8, 12 and 31 the tests were not quite 
complete. 
The hormone levels were measured by specific radioimmunoassays as 
described earlier with coefficients of variation of 13.1% for GH and of 
6.9% for prolactin (Smais et al.1986). Unless stated otherwise the mean 
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values ± 1 SEM are given. S t a t i s t i c a l analysis was performed using 
Spearman's rank correlat ion test (P denoted by P). 
RESULTS 
BASAL GH AND PROLACTIN LEVELS (Table 1) 
Basal plasma GH levels showed a wide interindividual variation ranging 
from 4 to 230 ng/ml (mean 48 ± 9 ng/ml). The basal prolactin levels ranged 
from 80 to 1739 mU/1 (mean 464 ± 74 mU/1). Ten of the patients had prolac­
tin levels higher than 450 mU/1 and were arbitrarily considered to be 
hyperprolactinemic. No statistically significant correlation was found 
between basal prolactin and GH levels (r= +0.24, Ρ > 0.10, n=30). 
GH RESPONSES TO GHRH, TRH AND Br 
Plasma GH levels increased in response to GHRH in all patients, but the 
answer was highly variable both in absolute (дтах 1 to 995 ng/ml, mean 175 
+ 49 ng/ml) and relative terms (10 to 850%, mean 281 + 43%). A direct 
relation still was found between the basal GH level and both the absolute 
and relative peak responses to GHRH (r= +0.85, Ρ < 0.0001 and r= +0.44, Ρ 
< 0.02. respectively, n=31). The peak GH responses to TRH ranged from 0 to 
1245 ng/ml and from 0 to 2264%. 
Br lowered GH levels in all patients (maximum decrease 26 to 95%, mean 
68 + 4%). A statistically significant correlation was found between basal 
prolactin levels and the relative GH decrease after Br (r= +0.45, Ρ < 
0.02, n=29), i.e. the higher the basal prolactin the more pronounced were 
the relative GH decreases in response to Br. 
RELATIONSHIP BETWEEN THE GH RESPONSES TO GHRH, TRH AND Br 
In the acromegalic patients a close relationship was found between the 
percentage of peak increments of GH response to TRH (p TRH) and the de­
creases in response to Br (pBr) (r= +0.66, Ρ < 0.0001, n=30). The percent­
age of peak increments to GHRH (pGHRH) and to TRH were inversely correla­
ted (r= -0.43, Ρ < 0.02, n=29). A negative correlation was also found 
between pGHRH and pBr (r= -0.49, Ρ < 0.01, n=30). 
DISCUSSION 
This paper is the first to demonstrate the presence of an inverse rel a-
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tionship between the percentages of peak GH increments to GHRH and to TRH 
in acromegalic patients, i.e. the higher the GH response to GHRH the lower 
was the response to TRH. An inverse relation has been established for the 
GH responses to GHRH and Br (Chiodini et al.1985; Cozzi et al. 1986). 
Chiodini et al.(1985) explained this by suggesting that in acromegalic 
patients responsive to Br, the GH secreting cells possess membrane dopa­
mine receptors similar to those on lactotrophs, which therefore strongly 
respond to specific stimuli for prolactin secretion, dopamine and TRH but 
respond poorly to GHRH. Nevertheless, despite the existence of a close re­
lationship between the GH responses to TRH and Br (Liuzzi et al.1974; 
Lamberts et al.1983,1985; Chiodini et al.1985), several authors (Chiodini 
et al.1985; Gelato et al.1985; Losa et al.1985) have failed to demonstrate 
a statistically significant relationship between the GH responses to GHRH 
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and TRH. In the discussion of their results Chiodini et al.(1985) state 
that a dissociation in the response to both stimuli was frequently present 
in their patients. 
The data on the close relationships between GH responsiveness to GHRH, 
TRH and Br in the present study give strong additional evidence for the 
hypothesis put forward by Chiodini et al.(1985) and Cozzi et al.(1986) 
that in GH secreting adenomas, cells sensitive to GHRH and less sensitive 
to TRH and Br (pure somatotrophs) may coexist with cells responsive to TRH 
and Br, but less responsive to GHRH (lactotroph-1 ike cells). The wide 
inter-individual variability of GH responses to the different stimuli 
(Pieters et al.1984; Chiodini et al.1985; this study) may depend on the 
degree of dedifferentiation of the somatotrooh to lactotroph-1ike cells 
(Melmed et al.1983). The recent demonstration of Bassetti et al.(1986) of 
co-localization of cells secreting only GH, together with mixed cells si­
multaneously producing GH and prolactin (mammosomatotrophs) in pituitary 
adenomas of acromegalic patients with hyperprolactinemia, also fits into 
this concept. Depending on the preponderance in the tumour of the cell 
types, the GH response to GHRH, TRH or dopamine will vary from more "soma-
totroph-1ike" to more "lactotroph-1ike". 
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Chapter 4.3 
GROWTH HORMONE RESPONSES TO THE RELEASING HORMONES GHRH AND LHRH AND THE 
INHIBITORS SOMATOSTATIN AND BROMOCRIPTINE IN TRH-RESPONSIVE AND NON-RE­
SPONSIVE ACROMEGALICS 
A.E.M. Smals, G.F.F.M. Pieters, A.G.H. Smals, A.R.M.M. Hermus, Th.J. 
Benraad*, P.W.C. Kloppenborq 
Div of Clin Endocrinol, Dept of Med and Dept of Exp and Chem Endocrinol*,-
Univ of Nijmeqen, The Netherlands 
ABSTRACT 
In acromegalics, the % peak GH responses to TRH (pTRH) and bromocrip­
tine (pBr) are inversely related with those to GHRH, favouring the 
hypothesis that in the adenomas of some patients there is a prepon­
derance of GH producing cells with lactotroph-like characteristics, 
whereas in others pure somatotrophs predominate. The aim of the 
present study was to investigate whether patients responsive to TRH 
with allegedly lactotroph-like tumors differ from those patients non-
responding to TRH with more somatotroph-1ike adenomas in their answer 
to the GH inhibitors Br and somatostatin (SRIF) and the releasing 
hormones GHRH and luteinizing hormone-releasing hormone (LHRH). The 
present study demonstrates that the observed reciprocal relations 
between the GH responses to GHRH, TRH and Br are only present in 
acromegalics paradoxically responding to TRH (pGHRH vs pTRH -0.73, 
pGHRH vs pBr -0.60, pTRH vs pBr + 0.54, p<0.0002 - p<0.02, n=20), not 
in TRH non-responders (n=10). In contrast, in these latter patients, 
not in the former, close relations were found between the % peak GH 
responses to LHRH (pLHRH) and pGHRH (r= +П.81 p<0.005) and between 
pLHRH and the % maximum GH decrements in response to somatostatin 
(pSRIF) (r= +0.64, D < 0 . 0 5 ) . Expectedly the GH response to Br in the 
TRH responders was significantly higher than in the non-responders 
(75 ± 4Я vs 54 ± 3%, p*<0.02), although it was also substantial in 
the latter. The GH response to SRIF was remarkedly similar in both 
groups (64 ± 5 vs 57 ± 9%, p*>0.10). Although the close relations 
between the GH responses to releasing and inhibiting agents favour 
the presence of GH-secreting tumours with more somatotroph or more 
lactotroph characteristics in subsets of acromegalics, they do not 
effectively predict the therapeutic response to these suppressive 
agents. 
Acta Endocrinol (Copenh) 1987 (116): 53-58 
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INTRODUCTION 
Suppression of growth hormone (GH) by the dopaminergic drug bromocriptine 
(Br) in acromegalics is the more pronounced the higher the basal prolactin 
level and the GH response to thyrotropin releasing hormone (TRH) (Liuzzi 
et al.1974) and the lower its answer to growth hormone releasing hormone 
(GHRH) (Chiodini et al.1985; Smals et al.1987). The GH responses to the 
two latter stimuli are inversely related, i.e. the higher the answer to 
GHRH, the lower the response to TRH (Smais et al.1987). The data have been 
explained by hypothesizing that in GH secreting adenomas, cells responsive 
to GHRH and hardly or not to TRH and Br (pure somatotrophs) and cells re­
sponsive to TRH and Br but less to GHRH (1 actotroph-1 ike cells) coexist 
(Chiodini et al.1985). Depending on which cell type predominates the GH 
answer will vary from somatotroph-like to lactotroph-like. 
Similarly as has been demonstrated for TRH and Br, a linkage between the 
GH responses to luteinizing hormone releasing hormone (LHRH) and to soma­
tostatin (SRIF) has been suaqested (Hanew et al.1980; Pieters et al.198?; 
Pieters 1982), whereas there is an antagonism between the effects of SRIF 
and GHRH on GH secretion (Vale et al.1983; Adams et al.1984; Lamberts et 
al.1984; Pieters et al.l984a). In view of the hypothesis mentioned above 
we wondered whether acromegalics responsive to TRH with alleaedly lacto­
troph-like adenomas differ from TRH non-responders with more somatotroph-
like tumors, not only in their GH response to Br and GHRH, but also in 
their answers to somatostatin and LHRH. 
MATERIALS AND METHODS 
Thirty-one patients (18 women and 13 men) with active acromegaly (mean age 
45.8 ± (S.D.) 13, range 21-73 yr) participated in this study. Four of the 
patients were previously treated without success by transsphenoidal pitui­
tary surgery. One patient in addition underwent pituitary irradiation. 
Informed consent was obtained from all patients after approval of the pro­
tocol by the hospital ethical committee. Growth hormone releasing hormone 
(hpGRF 1-44 100 μα, Bachern Ltd, Torrance CA), thyrotropin releasing 
hormone (Thyroliberin" 200 μς, Roche Ltd, Basle Switzerland) and lutein­
izing hormone releasing hormone (LHRH 100 μς, Hoechst AG, Frankfurt AM, 
Germany) were administered in random order on separate days at 9 a.m. with 
the patients fasting and at bedrest. Blood samples for GH and prolactin 
assays were obtained via an indwelling intravenous cánula at -30, 0, 10, 
20, 30, 60 and 120 minutes after the administration of the releasing 
hormone. On separate occasions in the study period, a bromocriptine (Br) 
and a SRIF test were performed. In the Br test the patients received 5 mg 
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Br orally at 8 a.m. Blood for GH assay was sampled immediately before and 
at 1, 2, 3, 4 and 5 hours after Br ingestion. Cyclic somatostatin (SRIF 
250 μ9, Serono-GmBH, Freiburg, Germany) dissolved in saline was given 
i.v. for 1 hour at a rate of 300 μς/ϊιουΓ. Blood samples for GH assay were 
taken immediately before and at 5, 10, 20, 30 and 60 minutes after 
starting the SRIF infusion. Unfortunately the panel of data was incomplete 
in 7 patients. 
Plasma GH and prolactin levels were determined by specific radio-immuno-
assay as described earlier (Smais et al.1986). 
Using criteria described in the literature (Trie & Tsushima 1972; 
Schwinn et al.1977; Winkelmann 1977; Schneider et al.1978; Carlson et al. 
1984; Pieters et al.1982; Pieters et al.l984b; Tanaka et al.1984; Faglia 
et al.1985) the GH responses to TRH or LHRH were considered paradoxical if 
they exceeded the baseline values by 50% or more in at least 2 samples 
obtained within 30 minutes after the injection. 
Statistical analysis was performed using Spearman's rank correlation 
test (P denoted by P), Wilcoxon's two sample test (P*) and Fisher's Chi 
Square test (P**). 
Unless otherwise stated, the mean + SEM is given. 
RESULTS 
GH RESPONSES TO GHRH, TRH AND Br (Table 1, Fig.l) 
A tendency to a direct relation was found between basal GH and basal pro­
lactin levels (r= +0.32, ρ < 0.10, n=30). Plasma GH levels in response to 
GHRH increased in all patients. The absolute and percentage peak incre­
ments of GH to GHRH (pGHRH) were highly variable (1-995 μg/l resp. 10 to 
850%) but correlated with the basal GH level (r= +0.85, ρ < 0.0001 resp. 
r= +0.44, ρ < 0.02). The GH decrease in response to Br was the more 
pronounced, the higher basal serum prolactin levels (r= +0.45, ρ < 0.02, 
n=29). Furthermore, the percentage peak prolactin response to TRH was the 
higher the lower the basal GH levels (r= -0.49, ρ < 0.01, n=30) and the 
higher the percentage peak prolactin response to GHRH (r= +0.41, ρ < 
0.025, n=27). In the whole group of acromegalics, a close relation was 
found between the percentage peak GH increments to TRH (pTRH) and the 
decreases after Br administration (pBr) (r= +0.66, ρ < 0.0001, n=30). 
pGHRH and pTRH were inversely related (r= -0.43, ρ < 0.01, n=30). A simi­
lar relation was found between pGHRH and pBr (r= -0.49, ρ < 0.01, n=30). 
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GH RESPONSES TO GHRH, TRH AND Br IN RELATION TO TRH RESPONSIVENESS 
According to their GH answer to TRH, the acromegalics could be subdivided 
in those paradoxically responding to TRH (n=20) and those non-responding 
(n=10). The two groups did not differ significantly from each other, 
either in age (45.6 ± (S.D.) 16.0 vs 46.5 + 11.0 year, p* > 0.10), or in 
sex distribution (males 38 vs 40%, females 61 vs 60%, p** > 0.10), or in 
duration of disease (7.15 + (S.D.) 3.7 vs 6.2 t 4.5 year, p* > 0.10). The 
GH decrements in response to Br, however, were more pronounced in the 
former group than in the latter (74.9 ± 4.4 vs 54 2 t 5.5%, p* < 0.025). 
Only in the TRH-responder qroup - not in the TRH non-responders - were 
statistically significant correlations found between pGHRH and pTRH (r= 
-0.73), between pTRH and pBr (r= +0.54) and between pBr and pGHRH (r= 
-0.60) (Fig.l). Furthermore, only in this group were the basal serum pro­
lactin levels and the GH responses to Br directly correlated (r= +0.60, Ρ 
< 0.02). Moreover, only in the TRH-responders were the prolactin responses 
to TRH and GHRH positively correlated (r= +0.54, ρ < 0.02, n=20). 
GH RESPONSES TO GHRH, LHRH AND SRIF 
Ten of the 30 patients tested showed an increase of their GH levels after 
LHRH, exceeding 50% of the baseline value (range 50 to 445%). In the whole 
group of acromegalics, no statistically significant correlation was found 
between the % GH increments in response to GHRH and to LHRH (pLHRH) (r= 
+0.25, ρ > 0.10, n=30). 
During SRIF infusion, plasma GH levels declined in all patients to nadir 
values -7 to -92% (mean -61 + 5%). No statistically significant cor­
relation was found between the % GH decrements in response to SRIF (pSRI17) 
and the % increments after either GHRH (r= +0.27, n=27, ρ > 0.10) or LHRH 
(r= +0.25, π=27, ρ > 0.10). 
GH RESPONSES TO GHRH, LHRH AND SRIF IN RELATION TO TRH RESPONSIVENESS 
(Table 1, Fig.l) 
The median GH response to GHRH in the TRH-responder group was 140% (range 
10 -850%), in the TRH-non-responders 210% (range 64-536%). A paradoxical 
GH answer to LHRH was observed in 6 out of 20 of the former patients and 
4 of the latter (p** > 0.10). GH decrements in response to SRIF were simi­
lar in the TRH-responders and non-responders (64 + 5 vs 57 ± 9%, o* > 
0.10). 
In the TRH-responder group, no statistically significant correlations 
were present between the % GH answers to SRIF, GHRH or LHRH. In the non-
responder group, however, a tight relation was found between the GH re-
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sponses to SRIF and LHRH (r= +0.81) and between those to LHRH and GHRH (r= 
+0.64). The correlation between pGHRH and pSRIF lacked statistical signif-
icance (r= +0.42). 
DISCUSSION 
In acromegaly, a direct relation has been demonstrated between the GH sup-
pressive effect of Br and both the basal prolactin level and the GH 
response to TRH (Liuzzi et al.1974; Smals et al.1987). Furthermore an 
inverse relation was found between the GH responses to Br and to GHRH 
(Chiodini et al.1985; Smals et al.1987) and finally, also between the 
answers to GHRH and TRH (Smais et al.1987). The present study extends 
these data, demonstrating that the close relations between the GH respon-
ses to the stimulatory and inhibitory agents only hold true for those 
acromegalic patients presenting a paradoxical GH increase in response to 
TRH, not for the TRH-non-responders. The data favour the hypothesis put 
forward by Chiodini et al.(1985) that depending on the preponderance of 
the cell type in the adenoma of these acromeqaiics, the GH answers to 
GHRH, TRH and Br will vary from "lactotroph-1ike" to "somatotroph-!ike". 
Indeed GH suppression by Br in the patients of the present study was more 
pronounced in the TRH-resoonders. Also in line with the hypothesis is the 
presence of a direct relation between basal orolactin and GH response to 
Br at least in the TRH-responders, and the inverse relation between basal 
GH and the answer of prolactin to TRH. Furthermore, only in the TRH-re-
sponding acromegalics were the prolactin responses to TRH and GHRH highly 
correlated. The data of Losa et al.(1985) of a linkage between the TRH-
induced GH rise and the GHRH-mediated prolactin increase also fit in a 
forementioned concept. 
Similarly as has been demonstrated for TRH and Br, a linkage between the 
GH stimulating effect of LHRH and the inhibitory effect of SRIF has been 
suggested in the literature (Pieters 1982; Pieters et al.1982). Further-
more, there is the well-known antagomsm between SRIF and GHRH in their 
action on GH (Vale et al.1983; Adams et al.1984; Lamberts et al.1984; 
Pieters et al.l984a). From the present study it appears that in the TRH 
non-responsive acromegalics - not in the responders - there is a close re-
lation between the GH responses to LHRH and to SRIF and between those to 
LHRH and to GHRH. Together the data suggest that in acromegalics with 
supposed mixed mammosomatotroph adenomas TRH predicts the GH responses to 
GHRH and Br, whereas in the more somatotroph-!ike tumors LHRH presages GH 
responsiveness to LHRH and SRIF. Considering, however, the GH responses to 
the suppressive agents in both subgroups of acromegalics it appears that 
GH suppression by Br is admittedly more pronounced in the TRH-responders, 
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but is still substantial in the non-responders. This suggests that also in 
these patients dopamine-sensitive GH secreting cells are present. Further­
more, it has to be noted that GH suppression by SRIF is almost identical 
in both groups of acromeqalics, whereas such effect would be expected to 
be more pronounced in those acromegalics not responding to TRH. 
Summarizing, the data illustrate that although there may be close re­
lations between the GH responses to releasing and inhibiting agents 
favouring a more "lactotroph-" or "somatotroph-!ike" origin of GH overpro­
duction in subgroups of acromegalics, these do not yet allow the drawing 
of firm conclusions with respect to the choice of therapy in individual 
patients. 
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Chapter 4.4 
GROWTH HORMONE RESPONSIVENESS TO HUMAN PANCREATIC GROWTH HORMONE RELEASING 
FACTOR IN ACROMEGALY: MODULATORY EFFECTS OF BASAL HORMONE LEVELS AND OF 
CONCOMITANT SOMATOSTATIN ADMINISTRATION 
G.F.F.M. Pieters, A.E.M. Smals, Α.R.M.M. Hermus, A.G.H. Smals, Th.J. 
Benraad* and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology, and Department of 
Experimental and Chemical Endocrinology*, St.Radboud Hospital, University 
of Nijmegen, Nijmegen, The Netherlands. 
SUMMARY 
Human pancreatic growth hormone releasing factor 1-44 (hpGRF), 
100 \iq was administered as an i.v. bolus injection to eleven 
patients with acromegaly. The mean serum growth hormone (GH) 
levels rose (p<0.001) from 54 t 20 ng/ml to 215 ± 126 ng/ml (± 
SEM) 20 min after the injection. Although the maximum response of 
GH levels was highly variable it correlated positively with the 
individual GH levels (p<0.01, R
s
= +0.80). Thus the hiaher the 
GH levels, the greater the responsiveness to hpGRF. Administra­
tion of somatostatin (SRIF), 300 μς/ίι, lowered basal GH levels 
from 76 ± 38 ng/ml to 13 ± 5 ng/ml (p<0.01) after 1 h. hpGRF ad­
ministration during concomitant SRIF infusion also led to highly 
variable growth hormone responses. The maximum GH responses again 
correlated positively with the GH levels before hpGRF after 1 h 
of SRIF administration (p<0.05, R
s
= +0.79). GH responses to 
hpGRF were completely blocked by SRIF in three out of four 
patients whose GH levels decreased to normal levels during SRIF 
infusion. Our data illustrate that the pituitary in acromegaly is 
normally responsive to both SRIF and hpGRF but at a higher 
setting of basal GH levels. 
Clin Endocrinol 1984 (21): 701-707 
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INTRODUCTION 
After the isolation, purification and subsequent synthesis of a growth 
hormone (GH) releasing factor (from pancreatic tumors causing acromegaly 
by GH cell hyperplasia of the pituitary; Guillemin et al.1982; Rivier et 
al.1982), several investigators have shown the specific GH-releasinq ac­
tivity of the human pancreatic growth hormone releasing factors (hoGRF 
1-40 and hpGRF 1-44) in laboratory animals. These peptides appeared to be 
devoid of action on the secretion of the other anterior pituitary hormones 
(Guillemin et al.1982; Rivier et al.1982; Vale et al.1983; Wehrenberg et 
al.l982a,b). In healthy men, hoGRF 1 μg/kg, or 100 μς per subject, i.V., 
specifically stimulated GH release to a highly variable degree (maximal 
responses from 2 to 80 ng/ml) (Thorner et al.1983; Wood et al.1983; 
Rosenthal et al.1983; Gelato et al.l983a). In acromegaly, hpGRF also spe­
cifically stimulated GH release in vivo (Wood et al.1983; von Werder et 
al.1983; Gelato et al.1983b; Shibashaki et al.1984), as well as in surgi­
cally removed pituitary tumour tissue in vitro (Adams et al.1983a,b; Webb 
et al.1983; Lamberts et al.1984). So far, the effect of concomitant admin­
istration of hpGRF and somatostatin (SRIF) has only been reported from 
studies in vitro, in rat pituitary tissue (Vale et al.1983; Harwood & 
Grewe 1983) and in pituitary tissue from patients with acromegaly (Adams 
et al.1983a,b; Lamberts et al.1984). In the latter investigations coincu-
bation of the culture medium with high doses of SRIF completely blocked 
the stimulatory effect of hpGRF in the acromegalic tissue. In the rat pi­
tuitary tissue SRIF did not block hpGRF-induced GH release completely 
(Vale et al.1983). From similar in vitro experiments Brazeau et al.(1983) 
concluded that the interaction between hpGRF and SRIF at the m'tuitary 
level was non-competitive. We report observations of hpGRF-induced blood 
GH patterns in patients with acromegaly in the absence and in the presence 
of exogenous SRIF. 
METHODS 
Eleven patients with acromegaly (five men of 41 + 7 (SD) years and six 
women of 48 ± 15 years) were studied. Five patients were temporarily 
treated with bromocriptine. This treatment was discontinued at least 2 
weeks before the start of this investigation. The remaining six patients 
had never previously been treated for acromegaly. Clinical and biochemical 
data of these patients are given in Table 1. Informed consent was obtained 
from all patients. hpGRF 1-44 was purchased from Bachern (Torrance, Cali­
fornia, USA) One mg of the peptide was dissolved in sterile 1 mmol/1 
hydrochloric acid, 1 nmol/l ascorbic acid and 154 mmol/l bacteriostatic 
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sodium chloride containing 10% (w/v) mannitol (USP) and 0.25% human serum 
albumin (USP), giving a final concentration of 100 μg hpGRP 1-44/ml. This 
solution was then sterilized by filtration. Sterility was confirmed by 
negative culture of bacteria. The pyrogen free solution (Pyrogentest, 
Mallinckrodt) was placed in sterile vials and stored at-56PC. One vial 
(100 vq) per patient was thawed immediately before administration at 0900 
h with the patients fasting and at bedrest. Blood samples for hormone 
assay were collected at -30, 0, 5, 10, 20, 30, 60 and 120 min via an in­
dwelling intravenous cannula kept open with a diluted (10%) solution of 
heparin. After an interval of 2-14 days, cyclic somatostatin 1-14 750 μq 
(Serono-GmBH, Freiburg, Germany) dissolved in 75 ml saline was given in­
travenously, using a micro-infusion pump at a speed of 30 ml/h (300 μς/ϊι) 
for 2 h. After 60 min of SRIF infusion, 100 μς of hpGRF was administered 
as a bolus injection. Blood samples for hormone assay were collected at 
regular intervals before and during the first hour of SRIF administration 
and at 0, 5, 10, 20, 30 and 60 min after the bolus injection of hpGRF. 
Plasma GH (coefficient of variation, CV, 15%) was determined by a specific 
radioimmunoassay as described previously (Smais et al.1978). Statistical 
analysis was performed using Wilcoxon's paired rank test (p values denoted 
by p). Friedman's non-parametric analysis of variance (p= p x) and 
Spearman's rank correlation test (correlation coefficient: R
s
, D= 
p x x ) . Unless otherwise stated, the mean values ί 1 SEM are given. Sellar 
volume was determined according to the method of Di Ghiro Λ Nelson (1962). 
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FIG. 1. Individual GH levels before and after hpGRF administration 
(arrow) in 11 patients with acromegaly. The levels of Patients 1 and 2 
are indicated in digits at the top of the figure. Note the tiqht correla-
tion between basal and stimulated GH levels. 
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RESULTS 
EFFECTS OF hpGRF 
Figure 1 illustrates that hpGRF stimulated GH release in all patients with 
acromeqaly. The mean GH level rose from 54 ± 20 ng/ml at 0 m m to 215 ± 
126 nq/ml after 20 min (p*<0.001) and afterwards declined gradually to 103 
± 44 nq/ml after 120 min. In the individual patients, maximal GH values 
were achieved 20 + 2 m m after hpGRF administration with the exception of 
patient No.3, who showed a rather sluqqish responsp. The relative chanqes 
in all patients varied from +57% to +624% of the basal value. It is 
strikinq that we found a hiqhly significant positive correlation between 
the individual GH levels and the maximal GH increases (p**<0.01, R
s 
= +0.80). Thus the higher the GH levels, the greater the response to 
hpGRF. 
EFFECT OF CONCOMITANT SRIF ADMINISTRATION ON hpGRF-INDUCED GH-RESPONSES 
Figure 2 illustrates that SRIF, 300 μς/Ιι, lowered GH levels in all 
patients from a mean value of 76 + 38 nq/ml to 13 + 5 ng/ml (p<0.01) after 
1 h. Subsequently hpGRF administration during concomitant SRIF infusion 
elicited an increase of GH to a mean of 65 + 27 nq/ml after 20 m m 
(p<0.01). This response was less than after the administration of hpGRF 
alone (p<0.01). In the individual patients maximal responses durinq SRIF 
were obtained 22 + 7 m m after hpGRF. The relative chanqes varied from 40% 
to 978% (mean 219 + 16%) of the GH levels achieved after 1 hour of SRIF 
administration. The responses to the combined administration of SRIF and 
hpGRF amounted to between 4% and 39% (mean 18 t 5%) of those achieved 
after hpGRF alone. 
The GH levels achieved after 1 h of SRIF-infusion in the individual 
patients were aqain positively correlated with the maximal GH increase 
after hpGRF administration (p**<0.05, R
s
= +0.79). In the patients whose 
GH levels were suppressed to levels below 15 nq/ml, the GH responses to 
hpGRF were almost completely blunted by SRIF with the exception of patient 
No.2. In the patients with hiqher GH levels durinq SRIF, this peptide was 
unable to block the hpGRF-induced GH response. 
DISCUSSION 
This study confirms that hpGRF stimulated GH secretion in a l l 11 patients 
with acromeqaly. The maximal GH response was achieved 10 to 60 mm after 
hpGRF-admimstration. GH responsiveness appeared to be hiqhly variable 
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FIG. 2. Individual GH levels before, after one hour of SRIF (300 μς/ή) 
and during concomitant SRIF and hpGRF administration. Arrow marks hpGRF 
administration and bar marks SRIF. 
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with responses ranging from 7 to 995 nq/ml. In addition, we found that GH 
responsiveness to hpGRF was positively correlated with the GH levels, i.e. 
the higher the GH levels were, the greater was the rise after hpGRF admin-
istration. In our opinion this observation argues against hypersecretion 
of endogenous GRF as the cause of acromegaly in these patients. 
GH levels achieved after 1 h of SRIF infusion were positively corre-
lated with the GH values obtained in response to hpGRF during SRIF-
blockade, i.e. the lower the GH levels during SRIF administration were, 
the lower the responsiveness to hpGRF during concomitant SRIF administra-
tion. 
It is known that SRIF is able to lower GH levels in all patients with 
acromegaly, though to a highly variable extent as we discussed earlier 
(Pieters et al.1982). In this study the extent of SRIF-blockade of GH 
levels in acromegaly appears to concur with the degree of stimulation of 
the SRIF-blocked pituitaries by hpGRF. 
In both circumstances with and without exogenous SRIF, the GH level 
before hpGRF-administration determines GH responsiveness to hpGRF-adminis-
tration. A possible explanation for these findings is that in acromegaly 
the number of GH-producinq cells is increased, influencing the GH levels 
accordingly. Responsiveness to hpGRF is essentially normal and increased 
pari passu with the increased number of GH-producing cells. Exogenous SRIF 
is able to inhibit GH release and GH synthesis. The more the GH levels 
decline during SRIF administration, the smaller the intracellular stores 
of GH are expected to be causing a comparable decrease of GH responsive-
ness to hpGRF. 
Our in vivo data differ from the in vitro data obtained using pituitary 
tissue from patients with acromegaly as mentioned above. The difference 
between the in vitro experiments with SRIF and hpGRF and our in vivo data 
might be explained by: (i) the great variability in SRIF sensitivity 
between acromegalic patients; (ii) differences in the doses of SRIF used 
in the two types of experiments; and (iii) differing behaviour of the 
pituitary tissue when removed from its natural environment. 
Finally, our data do not favour the concept of autonomously GH pro-
ducing cells in acromegaly, nor a hypothalamic cause of this disease, but 
rather argue for principally normal responsiveness to both SRIF and hpGRF 
at a higher setting of basal GH levels. It is therefore likely that long-
acting SRIF analogues will be of benefit in the treatment of acromegaly. 
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Chapter 4.5 
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versity of Nijmegen, Nijmegen, and Sandoz B.V. Netherlands1, Loopkant-
straat, Uden, The Netherlands 
ABSTRACT 
Twelve patients with active acromegaly were treated with the long-
acting somatostatin analogue SMS 201-995 at a dose of 50 μg sc 
twice daily in the first 2 weeks of treatment and 100 μς twice 
daily thereafter. Four hours after the first injection of SMS, GH 
levels became normal in 8 of the 12 patients. The GH response 
after GHRH administration was strongly suppressed by SMS. Para­
doxical GH responses to TRH disappeared in 6 out of 7 patients 
during SMS. Paradoxical responses to LHRH, however, persisted in 4 
out of 4 patients. Paradoxical responses of GH after glucose 
loading disappeared in 2 out of 2 patients. We conclude that SMS 
normalizes most anomalous growth hormone kinetics in acromegaly. 
This drug offers a new tool in the treatment of this disease. 
Acta Endocrinol (Copenh) 1987 (114): 537-542 
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INTRODUCTION 
In acromeqaly, paradoxical increases in GH levels occur in about 25% of 
the patients after oral glucose loading (Beck et al.1966), in approximate­
ly 60^ after the administration of thyrotropin-releasing hormone (TRH) 
(Irie & Tshushima 1972), and in about 25% after luteinizing hormone re­
leasing hormone (LRH) (Rubin et al.1973; Pieters et al.1982). The response 
of the GH levels to growth hormone releasing hormone (GHRH) administration 
is generally enhanced in acromegaly (Wood et al.1983; Pieters et al.1984). 
Patients whose GH levels rise after TRH administration are more sensi­
tive to the GH inhibitory effect of dopaminergic drugs (Liuzzi et al. 
1974) whereas those whose GH levels rise after LRH are more prone to the 
inhibitory effect of somatotropin-releasing inhibiting factor (SRIF) 
(Pieters et al.1982). During bromocriotine treatment, the paradoxical GH 
response to LRH disappears, but not the response to TRH (Ishibashi et 
al.1977,1978). The GH response after GHRH administration also persists 
during bromocriptine treatment (Cozzi et al.1986). 
Until now, only few data are available on the ability of SRIF to blunt 
the anomalous GH responses to the stimuli mentioned above. With the devel­
opment of the long-acting somatostatin analogue SMS 201-995 (minisomato-
statin, SMS) it became possible to normalize the GH levels in the majority 
of patients with acromegaly (Bauer et al.1982; von Werder et al.1984; 
Plewe et al.1984; Ch'ng et al.1985; Althoff et al.1984; Lamberts et 
al.1985,1986; Pieters et al.1986). We studied the effects of 4 weeks of 
treatment with SMS on the GH responses to glucose loading, TRH, LRH and 
GHRH administration in 12 patients with acromeqaly. 
MATERIALS AND METHODS 
Twelve patients with active acromegaly, 9 women (mean age ± SE, 50 + 5 
years) and 3 men (39 ± 7 years), participated in this study. Informed 
consent was obtained from all patients after approval of the protocol by 
the hospital ethical committee. All patients were resistant to bromocrip­
tine therapy or developed serious adverse reactions. 
TRH (200 μς, Roche Ltd, Basle, Switzerland), LRH (100 μς, Hoechst A.G., 
Frankfurt a.M., FRG), and GHRH (hpGRFi.44, 100 μς, Bachern Ltd, Torrance 
CA) were administered in random order on separate days at 09.00 h with the 
patients fasting and at bed rest. Blood samples for hormone assays were 
obtained via an indwelling iv cannula at -30, 0, 5, 10, 20, 30, 60 and 120 
min after the administration of the releasing hormone. On a separate occa­
sion during the study period, an oral glucose tolerance test (100 g of 
glucose) was also performed at 09.00 h. In the fifth week of SMS 
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treatment, the glucose tolerance test and the GHRH test were repeated and 
so were those releasing hormone tests to which a paradoxical response 
occurred - according to the criteria reported earlier, i.e. an increase 
in GH levels exceeding 50% above baseline in at least 2 samples and within 
30 min (Pieters et al.1982). SMS was provided by Sandoz A.G., Basle, Swit­
zerland, and was administered sc at a dose of 50 μη twice a day at 08.00 
and 20.00 h. After 2 weeks of treatment, the dose was increased to 100 μς 
twice daily. Blood samples for hormone assay were obtained hourly from 
08.00 to 12.00 h the day before SMS treatment, the first day of treatment, 
and in the fifth week of treatment. 
The growth hormone levels were determined by a specific radio-immuno-
assay as described before: GH (intra-assay coefficient of variation, CV 
15%) (Pieters et al.1982). 
RESULTS 
BASAL GH LEVELS BEFORE AND DURING SMS ADMINISTRATION 
On the first day of treatment, the plasma GH levels declined in all 
patients from a mean basal value of 73 ± 20 μς/1 to a nadir value of 10 ± 
4 μς/1 after 3-4 h (Fiq.l). The GH levels normalized (< 7.5 μς/1) in 8 of 
the 12 patients. This GH lowering effect of SMS persisted during the fol­
lowing weeks of treatment (data not shown). 
GHRH ADMINISTRATION 
All patients who underwent a GHRH test before and during SMS treatment, 
except Nos. 6 and 8 who had the lowest basal GH levels, showed fair GH re­
sponses after GHRH administration (Fig.2). After SMS administration, GH 
responsiveness to GHRH completely disappeared in 3 of the 8 responders and 
was almost completely blunted in 4. The responsiveness to GHRH persisted 
in only one patient (No.5), although the maximal GH response was 35% lower 
than before treatment. 
TRH ADMINISTRATION 
Seven patients showed paradoxical responsiveness of GH levels to TRH ad­
ministration before SMS treatment (Fig.3). During SMS, this paradoxical 
responsiveness completely disappeared except in patient No.6. In this 
patient, the paradoxical responsiveness persisted, although the maximal 
increase was only 30% of the response before treatment. 
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FIG. 1 . I n d i v i d u a l basal GH l e v e l s (μς/1) and GH l e v e l s ( μ ς / Ι ) 4 h a f t e r 
the f i r s t i n j e c t i o n of SMS (50 μg sc) in 12 p a t i e n t s w i t h acromegaly. The 
f i g u r e s in parentheses i n d i c a t e the i n d i v i d u a l p a t i e n t s . 
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FIG. 3. Individual GH responses of paradoxically responding patients to 
TRH (left panel) and LHRH (right panel) before SMS (upper panel) 
and during SMS, 100 μq twice daily (lower panel). 
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LRH ADMINISTRATION 
Before treatment, 4 patients responded paradoxically to LRH. In all these 
patients, paradoxical responsiveness persisted during SMS with a mean max­
imal GH increase of 70% in comparison to the response before treatment. 
GLUCOSE ADMINISTRATION 
GH levels showed a paradoxical increase during glucose loading in 2 
patients out of 8 nondiabetic acromegalics. This paradoxical response dis­
appeared during SMS administration in both patients. 
DISCUSSION 
The results in this study on the acute effects of SMS 201-995 on GH secre­
tion in acromegaly are in agreement with those of other investigators 
(Bauer et al.1982; von Werder et al.1984; Plewe et al.1984; Ch'ng et 
al.1985; Althoff et al.1984; Lamberts et al .1985,1986; Pieters et al.1986) 
who reported normalization of GH in the majority of the patients after in­
jection of 50 μς SMS. 
The GH responses after GHRH admnistration are exaggerated in patients 
with acromegaly with high basal GH levels (Pieters et al.1984). Earlier we 
described that native somatostatin (SRIF) given as a continuous iv in­
fusion at a dose of 300 μg per hour was not able to blunt completely the 
GH responses after GHRH injection (Pieters et al.1984). In the present 
study we observed that GHRH responsiveness disappears almost completely 
during chronic SMS administration. This discrepancy between the effects of 
SRIF and SMS may be due to differences in efficacy of the dosis used in 
the acute SRIF test and the chronic SMS treatment. 
The TRH-induced paradoxical growth hormone release was completely 
blunted in all patients except one. These data are at variance with those 
of other investigators who failed to demonstrate an effect of SRIF, 100 
μg per hour iv, on TRH-induced GH release in acromegalics (Giustina et 
al.1974; Faglia et al.1975). It was later demonstrated that the paradoxi­
cal GH response to TRH was blunted during the infusion of 1000 μg of SRIF 
per hour (Gomez-Pan et al.1975). Again differences in the dose of somato­
statin may account for these seemingly contradictory results. 
Interestingly, SMS could not prevent the paradoxical responsiveness of 
GH after LRH administration in any of the 4 patients who showed such a 
response. Similar results on LRH-responsiveness during SRIF infusion have 
been reported earlier (Giustina et al.1974), although these authors used a 
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rather inappropriate dose of 100 uq of SRIF per hour. 
It has been suggested that the anomalous GH responses after TRH and/or 
LRH administration occur by dedifferentiation of the GHRH-receptor of the 
somatotrophs in the adenomas (Liuzzi et al.1974). According to this dedif­
ferentiation, TRH and/or LRH should stimulate GH release via a mechanism 
similar to that of GHRH. If this hypothesis were true, one would expect 
that the GH responses to TRH and LRH would disappear during an SMS admini­
stration that is comparable to the blunting of the GH responses after GHRH 
administration. 
Our data and those of other investigators illustrate the disparity of 
the effects of SMS and bromocriptine on the dynamics of GH secretion in 
patients with acromegaly. Chronic treatment with SMS blunts the response 
of the somatotrophs to TRH and to GHRH completely in the great majority of 
the patients, but leaves the response to LRH, if present, largely unaffec­
ted. In turn chronic treatment with bromocriptine leaves the response to 
GHRH intact (Cozzi et al.1986) and reduces the response to TRH only by ap­
proximately 50% (Ishibashi et al.1977; Cozzi et al.1986), but it complete­
ly blunts the response to LRH, if present (Ishibashi et al.1978). 
Thus, the effects of SMS and bromocriptine on the dynamics of GH se­
cretion in acromegaly to a certain extent are complementary. 
From these data we infer that combined treatment with SMS and bromocrip­
tine may be beneficial in some patients with acromeqaly who do not 
successfully respond to treatment with SMS or bromocriptine alone, as was 
demonstrated recently (Lamberts et al.1986). 
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Chapter 5 
COMMENTS 
An intriquinq observation in this thesis is the findinq of a sexual dimor-
phism in GH responsiveness to GHRH between younq adult men and women in 
favour of the men, whereas in midpubertal (tall) adolescents the reverse 
is true i.e. a twice hiqher GH response to GHRH in the qirls as compared 
to the boys. The findinq of a more pronounced GH response to GHRH in the 
pubertal girls is reminiscent of earlier studies, reportinq a sex differ-
ence in GH release after arqimne stimulation (1). It is also in line with 
data of Gelato et al.(2) usinq GHRH testing in normal statured midpubertal 
adolescents. These data all point to a more intensive hypothalamic drive 
in GH secretion from the somatotroph in midpubertal qirls than in boys, 
which is also reflected by the presence of hiqher circulatinq GHRH levels 
in the former (3). The data in human adolescents fit with those obtained 
in pubertal rats, which show a similar sex difference in GH responsiveness 
to GHRH in favour of the female, both in vivo and in vitro (4). There is 
much more controversy with respect to the sex difference in GH response to 
GHRH in younq adults. In 22 carefully selected healthy adults in their 
early twenties with normal Rohrer-indices an overt sex difference in GH 
responsiveness to GHRH was found, the GH increase in men beinq almost 
twice that in women. These findinqs contrast, however, with data from 
other studies, which either reported no sex difference in GH responsive-
ness between adult men and women (5,6) or a somewhat hiqher response in 
women (7,8). Lanq et al.(7) reported hiqher GH peak increments in oremeno-
pausal women (< 30 to 50 yr) than in age matched males. The maximum GH re-
sponses to GHRH and the area under the GH curve were positively correlated 
with plasma oestradiol levels. No sex difference in GH response was found 
in older subjects. In a recent report the qroup of Besser (9) reported an 
overt effect of oestroqen administration on the GH response to insulin-
induced hypoqlycemia, but not to GHRH in short statured girls. Evans et 
al.(10) and Barbarino et al.(8) did not find any difference in GH respon-
siveness to GHRH during the menstrual cycle, which arques against a major 
role of oestrogens in modulating the GH response. We have no explanation 
for the discrepancy between our data and those of Lang et al. (7) and 
Barbarino et al.(8), althouqh they partially may be due to the larqe 
mterindividual variation in GH responsiveness to GHRH. Nevertheless, our 
data are in line with those in animal studies. In intact adult male rats 
the GH response to GHRH is more pronounced than in intact females (11). 
The male pituitary contains a significantly greater percentaqe of somato-
trophs, the GH secretion in vitro is hiqher in response to GHRH whereas 
the sensitivity of the male somatotroph is about 5 times that of females 
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(11,12). Testosterone treatment of castrated male rats, but not oestra-
diol, stimulates the GH response to GHRH (11). Recently Ohlson et al.(13) 
also demonstrated that testicular androaen secretion in adult male rats 
increases pituitary GH release in response to GHRH in vitro, whereas ovar­
ian oestrogen secretion is of less importance for the GHRH responsiveness 
of female rat pituitaries. In human adults not only a sex difference in GH 
responsiveness to GHRH is present but also sexual dimorphism in the endo­
genous opioiderqic modulation of pituitary GH secretion. Administration of 
the opiate receptor antagonist nalaxone was capable of inhibiting GH 
release induced by direct stimulation with GHRH in younq women, but not in 
age matched male controls (8). The absence of such an effect in normal men 
strongly indicates a sex dependence of naloxone effects and suggests a 
role of the sex steroids in modulating pituitary GH secretion (8). Further 
studies are needed to precisely define the sex difference in GH respon­
siveness to GHRH between men and women in different aqe groups and to 
assess the role of sex steroids in this response. 
Besides these observations on some aspects of the physiology of GH-GHRH 
relations, the second part of this thesis, mainly deals with studies in 
patients with pathological hypersecretion of growth hormone. Strong ad­
ditional evidence was obtained for the hypothesis that in GH secreting 
adenomas, cells sensitive to GHRH and less to TRH and Br (pure somato­
trophs) may coexist with cells responsive to TRH and Br but less to GHRH 
(lactotroph-1ike cells) (14, Chapter 4.2). Remarkably we observed such re­
lations only in patients who showed a paradoxical GH response to TRH, not 
in the TRH "non-responders" (Chapter 4.3). Only in the TRH responders the 
GH response to Br was linked to the basal prolactin level, whereas also 
the prolactin increments to GHRH and TRH were closely related, suggesting 
according to Chiodini et al.(14) dedifferentiation of the somatotrophs in 
the adenoma to a more primitive lactotroph-like (GH producing) cell. 
Indeed, GH suppression by Br appeared more pronounced in the acromegalic 
patients responding to TRH than in the non-responders. Nonetheless, also 
in these latter patients with allegedly more pure somatotroph adenomas, Br 
reduced GH levels to less than 50% of the preteatment value. These appar­
ently confusing data became more intelligible in the light of a very 
recent publication of Кода et al. (15), demonstrating the presence of 
specific dopamine receptors even in 8 out of 14 pure GH secreting adeno­
mas. 
Remarkable is also the close relation between GH responsiveness to GHRH 
and LHRH and between the responses to LHRH and SRIF at least in TRH non-
responsive acromegalics (Chapter 4.3). Recently Faglia et al.(16) noted 
that the higher GH responses to GHRH were found in patients paradoxically 
responding to LHRH. Earlier Pieters et al.(17) demonstrated that paradoxi-
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cal GH responses to LHRH mainly occurred in acromegalic patients, with a 
high sensitivity to somatostatin. In view of these close relations it was 
expected that GH suppression by SRIF would be more pronounced in the 
patients with allegedly pure GH producing adenomas (TRH non-responders) 
than in those with mixed, lactotroph-1ike adenomas (TRH-responders). Sur-
prisingly, however, GH suppression by somatostatin appeared similar in 
both groups of acromegalics. Lamberts et al.(18) administering the long 
acting somatostatin analogue MS 201-995 reported favourable GH responses 
to the drug in 3 out of 5 acromegalic patients with pure GH secreting ade-
nomas and in 3 out of 4 with mixed GH/Prl adenomas. An additive response 
of SMS and Br was observed in 2 out of 3 patients with the pure adenoma 
and in all acromegalics with the mixed adenoma. The in vivo data paral-
leled the findings in vitro (19,20). In a recent study Moyse et al.(21) 
and Reubi et al.(22) using autoradiographical and/or immunohistochemical 
staining, demonstrated the presence of specific somatostatin receptors in 
about 70% of pure GH secreting adenomas as well as in mixed GH/Prl 
tumors. Together with the data on the presence of dopamine receptors in a 
subset of pure GH adenomas and in almost all mixed tumors (15), the 
presence of SRIF receptors in both types of tumor in most, but not all 
acromegalie patients, may explain the clinically variable response to each 
of the drugs or to their combined administration. Testing the sensitivity 
to Br and/or SRIF in acromegalic patients in vivo or in vitro may 
therefore be worth to determine the treatment of choice in acromegaly. 
Testing GH responsiveness to GHRH and also to TRH and LHRH, although 
interesting for a better understanding of the pathogenesis of acromegaly, 
hardly has therapeutical implications. Dynamic testing of GH secretion by 
means of GHRH, TRH or LHRH is, however, of value to assess the residual GH 
secretion of the somatotroph during treatment with SMS or Br. The GH 
responses to GHRH and to TRH are dramatically blunted or even disappear 
completely in most acromegalic patients treated with SMS (23,24, Chapter 
4.5), whereas the paradoxical GH response to LHRH persists (Chapter 4.5). 
In turn chronic treatment with Br leaves the response to GHRH intact (25), 
reduces the answer to TRH by approximately 50%, but completely blunts the 
paradoxical answer to LHRH (26). These findings are rather unexpected in 
the light of the earlier described tight associations between the GH re-
sponses to GHRH, somatostatin and LHRH in a subset of acromegalics and the 
inverse relation between GH responsiveness to GHRH at one end and to TRH 
and Br at the other in most patients. It has to be emphasized, however, 
that these associations were found during acute testing using different 
doses of Br and short acting native somatostatin. Nevertheless the data 
again suggest that the effects of SMS and Br on GH secretion are mediated 
via separate pathways, involving different receptors as illustrated 
earlier. The complementary effects of Br and the more potent long acting 
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somatostatin analogue (24,27) on GH secretion in acromegalics, justify 
combined treatment in patients who only partially respond to one of either 
drugs. 
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SAMENVATTING 
In dit proefschrift worden de effecten beschreven van intraveneuze (i.v.) 
toediening van groeihormoon-'Veleasing" hormoon (GHRH) aan gezonde jonge 
volwassenen, aan te lange adolescenten, patiënten met het syndroom van 
Cushing en in het bijzonder patiënten met acromegalie. In 1982 slaagden 
twee, onafhankelijk van elkaar in hetzelfde instituut werkende, onderzoe-
kers (Vale c.s. en Guillemin c.s.) er in de structuur van GHRH op te hel-
deren. Drie peptiden welke in vitro de afgifte van groeihormoon (GH) door 
geïsoleerde ratte-hypofyse-cellen konden bevorderen, werden geïsoleerd uit 
pancreastumoren afkomstig van twee patiënten met acromegalie. Deze pepti-
den bevatten respectievelijk 44, 40 en 37 aminozuren (GHRHi^, GHRHm), en 
GHRH37). Aangetoond werd dat in de hypothalamus van de mens twee vormen 
van GHRH voorkomen, nl. GHRH44 en GHRH^Q met een structuur identiek aan 
die van de ectopische geproduceerde peptiden. In een overzicht van de li-
teratuur (tot en met juli 1987) worden in Hoofdstuk 1 de in vitro en in 
vivo experimenten met GHRH, bij proefdieren en bij de mens, beschreven. 
Om na te gaan of er een geslachtsverschil bestaat in de groeihormoonaf-
gifte werd het effect onderzocht van toediening van een i.v. bolus GHRHi^ 
(100 \LQ) aan jonge volwassen mannen en vrouwen (gemiddelde leeftijd 23 
jaar) (Hoofdstuk 2.1). Zowel bij de mannen als bij de vrouwen werden maxi-
male GH waarden binnen 45 minuten na de injectie bereikt. Bij beide groe-
pen werd bovendien een geringe stijging van het prolactine-gehalte waarge-
nomen, welke afwezig was na toediening van een zoutoplossing. Het antwoord 
van GH op toediening van GHRH was bij de mannen 45 minuten na de injectie 
significant hoger dan bij de vrouwen. Ook het maximale antwoord van GH op 
GHRH en de oppervlakte onder de GH-curve waren bij de mannen significant 
hoger dan bij de vrouwen. De fase van de menstruele cyclus bleek geen in-
vloed te hebben op het antwoord van GH. Bij ratten werd een vergelijkbare 
invloed van het geslacht op de GH-afgifte na GHRH, zowel in vivo als in 
vitro, vastgesteld: androgenen blijken een stimulerend effect te hebben, 
terwijl oestrogenen het antwoord niet beïnvloeden. Ook bij de mens zou een 
dergelijk mechanisme een rol kunnen spelen. 
In Hoofdstuk 2.2 werd de invloed onderzocht van toediening van een i.v. 
bolus van 100 цд СНРНцц aan te lange jongens en meisjes (lengte > 90ste 
percentiel, gemiddelde leeftijd 14.5 jaar). De fase van de puberteit was 
voor beide groepen ongeveer vergelijkbaar. Het bleek dat op alle gekozen 
tijdstippen, tot 30 minuten na de injectie, het antwoord van GH op toedie­
ning van GHRH bij de meisjes groter was dan bij de jongens. Ook de maxi­
maal bereikte GH-spiegels waren bij de (te lange) meisjes ongeveer twee 
maal hoger dan bij de jongens. Een duidelijke verklaring voor de gevonden 
verschillen in het GH-antwoord op toediening van GHRH tussen jonge volwas­
sen mannen en vrouwen enerzijds, en tussen te lange meisjes en jongens an-
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derzijds is moeiliik te geven. Vergelijkbare verschillen werden overigens 
ook gevonden bij de rat· in de puberteit is het GH-antwoord op GHRH bij 
vrouwelijke dieren sterker, terwijl bij volwassen dieren juist het omge-
keerde het geval is. 
Het feit dat het antwoord op GHRH in vitro wordt gestimuleerd door glu-
cocorticoiden, terwijl daarentegen behandeling van kinderen met cortico-
steroiden tot groeiremming leidt, vormde de aanleiding het effect van GHRH 
op de GH-afgifte te onderzoeken bij patiënten met hypercortisolisme door 
Cushing syndromen (Hoofdstuk 3). Zowel patiënten met de ziekte van Cushing 
als patiënten met een primair adrenaal hypercortisolisme lieten een duide-
lijk verminderd of geheel afwezig antwoord van GH op GHRH zien. Het is al 
lang bekend dat bij hypercortisolisme remming van de GH-secretie op-
treedt Het onderzoek in Hoofdstuk 3 leert dat de verminderde stimuleer-
baarheid van de GH-secretie door GHRH hiertoe bi]draagt. 
In Hoofdstuk 4 wordt het effect van GHRH-toediemng op de afgifte van 
GH door de hypofyse bij patiënten met acromegalie besproken. Allereerst 
werd nagegaan of er een relatie bestaat tussen de grootte van de sella, 
het basale GH-gehalte en het antwoord van GH na toediening van GHRH 
(Hoofdstuk 4 1). Een duidelijke correlatie bestond tussen de grootte van 
de sella enerziids, en zowel het basale GH-gehalte als de door GHRH-qein-
duceerde GH-stijqing anderzijds. Ook in deze studie bleek de basale GH-
spieqel in sterke mate het antwoord op GHRH te bepalen, zoals eerder was 
gerapporteerd (zie Hoofdstuk 4.4). Werden de patiënten ingedeeld op grond 
van hun geslacht, dan werden statistisch significante relaties alleen bij 
de mannen gevonden, echter met bii de vrouwen. Deze merkwaardige bevin-
ding wordt in de discussie van Hoofdstuk 4.1 van enig commentaar voorzien. 
Chiodini et al. verdedigden de stelling, dat GH-producerende adenomen 
zijn opgebouwd uit cellen met eigenschappen die passen bij zuiver somato-
trope dan wel lactotrope cellen. Daarom werd het effect van GHRH, TRH en 
bromocriptine (Br)-toediening op de afgifte van GH b n 31 patiënten met 
acromegalie onderzocht (Hoofdstuk 4.2). Het antwoord van GH op een i.v. 
bolus iniectip van GHRH (100 μq) was erg wisselend (Δ6Η 1-995 ng/ml), maar 
correleerde sterk met het basale GH-gehalte. Een negatieve relatie werd 
gevonden tussen de maximale procentuele {%) daling van het GH-gehalte na 
Br-toediening en de maximale % GH-stijging na GHRH, met andere woorden, 
hoe minder GH stijgt onder invloed van GHRH des te sterker is de daling na 
Br. Tevens werd een omgekeerde relatie vastgesteld tussen de maximale % 
GH-stijging na GHRH en na TRH. De reeds langer bekende samenhang tussen de 
uitkomsten van de GH-stijging na TRH en de daling onder invloed van Br kon 
worden bevestigd. Deze gegevens steunen de hypothese van Chiodini over het 
bestaan van GH-producerende adenomen die vooral reageren op GHRH, maar 
minder op TRH en Br ("pure somatotroph adenomas") en van gemengde adenomen 
die vooral gevoelig zijn voor TRH en Br, maar minder voor GHRH ("lacto-
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troph-like adenomas"). 
Vervolgens werd nagegaan of liiders aan acromegalie die op TRH ι eageren 
met een paradoxaal antwoord van GH ("TRH-responders") en dus wel lu ht een 
adenoom hebben met vooral lactotrope eigenschappen, verschillen van pati­
ënten die geen duidelijk antwoord op TRH vertonen ("pure somatotroph ade-
nomas") in hun GH antwoord op LHRH, Br en somatostatine (SRIF) (Hoofdstuk 
4.3). Statistisch significante correlaties tussen de antwoorden van GH op 
GHRH, TRH en Br werden alleen gevonden bij de TRH-responders, met bij de 
"non-responders". De groep die niet op TRH reageerde met een paradoxale 
GH-stijging toonde echter wel significante correlaties tussen zowel de 
maximale % GH-stijging na GHRH en LHRH als tussen de % GH toename na LHRH 
en de % dalinq na SRIF. Geen statistisch significante relatie werd gevon-
den tussen de stijging van GH op GHRH en de dalinq op SRIF-infusie, noch 
in de groep van de TRH-responders noch bij de non-responders De % GH-da-
ling na toediening van SRIF was voor beide groepen geliik, terwiil de GH-
daling na Br, zoals te verwachten, meer was uitgesproken in de TRH respon-
der- dan in de non-responder-groep. Tevens werd een duidelijke samenhang 
gevonden tussen de antwoorden van GH en prolactine. Zo bleek de % afname 
van het GH-gehalte na Br groter te zijn naarmate het basale prolactine-ge-
halte hoger was terwijl de % toeneminq van het prolactine-qehalte na TRH 
hoger was naarmate de % orolactine-stijging na GHRH meer was uitqespro-
ken. De laatst qenoemde correlatie was alleen aanwezig bij de TRH-respon-
ders. 
Uit het bovenstaande blijkt dat patiënten met acromegalie op grond van hun 
reactiepatroon op stimuli en remmers van de GH-afgifte kunnen worden 
onderverdeeld in patiënten met GH producerende adenomen met meer somato-
trope en patiënten met adenomen die meer lactotrope eigenschappen hebben 
deze notie zou van betekenis kunnen zijn met betrekking tot de keuze van 
de behandeling bij deze groep patiënten. 
In Hoofdstuk 4.4 worden de effecten van GHRH op de afgifte van GH,al 
dan met na gelijktijdige toediening van SRIF beschreven. Het maximale 
antwoord van GH werd bereikt binnen 20 minuten na de toediening van GHRH. 
Zoals boven reeds vermeld was het antwoord van GH zeer wisselend, maar 
bleek het des te sterker naarmate het basale GH-gehalte hoger was. Infusie 
van SRIF (300 μς/υυΟ, 1 uur voor toediening van GHRH, had een sterke 
daling van GH-spiegels tot gevolq. Toediening van GHRH tiidens SRIF-infu-
sie deed bij 3 van de 4 patiënten, bij wie het GH-gehalte volledig was ge-
normaliseerd, het antwoord van GH verdwijnen. Voor de gehele groep van pa-
tienten gold dat het antwoord van GH op GHRH wel was verminderd, maar dat 
nog steeds de mate van het antwoord werd bepaald door de hoogte van het 
GH-gehalte gevonden 1 uur na de start van de SRIF-toediemng. Deze waarne-
ming is een sterke aanwijzing dat primair gebrek aan SRIF of primaire 
overproduktie van GHRH zelden of nooit aan acromegalie van met-ectopische 
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origine ten grondslag l igt.Dus zowel met als zonder SRIF wordt het ant-
woord van GH op GHRH bepaald door de uitganqsspiegel van GH. Men kan ver-
onderstellen dat de toenemende r e a c t i v i t e i t van GH op GHRH b u hogere GH-
spiegels het gevolg is van een toegenomen aantal GH producerende cellen 
b i j acromegalie. In d i t kader past ook de bevinding van een groter se l la-
volume b i j patiënten met hogere GH-spiegels (zie boven). Het aantal soma-
totrope cellen bepaalt dus wel l icht het basale GH-gehalte. Onze conclusie 
is dan ook dat de a fg i f te van GH na toediening van GHRH en SRIF aan pa t i -
ënten met acromegalie in wezen normaal i s , z i j het op een hoger niveau. 
De effecten van toediening van een lanqwerkend analoog van SRIF (mimso-
matostatine, SMS 201-995) op de GH k inet iek, b i ] patiënten met acromegalie 
worden beschreven in Hoofdstuk 4.5. Bi l 8 van 12 patiënten normaliseerden 
na toediening van 50 μς SMS subcutaan de GH-spiegels binnen 4 uur. Conform 
de bevindingen met SRIF gaf toediemnq van SMS 1 uur voor GHRH i n i e c t i e 
aanleidinq tot een sterk verminderd GH-antwoord. Na SMS-behandeling gedu­
rende 1 maand bleken de GH-antwoorden op GHRH en op TRH b n de meeste pa-
tienten sterk te z i ] n gedaald of verdwenen Bi j de 4 patiënten met een pa-
radoxaal GH-antwoord op LHRH verdween d i t abnormale antwoord echter n ie t . 
In d i t kader is het interessant te vermelden dat in de l i te ra tuur na chro-
nische behandeling van acromegalie met Br geen verminderd antwoord van GH 
op GHRH werd gevonden, maar dat het abnormale GH-antwoord na TRH ongeveer 
halveerde en het paradoxale GH-antwoord op LHRH vol ledig verdween. Het lag 
daarom ook voor de hand SMS en Br te combineren b i j de behandeling van 
acromegalie. Deze waarnemingen kunnen als aanwijzing worden gezien voor 
het standpunt om b i j de behandeling van acromegalie van de combinatie van 
Rr en SMS meer te verwachten dan van de behandeling met elk van deze medi-
camenten afzonder l i jk . 
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SUMMARY 
This thesis describes the effects of iv bolus administration of qrowth 
hormone-releasinq hormone (GHRH) in healthy young adult men and women, in 
tall statured pubertal boys and girls, in patients with Gushing's syndrome 
and more specifically in acromegalics. Until 1982, GHRH was the last pos­
tulated releasing hormone of which the primary structure was unknown. In 
that year two groups of researchers (Vale et al. and Guillemin et al.) un­
raveled its structure from an ectopic source of GHRH. Three peptides with 
GH releasing activity i.e. СНРНці*, GHRH^o and GHRH37 were isolated and 
identified in pancreatic tumors from two patients with acromegaly. It was 
shown that in the human hypothalamus two forms of GHRH exist: GHRH^ and 
GHRH^g with a structure identical to that of the tumor peptides. 
To study the influence of sex in GH responsiveness to GHRH we investiga­
ted the effects of an acute iv bolus administration of 100 μg GHRH^, to 
young adult men and women in Chapter 2.1. Maximum GH levels were reached 
within 45 minutes both in the men and the women. The GH response to GHRH 
45 minutes after the injection, the maximum GH increments and the areas 
under the GH response curve were significantly higher in the men than in 
the women. In the women no differences in maximum GH responses after GHRH 
were found between the follicular and luteal phases of the menstrual 
cycle. Serum prolactin levels slightly but significantly increased in both 
the men and the women within 5 minutes after injection of GHRH (not after 
placebo). In vivo and in vitro data of GH responsiveness to GHRH in 
rodents reveal a similar sex difference and an enhancing effect of andro­
gens, but not of estrogens. Therefore, also in humans testosterone may 
play a role in the genesis of the sex difference in GH responsiveness to 
GHRH. 
Subsequently we investigated (Chapter 2.2) the GH response to a bolus 
injection of 100 \xq GHRH4i, in midpubertal tall girls and tall boys (height 
> Ρ 90). It appeared that at all time intervals up to 30 minutes after the 
bolus injection, the GH responses to GHRH were significantly higher in the 
girls than in the boys and the peak GH increments to GHRH were about twice 
as high in the former than in the latter. No ready explanation can be 
given for the observed sex related differences in GH responsiveness to 
GHRH between tall statured pubertal boys and girls, which contrast with 
that found in young adult men and women. Similar findings, however, have 
been reported in young rats, i.e. higher GH responses to GHRH in the 
females than in the males. In adult rats the higher GH responses are found 
in the males. 
The stunting of growth in children with glucocorticoid excess prompted 
us to investiqate GH responsiveness to GHRH in patients with endogenous 
hypercortisolism (Chapter 3). An absent or severely blunted GH response to 
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GHRH was found in all patients with Cushinq's disease and those with 
hypercortisolism due to an adrenocortical adenoma. 
In Chapter 4 studies on GHRH testing in patients with acromegaly are re­
ported. The first question we wanted to address is, whether there are re­
lationships between the basal GH, sellar volume (SV) and the GH response 
to GHRH in acromegalics (Chapter 4.1). In the whole qroup of acromegalics 
the basal GH levels and SV were directly correlated i.e. the larger SV, 
the hiaher basal GH level. SV was also correlated with the absolute GH in­
crements in response to GHRH. The latter was tightly related to the basal 
GH level. However, subdividing the patients according to sex, only in the 
men a close relation was found between SV and both basal and GHRH-stimula-
ted GH, not in the women. One miqht speculate that the well-known protec­
tive effect of estroqens on the action of GH in peripheral tissues is re­
sponsible for the observed differences, thereby probably delaying the ex­
pression of GH excess in women. The precise mechanisms underlyinq this sex 
difference await further elucidation, especially the modulatory effects of 
gonadal steroids. 
To verify the hypothesis of the existence of GH producing adenomas in 
acromegaly with more somatotroph or more lactotroph properties we compared 
the effect of GHRH, TRH and bromocriptine (Br) on GH levels in 31 patients 
with acromeqaly (Chapter 4.2). The GH response to GHRH^ was highly vari­
able (Δ GH 1-995 ng/ml), but strongly correlated with basal GH levels. We 
found an inverse relation between the percentage {%) maximum GH decrease 
after Br and the % peak GH response to GHRH i.e. the lower the GH increase 
after GHRH, the more pronounced the GH decrease after Br. Furthermore, a 
reciprocal relation was found between the % peak GH response to GHRH and 
to TRH. The already known relation between the % GH decrease after Br and 
the % peak GH responses to TRH could be confirmed. The data therefore are 
consistent with Chiodini's hypothesis of the existence of GH secreting ad­
enomas which are more sensitive to GHRH and less to TRH and Br (oure soma­
totroph adenomas) and of mixed (lactotroph-1 ike) adenomas responsive to 
TRH and Br, but less to GHRH. 
The next study (Chapter 4.3) was designed to investigate whether 
patients responding with a paradoxical GH increase after TRH with alleged­
ly lactotroph-1ike adenomas differ from those patients non-responding to 
TRH with more somatotroph-1ike tumors, in their GH answers to GHRH, LHRH, 
Br and somatostatin (SRIF). We could demonstrate that statistically sig­
nificant relations between the GH responses to GHRH, TRH and Br are only 
present in TRH-responding acro-megalics, not however in TRH non-respon-
ders. In contrast, in these latter patients, not in the former, close re­
lations were found between the % peak GH responses to LHRH and to GHRH and 
the % GH decrements in response to SRIF infusion. No statistically sianif-
icant relation was found between the % GH responses to GHRH and to SRIF, 
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neither in the TRH non-responders, nor in the TRH responders. The % GH 
response to Br was as expected significantly higher in the TRH responders 
than in the TRH-non-responders, although also in these patients the GH 
decrease was substantial. Furthermore, close correlations were found 
between the prolactin and GH data. The % GH decrease in response to Br was 
the more pronounced, the higher the basal serum prolactin levels, whereas 
the % peak prolactin response to TRH was the higher, the higher the % oeak 
prolactin response to GHRH. Only in the TRH responder qroup basal serum 
prolactin levels and the GH decrements to Br were tightly correlated, as 
were the prolactin responses to TRH and GHRH. The data further favour the 
concept of the existence of subgroups of acromegalics with a more "lacto-
troph-" or "somatotroph"-!ike adenoma with corresponding GH responses to 
releasing and inhibiting agents. Firm conclusions with respect to the 
choice of therapy in the individual patient can, however, not be drawn. 
In Chapter 4.4 we describe the effects of iv injection of 100 μς GHRH4i, 
and/or concomitant SRIF infusion to 11 patients with acromegaly. The maxi­
mum GH response to GHRH was achieved 20 minutes after the injection and 
was highly variable but closely correlated with basal GH levels. SRIF 
started one hour before GHRH injection (300 йд/Ьг) expectedly lowered 
basal GH levels. GHRH injection (100 μη) while con-tinuing SRIF infusion 
for another hour led to completely blunted GH responses in 3 out of 4 
patients whose GH levels normalized during SRIF infusion. Maximum GH re­
sponses to GHRH and concomitant SRIF infusion were highly variable but 
again positively correlated with the GH levels before GHRH testing i.e. 1 
hour after SRIF infusion. It is intriguing to note that GH responsiveness 
to GHRH is determined by the basal GH level both with and without concomi­
tant SRIF infusion. One might speculate that the increased responsiveness 
to GHRH at higher GH levels is the consequence of an increased number of 
GH-producinq cells in acromegaly. The finding of a larger sella in acro­
megalic patients with the higher GH responses to GHRH is in line with such 
thesis. By a similar way of reasoning the number of somatotrophs may in­
dicate the basal GH level. Therefore, we can conclude that responsiveness 
to GHRH and SRIF is essentially normal in acromegaly, but at a higher 
setting of basal GH levels. 
The effects of minisomatostatin (SMS), a long acting analogue of SRIF, 
on GH kinetic in acromegaly are described in Chapter 4.5. SMS at a dose of 
50 \iq subcutaneously normalized GH levels 4 hours after the injection in 8 
out of 12 patients. As was earlier found with SRIF, GH responsiveness to 
GHRH was strongly blunted when SMS was administered 1 hour before GHRH in­
jection. The GH response to GHRH and the paradoxical GH responses to TRH 
disappeared in the majority of patients after SMS treatment for 1 month. 
In contrast paradoxical GH responsiveness to LHRH persisted in 4 out of 4 
patients. It is interesting to note that other authors reported that 
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chronic treatment with Br had no effect upon the GH answer to GHRH, 
reduced the paradoxical GH responses to TRH with approximately 50% and 
completely blunted the anomalous GH responses to LHRH. Therefore SMS and 
Br may have complementary effects in correcting the anomalous GH kinetics 
in patients with acromegaly. Combination of the two drugs therefore may be 
justified in treating acromegalics and in fact has been reported to be 
more effective than each of the drugs alone in selected patients. 
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STELLINGEN 
1. Ook bij de mens lijkt er een qeslachtsverschil te bestaan in het ant-
woord van groeihormoon op de toediening van qroeihormoon-releasing-hor-
moon. 
Dit proefschrift 
2. Bij hypercortisolisme is het antwoord van qroeihormoon op qroeihormoon-
releasing-hormoon afwezig dan wel sterk verminderd. 
Dit proefschrift 
3. Het antwoord van groeihormoon op groeihormoon-releasing-hormoon bij pa-
tiënten met acromegalie is hoger naarmate het antwoord op thyrotropin-
releasing-hormoon en bromocriptine lager is. 
Dit proefschrift 
4. Patienten met acromegalie kunnen op qrond van hun reactiepatroon op 
stimuli en remmers van de groeihormoon-afqifte worden onderverdeeld in 
patiënten met adenomen met meer somatotrope en patiënten met adenomen 
die meer lactotrope eiqenschappen hebben. Deze bevindinq heeft evenwel 
voor de individuele patient nauwelijks betekenis met betrekking tot de 
keuze van de behandel ina. 
Dit proefschrift 
5. Aanwezigheid van de epidermal growth factor receptor in mammaweefsel 
bepaalt in belangriike mate het optreden van vroege recidieven en/of de 
overleving bij patiënten met een primair mammacarcinoom. Sainsbury et 
al. The Lancet 1987 i: 1398-1402. 
6. Het verband tussen roken en het optreden van endocriene ophthalmopathie 
dient nader te worden onderzocht (Hágq & Aspi und, Brit Med J, 1987, 
296: 634-635.) 
7. Toedieninq van hoqe doses qlucocorticoiden aan patiënten met septische 
shock lijkt achterhaald. (Bone et al. New Engl J Med 1987, 317: 653-
659). Deze stelling, onlangs nog eens door goed onderzoek onderbouwd, 
had 20 jaar geleden eveneens kunnen zijn geponeerd. 
8. Evenals bij het varken is ook bij de mens androstadienol de 
belangrijkste voorloper van sex-feromoon (Weusten et al. J Clin 
Endocrinol Metab, oct. 1987). 
9. De uitspraak- "Geen nieuws is goed nieuws" geldt niet voor een solli-
citatie. 
10. Als de overheid als een ontqrondingsbedri jf en de ontgrondingsbedri i-
ven als een overheid geleid zouden worden, dan zouden alle ontgron-
dinqsbedriiven failliet zijn en was Nederland één grote waterplas. 
11 Ook al zou de Riin in het jaar 2000 geheel schoon zijn, dan nog is het 
onwaarschi ini nk dat de zalm hierin terugkeert. 
12 De hoofdhuid leent zich uitermate voor onderzoek naar het effect van 
locaal te appliceren experimentele geneesmiddelen· bil behandeling van 
alopecia areata verdient het dan ook aanbeveling de ene schedelhelft 
wel en de andere niet te behandelen (Happle). 
13. Het is aannemeliik dat tussen nu en het jaar 2000 het aantal kanker-
patiënten zal toenemen van 200.000 tot 300.000 Wil men de problema-
tiek die hier mee gepaard gaat opvangen, dan dient nu actie te worden 
ondernomen (S.T.G. rapport Kanker in Nederland, 1987). 
14 Het wordt de hoogste tnd een "stel 1 ingenbank" voor promovendi op te 
richten. 
Niimegen 4 december 1987 



